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ABSTRACT 
 
The ability to reprogram somatic cells toward a stem cell phenotype has 
created a powerful method of reversing the fate of lineage restricted cells.  If 
the potential of reprogramming is realised we will be able to provide a 
source of autologous, functional cells circumventing many of the issues 
associated with donor transplantation and provide a source of stem cells free 
from the controversy surrounding derivation from embryos. 
MicroRNA (miRNAs) are an attractive substitute to foreign DNA for 
induction of reprogramming.  This thesis focused on a specific miRNA, 
miR-145 due to its role as a repressor of pluripotency during 
embryogenesis.   The majority of reprogramming approaches to date have 
utilised viral vectors to deliver inducing stimuli however a considerable 
amount of literature strongly suggests that cells reprogrammed using viral 
vectors are unsuitable from a clinical perspective due to risks associated 
with insertional mutagenesis and potential immunogenicity.  Therefore this 
investigation sought a non-viral method of delivering inducing stimuli and 
an electroporation based technique, known as nucleofection was identified.  
This non-viral delivery method was evaluated in terms of its efficiency and 
cell viability and was found to be highly effective in its capacity to deliver 
both plasmid DNA and miRNA inhibitors to human epidermal keratinocytes 
(hEKs).   
Nucleofection of hEKs with an antisense oligonucleotide, which effectively 
inhibits miR-145 was shown to significantly increase the expression of 
Oct4, Sox2, Klf4 and c-Myc all of which are required for the successful 
reprogramming of somatic cells.  MiR-145 inhibited hEKs were 
subsequently subjected to modified culture conditions in an attempt to 
further promote the expression of pluripotency-associated transcription 
factors.   hESC media containing growth factors, known to promote a 
  
 
human embryonic stem cell phenotype, lead to a distinctive change in cell 
morphology with cells clustering together to form colonies and also further 
stimulated the expression of pluripotency associated genes. While hEKs did 
exhibited re-expression of normally silenced pluripotency genes they had 
not undergone full cellular reprogramming however now presented a more 
„plastic‟ phenotype. 
A direct reprogramming approach was formulated where miR-145 
inhibition of hEKs was performed and post-nucleofection cells were 
incubated using either standard hEK media or growth factor supplemented 
hESC media for 5 days.  Defined osteogenic, chondrogenic or adipogenic 
differentiation media were then applied to stimulate reprogramming towards 
„tri-lineage‟ fates, whilst crucially demonstrating transgermal differentiation 
of hEKs.  A defined neurogenic media was also applied to further validate 
their differentiation potential and together this provided further evidence for 
acquisition of a „plastic‟ phenotype with identification of lineage specific 
markers following directed differentiation. 
Taken together this investigation details a novel, miRNA mediated strategy 
for the direct reprogramming of hEKs in the absence of foreign DNA or 
viral vectors whilst facilitating re-differentiation into a number of desirable 
lineages offering significant advances for clinical translation.  
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1.0 Introduction 
 
1.1 Stem Cells in Tissue Engineering 
Tissue engineering is the development of functional substitutes that restore, 
maintain or improve tissue function [1].  This field has progressed rapidly 
over the last decade with development of functional replacements for many 
tissues of the human body.  The requirement for improved tissue engineered 
products remains evident nevertheless with transplantation of tissues and 
organs considerably limited by the number of compatible donors while 
alternative strategies, such as mechanical devices or artificial prostheses, 
fail to completely restore tissue function.   If the promise of tissue 
engineering is realised it will provide an alternative solution to replace or 
repair tissue and ultimately patient quality of life, thus providing both 
economic and health benefits for the population. 
 
In order to develop functional alternatives for use in tissue engineering 
human cells are often manipulated either by modifying their extracellular 
environment or by altering the cell‟s own genetic program to direct it 
towards a desired tissue type.  In the search for a suitable source of cells for 
tissue engineering various candidates have been identified, each with 
benefits and limitations.   
 
Autologous, lineage committed cells were initially thought to be an ideal 
candidate for tissue replacement strategies due to the functional benefits of 
these cells.  However large numbers of cells are often required to repair 
damaged tissue, which must be generated either by extensive tissue 
harvesting or through expansion of smaller cell populations ex vivo.  
Investigations into lineage committed cells, such as osteoblasts and 
chondrocytes, revealed the cellular damage, incurred during harvesting, 
which contradicts the aim of tissue engineering in the first instance and 
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while smaller populations can be propagated in vitro this is often 
accompanied by loss of cellular function, rendering this approach 
inappropriate for tissue engineering. 
 
Lineage uncommitted stem cells have caught the public and scientific 
imagination as they have been identified as an attractive alternative to 
autologous, lineage committed somatic cells.  In terms of plasticity and self-
renewal capabilities they offer many advantages while still presenting a 
patient-specific source of cells thus avoiding many of the complications 
associated with immune rejection.  Their self-renewal characteristics are 
particularly important as this suggested these cells can be expanded 
indefinitely without loss of functionality [2].  The search for sources of adult 
stem cells has been one of the most prolific aspects in the field of tissue 
engineering with an abundance of sources identified within the human body.  
Stem cells reside within specific niches and are found amongst 
differentiated cells within a tissue or organ.  They are characterised 
primarily by their ability to self renew, through mitotic cell division and 
differentiate into a diverse range of specialised cell types, to maintain or 
repair the tissue in which they reside [3-7].  Despite the initial hypothesis 
that lineage uncommitted stem cells derived from adult sources were 
restricted in their differentiation capacity to mesoderm-derived cells, this 
has now been widely disproved with adult stem cells forming tissues 
derived from the three germ layers with some tissue sources displaying 
more plasticity than others [8, 9].   
 
Stem cells isolated from adult tissues have been extensively investigated as 
potential cell therapies for a wide range of diseases.  One area that has 
received much interest is the treatment of cardiovascular disease, which is a 
leading cause of death worldwide.  The majority of clinical trials aimed at 
treating cardiovascular disease have used bone marrow-derived 
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mononuclear cells however while there have been no reports of adverse side 
effects to these cells the improvement reported appears only marginal with 
no obvious long term improvements in heart function  [10-12].  Promisingly 
recent clinical trials suggest that the progression of heart failure can be 
prevented or even reversed using resident cardiac stem cell based therapy 
with initial reports indicating that intracoronary infusion of autologous 
cardiac stem cells (CSCs) can significantly improve heart function and 
reduce infarct size in patients with heart failure after myocardial infarction 
[13].  This illustrates why we need to understand the basic biology of stem 
cells in order to unlock their potential in a clinical setting.   
 
Diabetes mellitus, another debilitating disease affecting millions of people 
worldwide, has also been extensively targeted by adult stem cell therapy.  
Diabetes develops when the insulin-producing beta-cells are destroyed, 
resulting in an accumulation of glucose in the body, which produces an 
array of complications.  Stem cell therapy was proposed as an attractive 
strategy to replace beta-cells to restore normal insulin levels, which has 
proven to be an achievable target with varying success rates.  One study that 
demonstrates the potency of stem cell therapy as a treatment for diabetes 
reports autologous, non-myeloablative hematopoietic stem cell (HSC) 
transplantation in 15 newly diagnosed type I diabetes mellitus patients.  This 
clinical trial resulted in the majority of patients becoming insulin free after 
18 months [14] while a later follow-up study after 30 months confirmed an 
increase in beta-cell function [15].   
 
Perhaps one of the greatest success stories of adult stem cells (ASCs) to date 
is the identification and clinical application of HSCs.  These multipotent 
stem cells can be isolated from peripheral blood, bone marrow or cord blood 
and were first identified in mice in 1961 [16].  By 1999 over 50 diseases had 
been treated using bone marrow and stem cell therapy in humans including 
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leukaemia, inflammatory bowel disease and osteogenesis imperfecta [17].  
The first global survey of HSC transplantation revealed that it has now 
become an accepted cell therapy worldwide with over 50,000 
transplantations undertaken in 2006, providing one of the best examples of 
stem biology translated into the clinical arena [18].  
Despite ASCs being identified as an attractive cell for therapeutic purposes 
they do generally represent a more lineage restricted source of cells 
compared to pluripotent embryonic stem cells (ESCs).  Pluripotency is the 
term applied to a cell, which has the capacity to become any cell of an 
organism and was initially thought to be an exclusive property of early 
embryonic cells or their in vitro proxy, embryonic stem cells.  As these cells 
differentiate to become more specialised their pluripotent characteristics are 
diminished and unless disrupted by disease these cells become restricted to 
their ultimate cell fate.  Pluripotent ASCs, although rare and generally small 
in number, have been reported in the brain and umbilical cord blood [19, 20] 
however, these cell sources are not readily accessible and difficult to isolate 
therefore it is unlikely that stem cells isolated from these sources would be 
suitable for tissue engineering.  While ASCs can be isolated from more 
accessible tissues, such as adipose [21] and dental pulp [22], their potential 
faces greater restrictions and cannot match the pluripotent differentiation 
capabilities of ESCs.    
ESCs are derived from embryos, specifically epiblast tissue of the inner cell 
mass during the blastocyst stage of development.  This group of cells are 
recognised as the most pluripotent of all stem cells and as a result of their 
distinctive cellular biology have an indefinite capacity to self-renew and 
give rise to all cell types within the three germ layers of the developing 
organism [23, 24].  Despite their huge potential there are also major 
drawbacks associated with ESCs as a source of cells for tissue engineering.  
As ESCs are derived from donor embryos they are non-autologous therefore 
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tissues derived from these stem cells would likely be rejected by the host‟s 
immune system upon transplantation [25].   
 
Research into human embryonic stem cells (hESCs) has also been fraught 
with ethical concerns primarily due to the destruction of human blastocysts 
during isolation however it appeared there may be potential for the 
development of hESC therapies with the approval of the first human clinical 
trials using hESC-derived oligodendrocyte progenitor cells in patients with 
spinal cord injuries in 2010.  Unfortunately the coordinators of this project 
have recently halted these trials due to financial issues [26] therefore it 
appears that the translation of hESC biology to a clinical setting still faces 
some major hurdles.  In terms of the therapeutic use of hESCs on a large 
scale, the number of hESC lines required to provide a good match for 
specific patient populations would be vast, with the number of embryos 
required far exceeding the number available from assisted reproductive 
clinics, thus requiring both oocytes and sperm to be donated; in turn, having 
its own set of ethical and practical concerns.  These issues have led the 
research community to investigate other cell sources as alternatives to both 
ASCs and ESCs, which possess many of their desirable characteristics, such 
as pluripotency, patient specificity and accessibility from adult tissue.    
 
1.2 Reprogramming  
The differentiation of pluripotent cells along increasingly defined lineages 
involves considerable genetic and epigenetic changes and it was initially 
uncertain if it would ever be possible to completely reverse these changes in 
adult somatic cells.   
 
The reprogramming of somatic cells has been developed based on principles 
and techniques, which have been formulated over the last six decades.  The 
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first step towards overcoming restrictions imposed during development 
came in the 1950s, with Briggs and King establishing the technique of 
somatic cell nuclear transfer (SCNT).  This involves introducing nuclei of 
somatic cells into genetically inactivated oocytes, with nuclei consequently 
reprogrammed by the host oocyte.  Using this technique they investigated 
the developmental potential of cell nuclei isolated from late-stage embryos 
or tadpoles by transferring them into enucleated oocytes and were able to 
successfully generate viable offspring [27].  Gurdon et al. examined the 
capacity of differentiated nuclei, in this instance isolated from the intestinal 
epithelium of an adult frog, to be reprogrammed by the recipient oocyte, 
which also resulted in production of viable organisms [28].  This research 
established that differentiated cells contain a full complement of genes to 
support the generation of cloned offspring.  
 
Despite the success of SCNT using amphibian cells, transferring this 
knowledge to mammalian cells was not as simple as first anticipated, 
primarily due to the small size of mammalian oocytes.  The development of 
micromanipulation techniques facilitated SCNT using mammalian cells; 
Wilmut et al performed nuclear transfer of cultured mammary gland cells by 
electrofusing them into enucleated sheep eggs.  This experiment resulted in 
the generation of a single cloned sheep, known as „Dolly‟ [29].  This study 
demonstrated that fully differentiated mammalian cells remain genetically 
totipotent therefore it could be concluded that development imposes 
reversible genetic modifications rather than irreversible genetic changes.  
Despite the success of cloning mammalian cells, the majority of cloned 
animals exhibit genetic abnormalities, suggesting that SCNT results in 
defective epigenetic reprogramming.  Therefore the proposal to use this 
technique in human stem cell research was deemed unethical and as a result 
no human stem cell lines have been generated using SCNT.  This research 
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did however lead researchers to consider what factors contained within the 
cytoplasm of oocytes had enabled reprogramming of somatic nuclei.   
 
Due to the technical expertise involved in SCNT, researchers sought 
alternative methods to probe cell developmental potential.  An important 
step came with the establishment of immortal cell lines from tumours of 
germ cell origin, known as teratocarcinomas, which provided a source of 
cells that could be clonally expanded in culture whilst retaining their 
pluripotent characteristics [30].  These cells are termed embryonal 
carcinoma cells (ECCs) and provide an ideal model for studying the 
pluripotency network in more detail.  A number of laboratories went on to 
use ECCs to successfully reprogram both murine and human somatic cells 
using cell fusion.  However these cells contain two sets of chromosomes and 
with normal cell function depending on innumerable interactions between 
genes, altering the numbers of chromosomes effect these interactions, 
rendering this approach unsuitable for clinical application [31-33]. This 
research demonstrated the dominance of the pluripotent state over the 
somatic state while the factors responsible still remained unidentified. 
 
It was these efforts, which stimulated the isolation of ESCs initially from the 
inner cell mass of mouse blastocysts [34] and later from human embryos 
[23].  Pluripotent cell lines have also been generated from a variety of other 
sources, such as embryonic germ cells (EGCs) isolated from primordial 
germ cells of the middle gestation embryo [35] and epiblast stem cells 
(EpiSCs) isolated from post-implantation embryos [36].  One characteristic 
that they all share is that they are all derived from early embryos or germ 
lineage cells, however only ESCs are capable of tetraploid embryo 
complementation as a result of balanced parental imprints, which are 
required for normal development.   
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Investigations into reprogramming continued through a series of 
experiments incubating somatic cells with extracts of pluripotent cells.  This 
involved permeabilising somatic cells and exposing them to nuclear and 
cytoplasmic extracts derived from pluripotent cells from various origins 
including hESCs [37], xenopus oocytes [38] and ECCs [37].  While these 
studies provided some interesting findings with many cell lines showing re-
expression of the pluripotency marker Oct4 many reprogrammed cells only 
regained restricted pluripotency properties.  Ultimately the results obtained 
were not conclusive that expression of these characteristics was due to 
cellular extracts. 
 
Meanwhile attention had turned to lineage associated transcription factors, 
which would later prove to be the most influential factor in establishing 
fully reprogrammed somatic cells.  Lineage associated transcription factors 
were known to maintain cellular identity through inducing expression of 
lineage specific genes whilst inhibiting expression of plasticity associated 
genes.  The use of these transcription factors as a tool to dedifferentiate 
somatic cells was first demonstrated through the conversion of mouse 
embryonic fibroblasts (MEFs) to myoblasts through the over expression of 
the myogenic regulatory factor, MyoD [39].  Later researchers successfully 
converted B lymphocytes into macrophages through over expression of the 
myeloid transcription factor C/EBPα [40] demonstrating the versatility of 
using transcription factors to alter cell fate.       
 
1.3 Induced Pluripotent Stem Cells  
Although much research into the reprogramming of somatic cells had been 
undertaken, it was in 2006 that a major breakthrough occurred when 
Yamanaka et al determined four specific factors, which were sufficient to 
reprogram somatic cells to a pluripotent state [41].  Yamanaka and 
colleagues had devised an elegant screen for transcription factors capable of 
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reprogramming somatic cells from a pool of 24 thought to be implicated in 
pluripotency.  Each of these factors was retrovirally transfected into ESC-
specific Fbx15 reporter fibroblasts and selected according to expression of 
this marker gene.    Successive rounds of elimination narrowed down the 
initial number of 24 to four defined factors, Oct4, Sox2, c-Myc and Klf4 
(OKSM), which on their own were sufficient to induce pluripotency [42].  
Since Yamanaka‟s discovery, this four factor cocktail has been shown to 
reprogram both murine and human cells to a pluripotent stage, termed 
induced pluripotent stem cells (iPSCs) [41, 43-45].  IPSCs were capable of 
producing colonies morphologically similar to ESCs and displayed many 
markers typically associated with pluripotency including SSEA1 and Nanog.  
When iPSCs were injected subcutaneously into immunocompromised mice, 
teratoma formation occurred and furthermore upon blastocyst injection were 
found to contribute to a number of different tissues of the developing 
embryo [41]. 
 
Despite the “first generation iPSCs” generated in Yamanka‟s initial studies 
displaying many pluripotency markers, these cells appeared only partially 
reprogrammed.  These cells were unable to produce viable chimeras or 
contribute to the germ-line and also displayed incomplete promoter 
demethylation of ESC regulators, such as Oct4, strongly suggesting 
incomplete reprogramming.  The isolation procedure was thus modified, 
replacing the Fbx15 reporter with a reporter associated with either Nanog or 
Oct4 [46, 47], both of which are more closely associated with pluripotency.  
IPSCs isolated using this method were germline competent and represented 
a population of cells functionally indistinguishable from hESCs.  Since then, 
iPSCs have been generated from a number of different species including 
humans [45], rats [48] and rhesus monkeys [49] through expression of 
OKSM, demonstrating that key factors governing the pluripotency network 
remain conserved during evolution. 
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Variations of the four-factor cocktail have been used to successfully 
reprogram somatic cells.  Factors can be substituted by family members 
with Sox1 or Sox3 capable of replacing their counterpart Sox2.   Klf2 and 
Klf5 are able to replace Klf4 and c-Myc can be substituted by l-Myc and n-
Myc suggesting that proteins recognise similar DNA-binding motifs [50].   
It should also be noted that Oct4, Sox2, c-Myc and Klf4 are not the only four 
factor combination that can reprogram somatic cells.  Another group of 
factors Oct4, Sox2, Nanog and Lin-28 have also been used by several groups 
to successfully generate iPSCs [51].  This suggests that there is more than 
one route to pluripotency or that different transcription factors can activate 
the same route through promoting each other‟s expression.  In the case of 
Lin-28 this transcription factor represses let-7 miRNAs [52], which 
negatively regulate c-Myc expression [53] therefore likely functioning to 
indirectly increase levels of endogenous c-Myc.  In an attempt to reduce the 
number of factors required to induce pluripotency, successful 
reprogramming has also been achieved in the absence of both c-Myc and 
Klf4 [54] suggesting that Oct4 and Sox2 play a more pivotal role in this 
process, whereas c-Myc and Klf4 are thought to enhance reprogramming. 
 
In the vast majority of cases Oct4 is required to induce pluripotency.  In fact  
iPSCs have been generated from human neural stem cells (NSCs) using 
Oct4 alone [55] providing further evidence that Oct4 may be the master 
regulator of pluripotency in mammalian cells.  Until recently Oct4 remained 
the only factor that was irreplaceable with other transcription factors, 
including close family members Oct1 and Oct6 [56], until the discovery that 
the nuclear receptor Nr5a2 was capable of replacing exogenous Oct4 and in 
conjunction with Sox2 and Klf4 was capable of reprogramming MEFs [57].  
Nr5a2 is an upstream activator of Oct4; therefore it is likely that in this case 
indirect activation of endogenous Oct4 expression has driven the 
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reprogramming process. The orchestration of pluripotency involves many 
gene interactions and just a few of these are detailed in Figure 1.1.  
 
 
Figure 1.1 Schematic of gene regulatory network in pluripotent stem cells 
 
1.4 Reprogramming Factors 
1.4.1 Oct4 
The four factors initially identified by Yamanaka et al have been widely 
used for inducing pluripotency.  The transcription factor Oct4 is strongly 
implicated in maintenance of pluripotency and has become somewhat of a 
proxy for stemness.  Oct4 belongs to the Pit-Oct-Unc (POU) family of 
transcription factors [58] and appears to be almost exclusively expressed in 
ESCs and germline cells  playing a vital role in ontogenesis [58, 59].  Oct4 
is expressed in all blastomeres initially with expression becoming 
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progressively downregulated in the trophoectoderm and more profuse in the 
inner cell mass.  In late blastocysts, Oct4 becomes most abundant in the 
primitive endoderm [60] and eventually at maturity Oct4 expression 
becomes limited to germ cells [61].   
Niwa et al measured levels of Oct4 expression at various ESC states to 
understand its role in more detail [62, 63].  This work demonstrates that 
repression of Oct4 leads ESCs to differentiate into cells resembling 
trophoectoderm whilst over expression of Oct4 results in differentiation into 
several lineages, including extra-embryonic mesoderm and primitive 
endoderm lineages [62, 63].  This suggests Oct4 differs from many 
regulatory transcription factors in that it does not function in an on/off 
manner, with fluctuations in expression having profound effects on cell fate. 
Genome studies of human and murine ESCs using chromatin-
immunoprecipitation (ChIP)-on-chip assays have highlighted a large 
number of genes with Oct regulatory elements.   In hESCs 581 genes have 
been identified as Oct4 targets, whereas 963 genes have been identified in 
the case of mESCs [64, 65].  Oct4 can act either as a suppressor of genes 
responsible for ESC differentiation or as an activator of genes known to 
retain the pluripotency of ESCs while many of these genes also express 
regulatory elements for Sox2 and Nanog, which provides evidence for the 
existence of co-regulation of numerous genes in a positive regulatory loop 
[64].  
 
1.4.2 Sox2 
The transcription factor SRY-type high mobility group box 2, also known as 
Sox2 is part of a large family of 20 proteins strongly implicated in 
maintenance of pluripotency.  Downregulation of Sox2 promotes ESC 
differentiation in mESCs demonstrating the importance of Sox2 in 
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pluripotency regulation [66].  Sox2 is initially expressed in all blastomeres 
and later becomes restricted to the inner cell mass and
 
epiblast and then 
germ cells. However, unlike Oct4, Sox2 is also expressed in multipotential 
cells of
 
the extra embryonic ectoderm and in precursor cells of the
 
developing central nervous system [66].  In terms of regulating pluripotency 
Sox2 acts in combination with Oct4 to activate Oct–Sox enhancers, which 
regulates the expression of pluripotent stem cell-specific genes, including 
Nanog, Oct4 and Sox2 itself [67].  It was originally thought that Sox2 
maintained pluripotency through Oct-Sox enhancer activity however Sox2 is 
in fact dispensable for activation of these enhancers although it is required 
to stabilise ESCs in a pluripotent state by maintaining the appropriate level 
of Oct4 expression indirectly through regulation of  multiple transcription 
factors [68]. 
 
1.4.3 C-Myc 
The helix-loop-helix/leucine zipper transcription factor, c-Myc, is a known 
oncogene responsible for a number of cellular functions including cell 
growth, differentiation and proliferation [69].   Like the other transcription 
factors previously described, c-Myc interacts with a considerable number of 
genes acting as both a repressor and activator of its targets [69].  In terms of 
its role inducing pluripotency, it has been suggested that c-Myc serves as a 
major downstream target of two pathways known to promote pluripotency, 
the LIF/STAT3 and Wnt signalling pathways [70].   The LIF/STAT3 
pathway stimulates pluripotency in mESCs however, activation of this 
pathway is not required for hESC pluripotency [71].  In mESCs, LIF binds 
to hetero-dimeric LIF receptor stimulating a cascade of signalling events, 
eventually resulting in translocation of the transcription factor STAT3, 
required to maintain pluripotency.  The Wnt pathway on the other hand 
maintains pluripotency of both mESCs and hESCs.  Activation of the Wnt 
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pathway promotes pluripotency through inhibition of glycogen synthase 
kinase-3ß (GSK3β), which in turn results in a cascade of signalling events, 
including an increase in c-Myc expression [70].  While research has revealed 
that c-Myc is not strictly required for generation of iPSCs, its absence often 
makes the reprogramming process more inefficient.   One way in which c-
Myc is thought to aid the reprogramming process is through its ability to 
open the chromatin structure by binding various genome sites and recruiting 
histone acetylase complexes [72].  To exploit the attributes of c-Myc, many 
groups have explored reprogramming cells which endogenously express 
high levels of c-Myc and small molecules, such as Wnt3a, to promote 
reprogramming without exogenous c-Myc [73]. 
 
1.4.4 Klf4 
The Kruppel-type zinc-finger transcription factor Klf4 is also a downstream 
target of STAT3 and over expression leads to sustained expression of Oct4 
and inhibition of differentiation in ESCs [74].  Relatively speaking Klf4 is 
not required to the same degree as Oct4 and Sox2 in maintaining 
pluripotency, although its activation can also improve the efficiency of the 
reprogramming process. Klf4 has also shown to exhibit cofactor regulation 
of gene transcription along with Oct4 in a similar way to Sox2, however 
Klf4 acts on a much smaller scale with only a small number of genes 
regulated [75].  Klf4 may also serve to upregulate Nanog by suppressing 
p53, a negative regulator of Nanog [76, 77].   
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1.5 Mechanisms of Inducing Pluripotency  
Despite the identification of numerous factors, which are able to initiate 
pluripotency, the nature and sequence of events occurring during 
reprogramming remain unclear. A number of studies have focused on the 
stochiometry of reprogramming and provide further insight into 
mechanisms responsible for this remarkable event.  One particular study, 
which provides a clearer indication of the molecular and cellular changes 
during reprogramming, makes use of a doxycycline-dependent lentiviral 
system, which is able to transiently express OKSM.  This system allowed 
for the self-selection of iPSCs upon the removal of doxycycline from culture 
media, with surviving cells demonstrating pluripotent characteristics.  This 
study demonstrated that exogenous expression of the four factors is required 
for approximately 10 days and after this point the somatic genome is ready 
for conversion to pluripotency suggesting that reprogramming follows a 
defined set of events rather than a random sequence of reprogramming [78]. 
MacArthur et al also provided further insight into processes underlying 
reprogramming by putting forward a fundamental theory suggesting that in 
order to reprogram somatic cells it is necessary to supply them with enough 
energy to overcome barriers maintaining their differentiated state.  This 
switch is often induced by Oct4 and Sox2 and many studies have achieved 
reprogramming by inducing high levels of these genes using viruses.   This 
study demonstrates that low level, transient fluctuations of Oct4 and Sox2 
are adequate to induce expression of endogenous gene expression [79] 
suggesting considerably less invasive methods may be used to induce 
reprogramming.   Another important conclusion drawn from this study is 
that a general increase in transcriptional noise may assist reprogramming.  
Rather than specifically targeting the pluripotency regulatory circuit, non-
specific widespread gene amplification is thought to shake the system into  
pluripotency [79].  
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1.6 Reprogramming Efficiency 
Despite improvements in somatic cell reprogramming, induction of 
pluripotency largely remains an inefficient process.  Low efficiency and 
slow kinetics are evident when compared to the relatively efficient method 
of cell lineage switching.  In the case of B lymphocyte conversion to 
macrophages through forced expression of C/EBPα, the process is almost 
100% efficient with a switch in cell fate occurring after around 48 hours 
[40] compared to the reprogramming of somatic cells to a pluripotent state 
with the highest efficiencies reported at around 3% [80].  This suggests that 
induction of pluripotency faces greater restrictions due to decreased 
transcription and epigenetic similarity between somatic cells and pluripotent 
stem cells.  In addition to the inefficient nature of reprogramming, 
acquisition of a fully pluripotent phenotype is not necessarily complete upon 
endogenous expression of key pluripotency genes.  It may require several 
rounds of cell division to reach this stage as illustrated by distinct 
differences in telomere length [81], global transcription [82] and DNA 
methylation patterns [83] between early and late passage iPSCs.  
Reprogramming efficiency can largely be attributed to the method used for 
delivery of reprogramming factors with the greatest efficiency achieved 
using integrating viruses.  Lentiviruses generate the highest efficiencies of 
~0.1%-1% [51] closely followed by retroviruses at ~0.01%-0.05% [45].  
Excisable vectors, such as the piggyBac transposon system have also 
demonstrated relatively high efficiency levels of ~0.1% [84] whilst non-
integrating systems using adenoviruses or plasmids produce lower 
efficiencies of ~0.001% [85].  DNA free systems also produce low 
efficiencies with proteins and RNA reporting reprogramming efficiencies of 
~0.001% [86].  The efficiency of reprogramming also largely depends on 
inducing factors and the somatic cell type, which will be discussed in more 
detail later in this chapter.  
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1.6.1 Cooperative Factors 
The slow kinetics of reprogramming compared to cell fusion or SCNT 
suggests that a number of cooperative factors, which target Oct4, Sox2, Klf4, 
c-Myc, must exist.  In an attempt to improve efficiency of this process and 
identify novel molecules that may provide alternatives to existing factors, a 
number of antagonists have been identified.   The use of chromatin-
modifying agents to enhance the overall efficiency of reprogramming is 
well documented and can often be used as replacements for one or more 
inducing factors.   
All cells of the mammalian embryo prior to the eight-cell stage have 
potential to form all somatic and germ cells of the organism in addition to 
all extra-embryonic tissues and therefore are termed totipotent [87].  This 
potential is progressively restricted during development through epigenetic 
reprogramming of the cell nucleus to prevent the re-expression of undesired 
genes.  The epigenome of each cell is subsequently determined by the 
histone code, DNA methylation patterns and chromatin remodelling.  These 
modifications make up the epigenetic code, which is a series of specific 
changes in each eukaryotic cell, which adds an additional level of specificity 
above that of genes [88].  In addition, packaging of nucleosomes into higher 
orders of structure creates a physical barrier, which prevents molecular 
machinery from accessing information encoded in DNA for gene 
expression, replication and chromosome stability [89] . 
The histone code itself is generated by post-translational modifications to 
histone tails, which include acetylation, methylation, phosphorylation, ADP-
ribosylation, ubiquitination and sumoylation [90].  These modifications 
affect the electrostatic charge of the nucleosomes, which in turn affects the 
structure of chromatin, altering silencing or activation of chromatin domains 
[88].  The more open the chromatin structure, the more transcriptionally 
active it becomes, illustrated in Figure 1.2, where ESCs have an open, active 
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chromatin structure compared to somatic cells whose comparatively closed 
structure leads to a lack of plasticity [91].   
 
 
 
 
Figure 1.2 Schematic representing chromatin structure of ESCs and somatic cells.  
In ESCs chromatin is decondensed while in somatic cells regions of condensed 
heterochromatin form.  Green circles represent active histone marks while red 
circles represent silencing histone marks.  Adapted from [91] 
 
 
Although these changes are epigenetic and heritable they are also reversible 
and form part of the core regulatory machinery in cellular reprogramming.  
In order for somatic cells to be reprogrammed they must be converted from 
a differentiated cell to a default nuclear state.  This involves genome-wide 
epigenetic reprogramming, which is required in order to stimulate erasure of 
the somatic epigenetic memory, generating relatively naive chromatin with 
a broader developmental potential, known as the erase and re-build strategy 
[92].   
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One example of using chromatin-modifying agents to enhance 
reprogramming is inhibition of histone deacetylases (HDACs) using 
valproic acid (VPA), which results in reprogramming of human fibroblasts 
in the absence of Sox2 and c-Myc [93].  Similarly, inhibition of the histone 
methyltransferase G9a, using a small molecule BIX-01924, successfully 
reprogrammed mouse neural progenitors (NPCs) in the absence of Sox2 or 
c-Myc, at the same efficiency reported for four factor reprogramming.  
Inhibition of G9a can also successfully replace Oct4, which is consistent 
with events occurring during development; G9a functions to epigenetically 
silence Oct4 therefore subsequent inhibition allows reversal of this 
modification in somatic cells [94].  In an attempt to identify other small 
molecules that could synergise with BIX to improve the low efficiency of 
reprogramming, Shi et al. discovered a novel compound now recognised as 
BayK.  This calcium channel agonist does not demonstrate any identifiable 
reprogramming activity in the absence of BIX and rather than acting at the 
epigenetic level this molecule affects the cell at the signal transduction 
level.  However in combination with BIX this small molecule can further 
improve reprogramming efficiency and effectively compensate for Sox2 
enabling reprogramming of MEFs using Oct4 and Klf4 [95].  Together this 
demonstrates that erasure of a somatic epigenetic state is preferable in order 
to establish pluripotency. 
Modification of key signalling pathways, such as Wnt signalling, can also 
improve efficiency of reprogramming. Activation of this pathway is 
initiated by binding of Wnt proteins to frizzled and LRP cell surface 
receptors leading to signal transduction.  Wnt signalling inhibits the amino-
terminal phosphorylation of β-catenin mediated by GSK-3, which prevents 
β-catenin degradation.   Unphosphorylated β-catenin is able to translocate to 
the nucleus, where it interacts with members of the Lef1/Tcf family of 
HMG domain-containing DNA-binding proteins to activate target genes. 
These DNA-binding transcription factors activate transcription in the 
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presence of a Wnt signal and repress expression of target genes in the 
absence of a Wnt signal [96]. 
Exploiting this pathway, chemical inhibition of GSK-3 has been shown to 
facilitate reprogramming of human fibroblasts [48]. An aminopyrimidine: 
CHIR99021, is the most selective inhibitor of GSK-3 reported to date with 
350-fold selectivity toward GSK-3 compared with other potent inhibitors 
[97].  Combined inhibition of GSK-3 and mitogen activated protein kinase 
(MAPK) signalling also enhances reprogramming of NSCs and drives 
conversion of partially reprogrammed cells to pluripotency [98].  This is 
consistent with research demonstrating GSK-3 and MAPK inhibition are 
sufficient to maintain undifferentiated mESCs [99].  Inhibition of 
differentiation pathways enhancing reprogramming provides further 
evidence that reprogramming requires inhibition of lineage-specific genes 
and induction of a more primitive state.  In addition it should be noted that 
small molecules offer low host immunogenicity and lack permanent genome 
modification.  In addition, large scale production of small molecules is 
much simpler compared with viral vectors therefore offering a number of 
advantages. 
 
1.7 Direct Reprogramming  
Direct reprogramming of one specific cell type to another is one way of 
tackling autologous cell replacement therapies without establishing 
pluripotency. Through circumventing the pluripotent state, issues associated 
with tumorigenesis are largely removed while on the whole direct 
conversion of a mature somatic cell to another is altogether a much simpler 
process that can be acquired using fewer exogenous factors.   
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The first examples of direct reprogramming were reported in the 1980s with 
direct conversion of MEFs into muscle cells through forced expression of 
MyoD as previously described [39].  MyoD was subsequently used in many 
reprogramming studies and it was discovered that this transcription factor 
could convert many different cell types into myoblasts including dermal 
fibroblasts, chondroblasts, smooth muscle and retinal epithelial cells [100]. 
The first report that lineage committed cells could be transdifferentiated 
using transcription factors came in 2004 with B lymphocytes being 
converted to macrophages using the transcription factor C/EBPα [40].  
Since then, large numbers of cells have been converted into a variety of 
lineages using combinations of transcription factors.  One example of this is 
the conversion of fibroblasts into excitatory neurones, termed induced 
neurones (iNs) using a three factor combination of Ascl, Brn2 and Mytl1.  
iNs were generated using lentiviruses encoding the three reprogramming 
factors and upon expression of Tau, a microtubule-associated protein, cells 
co-expressed green fluorescent protein enabling neuronal identification. 
Extensive electrophysiological studies confirmed that iNs function as 
neurons in vitro [101]. 
Fibroblasts have also been directly reprogrammed into induced 
cardiomyocytes (iCMs) using Gata4, Mef2c and Tbx5, identified from a 
pool of 14 factors.  iCMs exhibit spontaneous contractions in vitro and when 
injected into mouse hearts, differentiate to form small isolated 
cardiomyocyte-like cells in vivo [102].  This further supports the argument 
that cells need not be fully reverted to pluripotency and instead directly 
reprogrammed to yield desirable, functional phenotypes.  
Unlike multi-factor reprogramming demonstrated in previous studies Szabo 
et al. detailed conversion of human fibroblasts into multilineage 
hematopoietic precursors using over expression of a single factor.  In this 
example expression of Oct4 initiated haematopoiesis without reverting cells 
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through a pluripotent intermediate or activating mesodermal pathways.  This 
report is somewhat unusual as Oct4 is not typically required for 
haematopoietic cell maintenance however it was proposed that in this case 
Oct4 binds the regulatory loci of haematopoietic-specific genes stimulating 
the expression of transcription factors required for a multipotent blood cell 
progenitor phenotype [103].  It has also been suggested that over expression 
of Oct4 allows cells to reach a near multipotent state so that in the presence 
of haematopoietic cytokines they could then differentiate towards a 
haematopoietic lineage.  Driving cells towards an intermediate pluripotent 
state has also been explored by Kim et al who induced murine fibroblasts 
into neural progenitors (NPCs) through transient expression of OKSM 
before exposure to neuronal cell culture conditions [104].  A similar 
investigation exposed MEFs to transgenic expression of OKSM for 4 days 
to gain a transient, plastic developmental state before directly differentiating 
into cardiomyocytes [105].  
Directing reprogramming of somatic cells is clearly feasible however the 
molecular mechanisms underpinning this dedifferentiation process remain 
largely unknown.  Specifically, it remains unclear whether a cell reverts to a 
progenitor before undergoing differentiation or rather directly differentiates 
into the terminal phenotype. However, dedifferentiation of somatic cells into 
desirable lineages undoubtedly presents a more elegant approach to 
reprogramming than the more robust method of reversing cell fate to 
pluripotency followed by differentiation to yield functional lineages. 
 
1.8 MicroRNA 
More than a decade since discovery of the first MicroRNA (miRNA), lin-4 
[106], we now know that miRNAs constitute ~1% of the eukaryote genome, 
however the cellular functions of many miRNAs remain unknown.   
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MiRNAs are non-coding RNAs, typically 20-22 nucleotides in length, 
which significantly impact almost every aspect of cellular biology [107].  
Their primary function is to control gene expression through regulation of 
specific messenger RNAs (mRNA) mediated by base-pairing interactions.  
The majority of miRNA-mRNA targeting occurs between a short sequence 
located at the 5‟ end of the miRNA, known as the seed sequence and the 
complementary sequences within the 3‟ untranslated region of the 
corresponding target mRNA.  Binding leads to destabilisation of mRNA or 
inhibition of protein synthesis [108] as illustrated in Figure 1.3. 
 
 
Figure 1.3 Schematic of protein inhibition with miRNA [109] 
 
MiRNA processing is crucial for production of mature miRNAs and is 
clearly illustrated in Figure 1.4.  Initial cleavage of primary miRNA 
transcripts (pri-miRNAs) is catalysed by the nuclear RNase III Drosha 
together with the double stranded RNA binding protein DGCR8/Pasha, to 
produce an imperfect stem-loop precursor miRNA (pre-miRNA) [110]. Step 
2 involves Exportin 5, which transports pre-miRNA across the nuclear 
membrane into the cytoplasm [111] where the cytoplasmic RNase III, Dicer, 
along with the transactivator RNA-binding protein (TRBP) produces 
imperfect double-stranded RNA duplexes.  The double-stranded RNA 
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consists of a mature miRNA strand and a complementary sequence.  During 
the final stage, the double stranded RNA is unwound and one strand enters 
an RNA-induced silencing complex (RISC) where argonautes are recruited 
for mRNA recognition and silencing [112].  The mature miRNA goes on to 
target mRNA either through mRNA cleavage or translational repression. 
 
 
Figure 1.4 MiRNA biogenesis and processing [113] 
 
Traditionally, miRNA phenotypic studies have focused on small numbers of 
targets regulated by a specific miRNA.  However, it is becoming 
increasingly apparent that miRNAs influence cell fate decisions through 
suppressing hundreds of mRNAs contributing to many pathways.  A classic 
example is introduction of miR-124 into HeLa cells, a cervical cancer cell 
line, which results in a complete shift in their expression profile towards a 
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neural lineage.  Further investigation has now identified that a number of 
miR-124s targets are functionally associated with neuronal differentiation 
[114].   
A subset of the miR-290 cluster, known as the embryonic stem cell cycle 
(ESCC) regulating miRNAs have been shown to improve efficiency of 
reprogramming.  An example of this is introduction of miR-291-3p, miR-
294 and miR-295 to MEFs along with Oct4, Sox2 and Klf4, which were able 
to effectively replace c-Myc in promoting reprogramming [115].   
MiRNAs have also been shown to facilitate reprogramming of somatic cells 
in the absence of further inducing stimuli.   Lentiviral over expression of the 
miRNA302/367 cluster, which was first identified as a direct target of Oct4 
and Sox2, can successfully reprogram mouse and human cells. Moreover, 
this miRNA-mediated reprogramming is up to 100x more efficient than 
traditional four factor over expression [116].  
Another similar study demonstrated that transfection of mature, synthetic 
miRNAs, mir200c, mir302s and mir-369, at 48 hour intervals also 
successfully produced iPSCs from mouse and human somatic cells.  Despite 
demonstrating lower efficiency, the numbers of iPSCs produced remained 
comparable to four-factor retroviral over expression systems [117].  
Interestingly, only mir302s are common between this study and the 
lentiviral-mediated strategy performed by Anokye-Danso et al.   
The promoters of the miR-290 and miR-302 clusters are bound by 
Yamanaka‟s four original factors and it is already known that increasing or 
decreasing expression of specific miRNAs results in fluctuations in 
corresponding mRNA expression [118].  Therefore, it is likely that these 
miRNAs are acting through their corresponding mRNAs to activate 
pluripotency.  The high efficiency experienced using miRNA for 
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reprogramming is also likely due to the fact that miRNA targets hundreds of 
mRNAs, compared to providing one mRNA at a time.  
One miRNA of particular interest is miR-145, due to its association with 
major pluripotency regulators; Oct4, Sox2 and Klf4, all of which feature in 
Yamanaka‟s classic combination of reprogramming factors.  miRNA 
profiling of embryoid body differentiation by Xu et al. uncovered a large 
increase in miR-145 expression upon hESC differentiation.  Reporter 
studies were able to pinpoint transcripts encoding Oct4, Sox2 and Klf4 as 
targets of miR-145 while gain- and loss-of-function experiments were able 
to demonstrate that forced expression of miR-145 prevented self-renewal of 
hESCs and inhibition of mir-145 had the opposite effect.  Another important 
finding of this study was identification of an Oct4 binding site upstream of 
miR-145 which together with reporter assays suggested that Oct4 occupies 
this site repressing transcription of miR-145 [119].  Given the role miR-145 
plays in the switch between pluripotent and committed cell lineages this 
miRNA may be exploited to enhance reprogramming of somatic cells. 
Researchers have long suspected a strong link between the molecular 
signature of cancer and stem cells; however this still remains largely 
unknown.  Neveu et al. developed a miRNA map through examining 
miRNA expression profiles of numerous cancer and stem cells, identifying 
almost 330 miRNAs in over 50 human cell lines and highlighting 11 
miRNAs shared by all cancer cells and a subset of pluripotent stem cells.  
Interestingly, each of these miRNAs targets genes responsible for down-
regulating proliferation or upregulating the p53 network [120] .   
The p53 pathway plays an important role in impeding cellular 
reprogramming.  Exemplified by inhibition of this pathway, which enhances 
efficiency of this process up to 100-fold [121]. Alternatively, using p53 null 
cells, up-regulating a negative regulator of p53, knocking down p53 or 
knocking down one of its targets, such as p21, also increases efficiency of 
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reprogramming up to 25-fold.  One example is the conversion of mouse 
fibroblasts to pluripotency using Oct4 and Sox2 alone in the presence of 
decreased levels of p53.  Interestingly keratinocytes, which have a higher 
reprogramming efficiency than fibroblasts, display lower protein levels of 
p53 and p21 than other cell types providing further evidence for the 
influential role of this pathway [122] .  Importantly p53 acts as a checkpoint 
to prevent cells with damaged DNA and chromosomal abnormalities 
prevailing [121] therefore cells reprogrammed by directly manipulating the 
p53 pathway would not be suitable for clinical use due to risks associated 
with mutated DNA.   
The role of p53 during reprogramming raises important questions about how 
p53 knockdown can exert such a pronounced effect.  If we consider miR-
145, we already know that this miRNA is essential for differentiation of 
ESCs by modifying the translation of Oct4, Sox2 and Klf4.  Interestingly 
p53 promotes the maturation of precursor miR-145 to the mature miR-145 
[123] so may provide a possible mechanism for the ability of p53 to alter 
reprogramming.  Specifically, disruption of p53 may lead to a decrease in 
mature miR-145, which in turn increases pluripotency gene transcripts as 
illustrated in Figure 1.5.  It is therefore possible to speculate that miR-145 
itself may influence the reprogramming of somatic cells. 
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Figure 1.5 proposed roles for miR-145 in reprogramming 
 
1.9 The Donor Cell 
The list of donor cells that have given rise to iPSCs continues to increase 
and to date iPSCs have been derived from a diverse range of cell type 
including CD34+ peripheral blood cells [124], kidney mesangial cells [125], 
amniocytes [126] and T lymphocytes [127] to name but a few.  
As detailed earlier, reprogramming can be achieved with different 
efficiencies and outcomes.  This is largely dependent on donor cell type 
with some cells being more amenable to reprogramming than others. To 
exemplify this, using the same process it can take between 8-12 days to 
reprogram MEFs, while human foreskin fibroblasts (HFFs) can take 
between 20-25 days to undergo the same transformation.  Many studies 
have compared the reprogramming capacity of alternative cell types, such as 
human fibroblasts and keratinocytes, with keratinocytes being 
reprogrammed up to 100 times more efficiently and two-fold faster [128].   
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Human umbilical vein endothelial cells (HUVECs) have been identified as 
one of the most efficiently reprogrammed cells to date with the fastest 
kinetics and highest efficiencies.  HUVEC-derived iPSCs appear as early as 
6 days after a single retroviral infection of Oct4, Sox2, Klf4 and c-Myc 
whilst demonstrating 2.5–3% efficiency. Furthermore, when HUVEC 
reprogramming was performed under hypoxia in the presence of a TGF-β 
family signalling inhibitor, colony formation increased an additional 2.5-
fold over standard conditions [80]. 
Other cell types, which require reduced numbers of factors are cord blood 
CD133+ cells that have been successfully reprogrammed using just Oct4 
and Sox2 [129] and NPCs, which can be reprogrammed through forced 
expression of Oct4 alone [55].  Differences in efficiency, kinetics and factor 
requirements can largely be attributed to higher endogenous levels of 
pluripotency factors, for example the high levels of Sox2 endogenously 
expressed by NPCs, which removes requirement for exogenous Sox2. 
 
1.10 Delivery of Inducing Stimuli 
1.10.1 Retroviruses 
Viruses have proven extremely useful tools in providing an efficient gene 
delivery system to primary cells, which are typically difficult to transfect.  
Retroviruses are infectious particles consisting of an RNA genome 
packaged within a protein capsid contained within a lipid envelope [130] as 
illustrated in Figure 1.6. 
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Figure 1.6 Structure of a retrovirus 
While transcription typically refers to conversion of DNA to RNA, 
retroviruses carry out this process in reverse hence the prefix „retro‟.  
Packaged within the protein capsid along with the viral RNA is the enzyme 
reverse transcriptase (RTase), which is able to synthesise complementary 
DNA (cDNA) from the RNA template in the cytosol of host cells upon 
infection [130].   
One of the characteristics of stem cells that distinguish them from somatic 
cells is their ability to silence retroviruses by de novo methylation [131].  
Successfully reprogrammed cells demonstrate silencing of Oct4, Sox2, c-
Myc and Klf4 genes, while partially reprogrammed cells exhibit incomplete 
silencing.  Silencing of retroviral genes during reprogramming is a gradual 
process that occurs as early as 4 days after induction of transcription factors 
and is only completed in cells that have reached a pluripotent state [78].  
Therefore initial attempts at reprogramming somatic cells utilised Moloney 
murine leukaemia-based retroviral vectors, which were known to undergo 
silencing in the pluripotent state [132].  It was due to their self-silencing 
properties that they became established as an attractive means of delivering 
transcription factors because the temporal requirement for factor expression 
was at the time undefined.   
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To facilitate delivery of inducing stimuli, genes encoding required 
transcription factors are artificially added to viral RNA so that they too are 
copied.  This integration step enables these genes to be inserted into host 
DNA however it is also this integration step, which makes these viruses 
unsuitable for clinical use due to risks associated with insertional 
mutagenesis [133].  Reverse transcription lacks the usual proofreading step 
that occurs during DNA replication, therefore mutations occur more 
frequently.  Also new genes are inserted at arbitrary points in the host DNA, 
which can harmfully affect the function of native genes while viral 
transgene reactivation may occur in reprogrammed cells leading to 
tumorigenesis as demonstrated in iPSC-derived chimeric mice [50].  These 
risks present a major limitation in deriving cells generated by retroviral 
infection to a pharmacopeia grade therefore suitable alternatives need to be 
sought. 
 
1.10.2 Lentiviruses  
Drug inducible lentiviruses share similar characteristics to retroviruses, with 
respect to genomic integration.  They provide an effective means of 
investigating events occurring during reprogramming as they allow 
temporal control over gene expression [51].  Lentiviruses have also proved 
useful by generating secondary systems, which involves production of 
iPSC-derived differentiated cells that have proviral integrations in their 
genomes in the same pattern that allowed primary iPSC production.  Upon 
secondary induction, the viral transgenes are reactivated leading to a 100-
fold increase in secondary iPSC generation [134].  This system has provided 
a means of screening chemicals and genes that enhance reprogramming. 
The low efficiency of reprogramming using viral vectors suggests that viral 
integration into specific genomic sites may be essential for reprogramming.  
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Viral integration sites were subsequently mapped in several mouse iPSC 
lines with no common integration sites identified [135].  Although a wider 
study would need to be performed to rule out the effect of insertional 
mutagenesis completely it does suggest that reprogramming is due to 
specific factors introduced irrespective of their integration sites.  The ability 
of adenoviruses to reprogram differentiated cells without viral integration 
into the genome also provides strong evidence against the idea that 
reprogramming is dependent upon viral integration into specific genomic 
loci leading researchers to conclude that it may be feasible to develop non-
integrative measures to stimulate cellular reprogramming.   
 
1.10.3 Non-Integrating Gene Delivery 
Non-integrating gene delivery techniques have been developed over recent 
years to overcome complications associated with sustained transgene 
expression and insertional mutagenesis.  The first integration-free iPSCs 
were generated using non-integrating adenoviruses combined with transient 
transfection [136].  As well as demonstrating feasibility of non-viral 
methods for reprogramming this also provided proof of principle that 
transient expression of the four classical reprogramming factors was 
sufficient to generate iPSCs.   
A significant difference between adenoviruses and retroviruses is that 
genetic material of the former consists of double-stranded DNA, like the 
DNA of the host. When an adenovirus infects a cell, its DNA is transcribed 
within the host cell‟s nucleus before being translated using the same 
processes used by the host cell.  This lack of integration is the reason that 
adenoviruses are favored for reprogramming compared to retroviruses 
[137].  Despite obvious advantages, a major drawback using adenoviruses is 
their low rate of efficiency, with 0.0001% to 0.001% of cells successfully 
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reprogrammed [85].  Another concern is that in one study, 3 out of 13 
adeno-iPSC lines were identified as tetraploid, which has not been observed 
using retroviruses or lentiviruses [136]. 
Another non-integrating method makes use of Epstein-Barr virus to generate 
an Epstein-Barr nuclear antigen-1 based episomal (oriP/EBNA1) vector.  
This vector can be transfected into somatic cells without viral packaging and 
later removed through drug selection.  As such, exogenous DNA is not 
integrated into resulting iPSCs producing vector- and transgene- free iPSCs 
after multiple rounds of cell division.  Despite the clear advantages of this 
system, the reported efficiency using this non-integrating method is very 
low with only 0.0003-0.0006% of cells successfully reprogrammed [138]. 
Research to date suggests that non-integrating methods of reprogramming 
are of typically extremely low efficiency, as insufficient factor expression 
results in a failure to induce complete epigenetic remodelling.  Attempts to 
overcome this led to the generation of integration dependent delivery 
vectors.  Doxycycline (DOX)-inducible lentiviral vectors containing a loxP 
site within the 3‟ long terminal repeat were developed so that transgenes 
could be subsequently removed following complete reprogramming using 
Cre-recombinase-mediated excision [139].  Despite the complete removal of 
transgenes using this method, residual vector sequences remain, therefore 
not completely removing risks associated with insertional mutations. 
Transgene-free reprogramming has also been achieved using piggyBac (PB) 
transposition.  PB transposon is a mobile genetic element that efficiently 
transposes between vectors and chromosomes via a „cut and paste‟ 
mechanism.  During this process transposase, an enzyme that catalyses this 
insertion or excision, recognises inverted terminal repeat sequences located 
at both ends of the transposon vector and efficiently integrates them into 
chromosomal sites.  The unique feature of this system is that the PB vector 
can be re-excised using transposase, leaving the genome transgene-free.  
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Successful and efficient reprogramming of murine and human fibroblasts 
has been reported using doxycycline-inducible transcription factors 
delivered using PB transposition.  However, like many non-integrating 
systems PB transposition also suffers from low efficiency of ~0.001% and 
may also leave behind residual vector sequences [84]. 
 
1.10.4 Proteins 
Successful reprogramming has recently been achieved in the absence of 
vectors through delivery of inducing factors as purified recombinant 
proteins or as whole cell extracts isolated from ESCs [86, 140, 141].  While 
this presents an attractive approach to reprogramming with the generation of 
transgene-free protein induced pluripotent stem cells (piPSCs), the 
efficiency of this process is extremely low and requires addition of small 
molecules, such as VPA to stimulate reprogramming [86].  Overcoming this 
has been demonstrated by delivery of synthetic mRNA molecules encoding 
reprogramming factors into somatic cells, which led to multiple cell lines 
termed RNA induced pluripotent stem cells (RiPSCs) [142]. 
 
1.10.5 Lipofection 
Lipofection is another non-viral method, which has been successfully used 
to deliver plasmids to induce reprogramming of somatic cells [143, 144].  
Lipofection is a lipid-based transfection technique, which can be effectively 
used to deliver DNA.  Lipofection was developed when scientists 
discovered that mixing lipids with DNA in water formed spheres known as 
liposomes containing a DNA core.  These liposomes were able to fuse with 
plasma membranes and internalised via endocytosis [145].  There are three 
types of lipids: anionic, neutral, or cationic; which are negative, neutral and 
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positively-charged respectively.  Initially, anionic lipids were used to 
produce liposomes; however they proved complex and time consuming to 
create.  Therefore attention turned to cationic lipids, which easily combine 
with negatively-charged DNA due to their positive charge.  When combined 
with DNA, cationic lipids spontaneously change to form structures known 
as lipoplexes, which are much more complex than simple liposomes.  Once 
they are prepared under appropriate conditions, lipoplexes maintain an 
overall positive charge, enabling them to efficiently bind negatively charged 
cell membranes and are subsequently internalised by endocytosis [146].   
Their organised structure helps protect DNA during transfection as DNA 
can become damaged upon entering the cell.  Lipoplexes taken up via an 
endocytic pathway would usually result in fusion with lysosomes and 
subsequent DNA degradation would occur.  Neutral helper lipids, such as 
dioleoylethanolamine (DOPE), are typically included with the cationic lipid, 
allowing entrapped DNA to escape the endosomes and migrate to the 
nucleus [147].  Although this method of gene delivery has fewer variables 
than alternative transfection techniques it does result in low efficiencies, 
therefore its application in reprogramming of somatic cells has been 
somewhat limited [144].    
 
1.10.6 Nucleofection 
Another non-viral transfection technique that may be used to deliver 
reprogramming factors to somatic cells is nucleofection.  This 
electroporation-based technique enables efficient transfer of nucleic acids, 
such as DNA and RNA into cells.  Nucleofection uses optimised electrical 
pulses generated by a device called a nucleofector with cell specific reagents 
to efficiently deliver nucleic acids to target cells [148].  Most transfection 
procedures transfer DNA to the cytoplasm and can only enter the nucleus 
upon disintegration of the nuclear envelope during cell division [149].    
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During nucleofection, the combination of cell-specific nucleofection 
solution and electrical pulses enables DNA to enter the nucleus.  This is the 
only non-viral method of introducing DNA into nuclei directly, which 
greatly increases the chance of chromosomal integration [148].  Unlike viral 
vectors, which are integrated via viral genome integration mechanisms, the 
exact mechanism by which nucleofection integrates nucleic acids is 
unknown.  However it has been hypothesised that integration into 
chromosomal DNA may occur through the cell‟s DNA repair and 
recombination enzymes [150]. 
As discussed previously, transfection of primary cells with common non-
viral methods, such as liposome-mediated transfer has proved problematic 
with low efficiencies reported.  This technique has been used successfully to 
transfect a variety of cell types including primary myoblasts [151], ESCs 
[152], NSCs [153] and of particular interest to this study, keratinocytes at 
relatively high efficiencies.  One study reports transfection of primary 
human epidermal keratinocytes  at an efficiency of 56%, the highest level of 
non-viral transfection reported [154].  Nucleofection has also been used to 
successfully reprogram human adipose stem cells (hADSc) through delivery 
of a minicircle vector containing a single cassette of Oct4, Sox2, Lin-28 and 
Nanog.  In addition, each transgene was separated by sequences encoding 
the self-cleaving peptide 2A, therefore generating transgene-free iPSCs in 
the absence of drug selection [144]. 
Optimal nucleofection conditions are not substrate dependent, therefore 
identical conditions are used for the nucleofection of DNA, RNA, siRNAs, 
shRNAs, mRNAs and other biologically active molecules.  As such, 
switching between substrates or performing co-transfections is much 
simpler using this technique.  Another benefit is that nucleofection can be 
used as a transient or stable transfection technique depending upon the 
desired outcome [148].  A transient approach is considered more attractive 
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with a view to clinical application as it excludes genomic integration, 
however this approach may involve the repeated transfection of inducing 
factors to stimulate reprogramming.    
 
1.11 IPSC Differentiation 
The major promise of iPSCs is that we can generate patient-specific cells for 
use in a vast array of cell therapies.  Many consider iPSCs superior to other 
resident progenitor cells due to their pluripotent characteristics however in 
order to harness this potential it is necessary to develop defined 
differentiation strategies to ensure the homogenous differentiation of iPSCs.  
The majority of differentiation protocols thus far have been derived from 
our knowledge of hESC differentiation however this is far from defined 
therefore the same problems that researchers face in deriving lineage 
specific cells from hESCs also apply to iPSCs.  Despite drawbacks a variety 
of functional cells have been derived from iPSCs including fetal-like red 
blood cells [155], retinal pigment epithelium (RPE) [156], MSCs [157] and 
hepatocytes [158] along with a number of disease-specific iPSCs including 
Parkinson‟s [139], lung disease [159] and acquired blood disorders [160].  
One of the most widely investigated lineages is iPSC-derived 
cardiomyocytes [161, 162] , likely due to the well established protocols for 
hESC-derived cardiomyocyte differentiation.   This rapid progression is 
exemplified with reports of large scale cardiomyocyte production with 
standardised, scalable processes able to manufacture hundreds of billions of 
cardiomyocytes for drug testing by the pharmaceutical industry [163].  This 
demonstrates that iPSCs are already able to provide a useful tool to 
efficiently select drug candidates and the focus for the future will be on 
developing safer ways of reprogramming to enable the development of 
cellular therapies. 
 38 
 
1.11 Hypothesis 
Reprogramming somatic cells circumvents not only
 
the ethical issues 
associated with the use of human embryos for research
 
but also provides a 
source of cells, which are patient specific.  To date most reprogramming 
strategies have employed viral vectors for the delivery of foreign genetic 
material, rendering the resultant cells unsuitable for therapeutic purposes.  
Therefore reprogramming cells in the absence of viral vectors whilst 
reducing the amount of genetic material used will offer significant advances 
for regenerative medicine. 
 
We hypothesised that a non-viral method of introducing both plasmid DNA 
and miRNA could provide an attractive alternative to viral reprogramming.  
In order to progress from traditional methods of reprogramming a novel, 
miRNA mediated approach was sought to revert the fate of differentiated 
hEKs isolated from the epidermis of normal adult donors.  The subsequent 
biological and genomic effects of inhibiting a specific miRNA, miR-145, 
known to be implicated in the maintenance of a pluripotent phenotype 
would need to be investigated.  In addition, we hypothesised that providing 
miR-145 inhibited hEKs with a microenvironment akin to that of hESCs 
would further stimulate the expression of endogenous pluripotency-
associated genes therefore a combination of extracellular matrix protein and 
stimulatory growth factors known to maintain the expression of hESCs 
would be evaluated.  In order to develop a clinically translatable approach it 
was hypothesised that a direct reprogramming strategy would be beneficial 
therefore one of the main drivers for this investigation was to direct the 
differentiation of miR-145 inhibited hEKs to derive functionally competent 
cells. 
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Figure 1.7 Reprogramming hEKs: A non-viral miRNA hypothesis 
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2.0 Materials & Methods 
 
2.1 Cell Culture 
2.1.1 Adherent Culture hEKs 
 
Primary hEKs were isolated from normal adult skin from multiple donors of 
both sexes (Invitrogen) and maintained in an animal product-free 
environment on plasma-treated tissue culture polystyrene (TCP) (Scientific 
Laboratory Supplies, UK) pre-coated with 1% human Type-I collagen (hCol 
I) for 30 minutes at room temperature.  hEKs were maintained in Epilife 
Media containing 1% S7 growth supplement, 1% 10,000 U/mL penicillin 
and 10mg/mL streptomycin.  Cell culture reagents were purchased from 
Invitrogen, UK unless stated otherwise.   
 
Upon reaching 75% confluence hEKs were passaged as follows: media was 
aspirated and the adherent cell monolayer washed with phosphate buffered 
saline (PBS) for 5 minutes at room temperature to remove residual protein 
which may inhibit enzymatic dissociation.  PBS was replaced with  
recombinant trypsin 10x, 0.2% ethylenediaminetetraacetic acid (ETDA) 
(Sigma Aldrich, UK) and 0.5% trypsin diluted to a working concentration of 
10% (v/v) in PBS.  Trypsinisation was performed at 37°C for 3-5 minutes.  
Cell detachment was monitored using transmitted light microscopy until 
approximately 90% of cells had detached, at which point trypsinisation was 
neutralised by addition of an equal volume of sterile defined trypsin 
inhibitor containing 0.0125% purified soybean trypsin inhibitor in PBS.  
The trypsin/cell suspension was centrifuged at 2000g for 5 minutes at 4°C to 
retrieve cells.  The resulting supernatant was aspirated and the remaining 
cell pellet resuspended in the required volume of Epilife media, pre-warmed 
to 37°C and reseeded at a density of 5.0 x10
3
 cells/cm
2
 before incubation at 
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37°C, in a humidified atmosphere, containing 5% CO2.    Culture media was 
refreshed 24 hours after seeding then every 3
rd
 day until confluence.   
 
2.1.1.1 Suspension Culture hEKs 
hEKs were maintained on TCP pre-coated with hCol I in Epilife media and 
cells from passage 2-5 were used in subsequent experiments.  Upon 
reaching 75% confluence hEKs were harvested as detailed in section 2.1.1 
and enumerated.  To induce terminal differentiation, hEKs were 
resuspended at a seeding density of 1x10
5
 cells/mL in DMEM (Invitrogen, 
UK) supplemented with 1.5% methyl cellulose (Sigma Aldrich, UK) (w/v), 
10% fetal bovine serum (FBS) (Lonza, UK) (v/v), 1% 10,000 U/mL 
penicillin and 10mg/mL streptomycin.  Cells were incubated at 37°C, in a 
humidified atmosphere, containing 5% CO2. 
 
 
2.1.2 Human Embryonic Stem Cells 
 
Human embryonic stem cells (hESCs), derived from the HUES7 cell line, 
were obtained from Harvard University (hES Cell Facility/Melton 
Laboratory, MA, USA).  hESCs were maintained on TCP, pre-coated for 1 
hour with 50µg/mL of human plasma fibronectin (hFN) (Millipore, UK) in 
PBS (v/v), at 37°C.  hESCs were sustained in 50:50 F12/DMEM media 
(Lonza, UK) supplemented with 10ng/mL Activin A (R&D, UK), 4ng/mL 
neurotrophin 4 (NT4) (Preprotech, UK), 40ng/mL basic fibroblast growth 
factor (bFGF) (Autogen Bioclear, UK), N-2 supplement (10g/L transferrin, 
500mg/mL insulin, 0.63mg/L progesterone, 1.611g/L putrescine), B-27 
supplement (components undisclosed), 2mM L-glutamine, 1% non-essential 
amino acids, 0.1mM β-mercaptoethanol (Invitrogen, UK) and 0.1% bovine 
serum albumin (BSA) (Sigma, UK). 
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When hESCs had reached approximately 75% confluence, media was 
removed and adherent cells washed with PBS for 5 minutes at room 
temperature.  PBS was replaced with 5% recombinant trypsin, 2% ETDA 
(Sigma Aldrich, UK) diluted to a working concentration of 1% (v/v) in PBS, 
and detachment was performed at 37°C for less than 1 minute.  
Trypsinisation was monitored using transmitted light microscopy until 
approximately 90% of cells detached.  At this point trypsinisation was 
neutralised by addition of an equal amount of Dulbecco‟s modified eagle 
medium (DMEM) (Invitrogen, UK) containing 10% FBS (Lonza, UK) 
(v/v).  The trypsin/cell suspension was spun at 2500g for 3 minutes at 4°C to 
retrieve cells.  The supernatant was aspirated from the cell pellet, which was 
then resuspended in culture media, pre-warmed to 37°C.  Cell suspension 
was distributed into the required number of tissue culture vessels at a 
density of 1.0 x 10
4
cells/cm
2
 and incubated at 37°C, in a humidified 
atmosphere, containing 5% CO2.  Culture media was refreshed 24 hours 
after seeding then on alternate days with fresh media pre-warmed to 37°C 
until cells reached confluence.   
 
 
2.1.3 Human Mesenchymal Stem Cells 
 
Human mesenchymal stem cells (hMSCs) were maintained on conventional 
TCP in mesenchymal stem cell basal media (MSCBM) supplemented with 
SingleQuots Bulletkit containing 10% mesenchymal stem cell growth 
supplement (MSCGS), 2% L-glutamine and 0.1% gentamicin/amphotericin. 
All hMSC culture reagents were purchased from Lonza, UK unless stated 
otherwise.   
 
Upon reaching 75% confluence hMSCs were passaged as follows. Media 
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was aspirated and the adherent cell monolayer washed with PBS for 5 
minutes at room temperature.  PBS was replaced with 5% recombinant 
trypsin, 2% ETDA (Sigma Aldrich, UK) diluted to a working concentration 
of 10% (v/v) in PBS. Detachment was carried out at 37°C for 3-5 minutes 
and monitored using transmitted light microscopy until approximately 90% 
of cells had detached at which point the reaction was neutralised by the 
addition of an equal volume of pre-warmed hMSC media.  Trypsin/cell 
suspension was centrifuged at 2000g for 5 minutes at 4°C.  The resulting 
supernatant was aspirated and the remaining cell pellet resuspended in the 
required volume of hMSC media, pre-warmed to 37°C.  The cell suspension 
was distributed into the required number of tissue culture vessels at a 
density of 5.0 x10
3
 cells/cm
2 
diluted in sufficient media to permit long-term 
culture and incubated at 37°C, in a humidified atmosphere, containing 5% 
CO2.  Media was refreshed 24 hours after seeding then every 3
rd
 day until 
confluence.   
 
2.2 Nucleofection 
hEKs were passaged 7 days preceding nucleofection, cultured until 75% 
confluent with daily media changes. Reagents were purchased from Lonza, 
UK unless otherwise stated.  hEKs were dissociated using a 5% 
recombinant trypsin, 2% ETDA (Invitrogen, UK) diluted to 1% in PBS (v/v) 
and enumerated using a haemocytometer.  An appropriate volume of cell 
suspension was aliquoted into sterile falcon tubes to a working 
concentration of 7x10
5
 cells/mL. Trypsin/cell suspension was centrifuged at 
2000g for 5 minutes at 4°C and the resulting cell pellet was resuspended in 
100µL keratinocyte nucleofector solution and transferred to a sterile cuvette.  
In addition, either 2µg pmaxGFP plasmid (GFP-P) (Lonza, Germany), 
1.5µg miRNA hairpin inhibitor control labelled with Dy547 or hsa-miR-145 
hairpin inhibitor antisense oligonucleotide sequence:  
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GUCCAGUUUUCCCAGGAAUCCCU (Dharmacon, USA) were added to each 
cuvette.  Controls consisted of 7x10
5
 hEKs resuspended in 100µL 
keratinocyte nucleofector solution, minus the addition of either GFP-P or 
miRNA inhibitor.  Cuvettes were immediately inserted into the nucleofector 
device and selecting the T-024 program, nucleofection was performed.  
Immediately after nucleofection, 500µL of pre-warmed media was added to 
each sample and the contents transferred onto TCP substrates, pre-coated 
with either hCol I or hFN, within wells containing cell culture media pre-
warmed to 37°C.  Samples were incubated at 37°C, in a humidified 
atmosphere, containing 5% CO2.  After 24 hours media was exchanged in 
order to remove dead cells and refreshed every 3
rd
 day.  
 
2.3 Immunohistochemistry 
 
Cells were cultured on TCP cover slips and immunohistochemistry carried 
out in situ.  Cells were fixed using 4% (w/v) paraformaldehyde solution 
(Sigma Aldrich, UK); 4g of paraformaldehyde was dissolved in 100mL 
ddH2O at 60°C with continuous stirring for 10 minutes, solution was cleared 
using sodium hydroxide and pH adjusted to 7.2.   
 
Culture media was aspirated and samples washed in PBS (without Ca
2+
 or 
Mg
2+
) for 5 minutes at room temperature.  Samples were fixed using 4% 
paraformaldehyde solution for 10 minutes at 37°C and washed with PBS for 
5 minutes at room temperature.  Non-specific antigens were blocked by the 
addition of 10% (v/v) animal serum (Invitrogen, UK) in PBS for 1 hour at 
room temperature.  Specifically the blocking serum used was the same 
speciation as the desired secondary antibody.  Where the detection of 
intracellular antigens was required, 0.1% Triton-X100 (v/v) (Sigma Aldrich, 
UK) was also added to the blocking solution to permeabilise samples. 
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Blocking solution was aspirated and primary antibodies added at working 
concentrations given in table 2.1.  Primary antibodies were diluted in 1% 
animal serum (v/v)/PBS.  For intracellular antigens 0.1% Triton-X100 (v/v) 
was also included. Incubations were performed overnight at 4°C.  Negative 
controls to establish non-specific binding were setup by replacing primary 
antibodies with relevant isotype controls (Autogen Bioclear, UK).   
 
Following incubation with primary antibodies samples were washed 3 times 
with PBS for 5 minutes at room temperature to remove unbound antibody.  
Samples were incubated with appropriate fluorescently conjugated 
secondary antibodies diluted to working concentrations, given in table 2.2, 
for 1 hour at 37°C.  Secondary antibodies were diluted in 1% animal serum/ 
PBS and where intracellular staining was required, 0.1% Triton-X100 was 
included. Following incubation with secondary antibodies samples were 
washed 3 times with PBS for 5 minutes at room temperature to remove 
unbound antibody.  Counter-staining was performed by illuminating f-actin 
using phalloidin (Invitrogen, UK) at a working dilution of 1:100.  This 
phallotoxin is conjugated to an Oregon Green fluorochrome (Ex495, 
Em518nm) allowing visualisation of F-actin filaments.  Prior to 
visualisation, cells were counterstained with vector shield mounting medium 
(Vector Laboratories, UK), containing the fluorescent 4‟,6‟-diamidino-2-
phenylindole (DAPI) (Ex358, Em461), which specifically stains cell nuclei.  
Immediately after mounting, samples were visualised using laser scanning 
confocal microscopy (LSM 510, Carl Zeiss). 
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Antigen Speciation Reactivity Clonality Supplier Dilution 
Oct4 Mouse Human Monoclonal Santa Cruz 1:500 
Nanog Goat Human Monoclonal R&D, UK 1:200 
Sox2 Mouse Human Monoclonal R&D,UK 1:100 
TRA-1-81 Mouse Human Monoclonal Abcam,UK 1:500 
TRA-1-60 Mouse Human Monoclonal Abcam,UK 1:500 
SSEA3 Rat Human Monoclonal R&D,UK 1:100 
SSEA4 Mouse Human Monoclonal Abcam,UK 1:100 
Cytokeratin14 Mouse Human Monoclonal Abcam,UK 1:500 
Involucrin Mouse Human Monoclonal Abcam,UK 1:100 
CBFA1 Rat Human Monoclonal Abcam,UK 1:100 
Osteocalcin Mouse Human Monoclonal Abcam,UK 1:100 
Aggrecan Mouse Human Monoclonal Abcam,UK 1:100 
Type II Collagen Mouse Human Monoclonal Abcam,UK 1:100 
Leptin Rabbit Human Monoclonal Abcam,UK 1:50 
Neurofilament Mouse Human Monoclonal Abcam,UK 1:50 
B-III Tubulin Mouse Human Monoclonal Abcam,UK 1:50 
 
Table 2.1 Primary antibodies used in immunohistochemical staining 
 
Antigen Speciation Reactivity Conjugate Supplier Dilution 
IgG2b Goat Mouse AlexaFluor 594 Invitrogen,UK 1:2000 
IgG Rabbit Goat AlexaFluor 488 Invitrogen,UK 1:500 
IgG2a Goat Mouse AlexaFluor 594 Invitrogen,UK 1:500 
IgM Goat Mouse AlexaFluor 633 Invitrogen,UK 1:100 
IgM Goat Rat AlexaFluor 488 Invitrogen,UK 1:500 
IgG Goat Mouse AlexaFluor 488 Invitrogen, UK 1:100 
IgG Goat Rat Texas Red Invitrogen, UK 1:100 
IgG Donkey Mouse AlexaFluor 594 Invitrogen, UK 1:500 
IgG Chicken Rabbit AlexaFluor 594 Invitrogen, UK 1:500 
 
Table 2.2 Secondary antibodies used in immunohistochemical staining 
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2.4 Live/Dead Staining 
Live/dead reagents were supplied in kit form by Invitrogen, UK in 
combination with a Hoechst counter stain (Invitrogen, UK).  The Live/Dead 
viability kit contains two dyes, calcein AM and ethidium homodimer-1 
(EthD-1).  Live cells can be identified with calcein AM due to their 
intracellular esterase activity.  This enzyme converts non-fluorescent calcein 
AM into intensely fluorescent calcein (Ex494, Em520).  Dead cells can be 
distinguished through EthD-1, which is exclusively taken up by cells with 
damaged membranes, binding double stranded DNA (Ex510, Em595).  
Hoechst was used to stain cell nuclei irrespective of their viability (Ex350, 
Em461).  
Live/dead reagents were diluted in PBS to give working concentrations of 
0.1mM EthD-1 and 0.1mM calcein AM.  Hoechst was diluted in PBS to a 
working concentration of 3mg/mL.  Media was aspirated and adherent cells 
washed with PBS for 5 minutes at room temperature to remove residual 
esterase activity resulting from serum-supplemented media.   Equal amounts 
of each solution were added to the cells and incubated at 37°C for 30 
minutes.  Samples were then washed with PBS for 5 minutes at room 
temperature and visualised immediately using inverted fluorescent 
microscopy (Axiovert 200, Carl Zeiss) or quantified using flow cytometry. 
 
2.5 Quantification of Cell Attachment to HFN 
hFN was diluted in PBS and added to TCP substrates at defined  
concentrations and incubated at 37°C for 45 minutes to ensure complete 
coating.  hFN solution was aspirated and replaced with cell suspension 
containing 5x10
4
 hEKs before incubation at 37°C, 5% CO2.  24 hours post-
seeding, the culture media was removed and the cells washed twice with 
PBS ensuring only hEKs that had successfully attached remained in the 
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culture system.  hEKs were detached and enumerated using a 
haemocytometer.   
 
2.6 Trypan-Blue Exclusion Assay 
hEKs were harvested as detailed in section 2.1.1 and the resulting cell pellet 
resuspended in 1mL PBS.  An aliquot of cell suspension was mixed with an 
equal volume of 0.4% trypan blue and incubated at room temperature for 3 
minutes.  10µL of this mixture was then added to a haemocytometer and the 
stained (non-viable) and non-stained (viable) cells enumerated. 
 
2.7 Von Kossa Staining for Visualisation of Mineralisation 
Prior to Von Kossa staining the following solutions were prepared: 1% 
silver nitrate (AgNO3) (w/v) (Sigma Aldrich) in ddH2O, 2.5% sodium 
thiosulphate (w/v) (Sigma Aldrich, UK) in ddH2O and 1% acid alcohol 
solution (v/v) generated by diluting 1% 1M HCl (hydrochloric acid) (Sigma 
Aldrich, UK) in ethanol. 
 
Samples were fixed using 4% paraformaldehyde (w/v) (Sigma Aldrich, UK) 
for 10 minutes, followed by a 5 minute wash using PBS then 3 changes of 
ddH2O for 5 minutes each: All reactions were carried out at room 
temperature.  Samples were submersed in 1% AgNO3 solution and subjected 
to UV light excitation for 1 hour.  The 1% AgNO3 solution was then 
replaced with 3 changes of ddH2O for 5 minutes each.  Samples were 
incubated with a 2.5% sodium thiosulphate solution for 5 minutes to remove 
any residual silver and subject to 3 changes of ddH2O for 5 minutes each 
before counterstaining with Harris‟ haematoxylin (Sigma Aldrich, UK) for 5 
minutes.  Samples were „blued‟ under running ddH2O for 5 minutes, 
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differentiated in 1% acid alcohol for 3 seconds and finally washed using 3 
changes of ddH2O for 5 minutes each before mounting with aqueous 
mountant (Sigma Aldrich, UK) and immediately visualised using 
transmitted light microscopy.  Positive staining of phosphates appeared as 
dark brown/black staining whilst nuclei appeared blue. 
 
 
2.8 Alizarin Red S Staining for Visualisation of Calcification 
 
Alizarin Red S can be used to identify calcium deposits, however it does not 
exclusively stain calcium since magnesium, manganese, barium, strontium 
and iron may also interfere with Alizarin Red S staining.  The presence of 
calcium results in the formation of an Alizarin Red S-calcium complex in a 
chelation process. 
 
Prior to staining, a 2% Alizarin Red S solution (w/v) was prepared by 
dissolving 2g of Alizarin Red S (w/v) (Sigma Aldrich, UK) in 100mL of 
ddH2O.  The pH of this solution was then adjusted to 4.1 through drop-wise 
addition of NaOH.   
 
Samples were fixed using a 4% paraformaldehyde solution for 10 minutes: 
All reactions were carried out at room temperature.  Post-fixation, this 
solution was aspirated and the samples washed 3 times with ddH2O for 5 
minutes each.  Samples were incubated in 2% Alizarin Red S for 5 minutes 
and the reaction was observed microscopically. Excess Alizarin Red S was 
blotted from the samples using filter paper (Whattman, UK) and 
subsequently dehydrated through immersion in 100% acetone (Fisher 
Scientific, UK) for 1 minute, followed by 50% acetone-xylene solution for 1 
minute before clearing in 100% xylene (VWR, UK).  Finally, samples were 
mounted with DPX mounting medium (VWR, UK) before visualisation 
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using transmitted light microscopy.  Positive staining of calcium deposits 
was observed as orange-red staining. 
 
 
2.9 Van Gieson Staining for Visualisation of Collagen 
 
Prior to Van Gieson staining the following solutions were prepared: 1% acid 
fuschin (w/v) (Sigma Aldrich, UK) in ddH2O which was subsequently 
added to saturated aqueous picric acid (Sigma Aldrich, UK) (v/v) at a 
concentration of 10% to generate the Van Gieson stain.   This solution was 
boiled for 3 minutes before filtering, cooling and adding 250µL 1M HCl.  
Weigert‟s iron haematoxylin was generated by mixing equal parts of A (1% 
haematoxylin in ethanol) & B (ferric chloride in dilute HCl) (Sigma 
Aldrich, UK) and a 1% acid alcohol solution (v/v) generated by diluting 1% 
1M HCl in ethanol. 
 
Samples were fixed in 4% paraformaldehyde for 10 minutes: All reactions 
were carried out at room temperature.  The 4% paraformaldehyde solution 
was aspirated and samples washed in PBS for 5 minutes.  Weigert‟s 
haematoxylin was applied to samples for 20 minutes before washing them in 
ddH2O for 5 minutes.  Samples were then differentiated in 1% acid alcohol 
for 3 seconds and again washed in ddH2O for 5 minutes before applying 
Van Gieson stain for 5 minutes.  Samples were blotted using filter paper and 
dehydrated through gradients of ethanol: 70%, 90% and 100% (v/v) for 2 
minutes each.  Finally samples were cleared in 100% xylene (VWR, UK) 
and mounted with DPX mounting medium (VWR, UK) before visualisation 
using transmitted light microscopy.  Positive staining of collagen was 
observed as pink/red staining while nuclei appeared brown. 
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2.11 Oil Red O Staining for Visualisation of Lipid Droplets 
 
Prior to Oil red O staining a 0.5% Oil red solution (w/v) (Sigma Aldrich, 
UK)  was prepared by dissolving 0.5g of Oil red O powder in 100mL of 
1,2,propandiol CH3(OH)CH2OH] (Sigma Aldrich, UK) at 95°C.  Once the 
Oil red O had completely dissolved the resultant solution was then filtered 
through coarse 25µm filter paper (Whattman, UK) overnight. 
 
Samples were air dried for 30 minutes before fixation in 4% 
paraformaldehyde for 10 minutes: All reactions were carried out at room 
temperature unless otherwise stated.  Post-fixation samples were washed in 
ddH2O for 5 minutes before being transferred to 100% 1,2,propanediol for 5 
minutes to avoid carrying H2O over into the Oil red O.  Samples were 
stained in pre-warmed 0.5% Oil red O for 8 minutes at 60°C before being 
washed in 100% 1,2,propanediol for 5 minutes.  Samples were washed in 
ddH2O for 5 minutes before being counterstained in Gill‟s haematoxylin 
(Sigma Aldrich, UK) for 2 minutes.  Samples were then „blued‟ in ddH2O 
for 5 minutes before mounting with aqueous mountant (Sigma Aldrich, UK) 
and visualised using transmitted light microscopy.  Positive staining of lipid 
droplets can be observed as pink/red staining whilst nuclei appear blue. 
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2.12 Real-Time Polymerase Chain Reaction (qRT-PCR)  
 
2.12.1 Primer Design 
 
A series of steps were undertaken to design suitable primers for qRT-PCR 
reactions.  Firstly, coding strand cDNA sequences (CDS) of genes of 
interest were identified using the genome search platform 
www.ncbi.nlm.nih.gov. The CDS sequence was copied into the primer 
design platform, Beacon Designer V.7.21 (Premier Biosoft International, 
USA).   A basic local alignment search tool (BLAST) was then used to 
search human genome sequence databases to find regions of local similarity 
within sequences.  Once a successful BLAST had been performed a primer 
search was carried out allowing the selection of regions of the coding strand 
sequence suitable for amplification.  A final product size of 75-200bp was 
selected for optimal compliance with SYBR green chemistry, along with 
low guanine-cytosine (GC) content and an annealing temperature of 55.0 +/- 
5.0°C.  In addition, all primers were designed between 18-24bp in length.  
The proposed amplicons were verified for tertiary structures using the DNA 
mfold server provided by M. Zuker at 
http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/dna-form1.cgi.  
Primers that formed complex hairpin loops at the annealing temperature 
identified by the primer design platform were discarded as it was unlikely 
that they would anneal correctly.  An example of a predicted tertiary 
structure of a target amplicon is illustrated in Figure 2.1. 
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Figure 2.1 Predicted tertiary structure of target amplicon for Oct4 generated using 
mfold application  
 
After identification of suitable binding sequences at the annealing 
temperature specified, primers were synthesised at a production scale of 
25nM by Invitrogen, UK.  All primers (table 2.3) were designed in-house 
with the exception of Klf4 and Cytokeratin-14, which were purchased from 
Primer Design Ltd, UK. 
  
 
Sense Primer 
Anti-sense 
Primer 
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Table 2.3 Details of primers used in qRT-PCR analysis 
 
Target Gene Accession  
Number 
Sense Primer Antisense 
Primer 
Tm 
β-Actin NM001101 GGACCTGACT
GACTACCTC 
GCCATCTCTTG
CTCGAAG 
53.9 
GAPDH NM002046 GAAGGTGAAG
GTCGGAGT 
CATGGTGGAA
TCATGTTGGA
A 
53.5 
18S rRNA NR003286.1 CGT CTG CCC 
TAT CAA CTT 
TC 
TGC CTT CCT 
TGG ATG TGG 
53.3 
Oct4 NM002701.4 TGGCTCTGCTG
ACACATC 
TGGTTCGCTTT
CTCTTTCG 
53.4 
Sox2 NM003106.2 GAGAGAAAGA
AAGGGAGAGA
AG 
GAGAGAGGCA
AACTGGAATC 
53.0 
Nanog NM024865.2 CTGGCTGAAT
CCTTCCTCTCC 
TGATTAGGCTC
CAACCATACT
CC 
57.0 
C-Myc NM002467.3 CAC ATC AGC 
ACA ACT ACG 
GTT CGC CTC 
TTG ACA TTC 
50.1 
Klf4 NM004235.3 Custom Design Custom Design 60.0 
Cytokeratin14 NM000526 Custom Design Custom Design 60.0 
CBFA1 AH005498 GGCAGTTCCC
AAGCATTTC 
GCAGGTAGGT
GTGGTGTG 
54.5 
Osteonectin BC008011 GCTGGATGAT
GAGAACAACA
C 
AAGAAGTGGC
AGGAAGAG 
53.4 
Osteocalcin NM000711 AGCGAGGTAG
TGAAGAGAC 
GAAAGCCGAT
GTGGTCAG 
55.2 
Collagen II NM001844 GAGCAGCAAG
AGCAAGGAGA
AG 
TGGACAGCAG
GCGTAGGAAG 
54.3 
PPAR-γ NM005037 GACCACTCCC
ACTCCTTTG 
GTGAATGGAA
TGTCTCGTAAT
G 
50.7 
Adiponectin EU420013 ATATGAAGGA
TGTGAAGGTC 
CAGCATAGAG
TCCATTACG 
54.1 
Nestin NM006617 GGAAAGTCAA
AGGAATCTG 
CTTCTCCACCG
TATCTTC 
53.7 
Neurofilament NM006158 CTTCCAGAAG
CCAAGACTCC
AG 
GAAGCAGATG
TCGTAGAGC 
55.0 
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2.12.2 Primer Optimisation 
 
Using this design process the most suitable primers were selected, however 
further optimisation was required to ensure correct efficiency.  For each 
primer set a plate was prepared to include a no template control followed by 
serial dilutions of target cDNA.  The Bio-Rad software was then used to 
calculate the efficiency of each primer set through selecting the appropriate 
annealing temperature, highlighting the wells to be detected and identifying 
the dilution factor for the defined standards.  At the end of the qRT-PCR 
reaction a standard curve graph was produced and from this, the efficiency 
of the reaction calculated an example of this is illustrated in Figure 2.2.  
Only primers sets with an efficiency of 90% or more were used in 
subsequent qRT-PCR experiments. 
 
 
 
Figure 2.2 Efficiency standard curve for Sox2 primers 
 
2.12.3 RNA Isolation 
The following solutions were prepared prior to total cellular RNA isolation 
with all reagents used purchased from Qiagen, UK unless stated otherwise.  
44mL of ACS grade 100% ethanol were added to 6mL of wash buffer 
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(RPE), while 10µL of 1M β-mercaptoethanol (Sigma-Aldrich UK) were 
added to 1mL of lysis buffer (RLT).   
Samples were washed for 5 minutes with PBS at room temperature:  This 
was repeated three times to ensure complete removal of culture media.  
Following this, 350µL of buffer RLT was added to each sample and 
incubated for 5 minutes at room temperature.  The resulting lysate was 
transferred to a QIAshredder column and spun at 13400g for 2 minutes.  
250µL of 100% ethanol was added to the eluant, transferred to an RNeasy 
mini column and spun at 13400g for 15 seconds.  500µL of wash buffer 
(RW1) was then added to the column and incubated for 5 minutes at room 
temperature before being spun at 13400g for 15 seconds.  Following this, 
500µL of pre-warmed buffer RPE was added to the column and spun for 
13400g for 15 seconds.  This step was repeated a second time and spun at 
13400g for 2 minutes.  Finally, to elute RNA this column was transferred to 
an RNase free tube and 30µL of RNase free ddH2O added, incubated at 
room temperature for 2 minutes then spun at 13400g for 1 minute.  The 
quantity and purity of isolated RNA was determined by 260/280nm 
absorbance using a spectrophotometer and only samples that had a 
260/280nm absorbance between 1.9 and 2.1 were used in subsequent 
experiments.  Once the quantity and purity had been recorded RNA samples 
were stored at -80°C until required.   
 
2.12.4 cDNA Synthesis 
The following stock solutions were prepared prior to reverse transcription: 
All reagents were purchased from Invitrogen, UK unless otherwise stated.   
Stock 1 consisted of 1µL 50 µM Oligo (dT)20, 1µL 10mM 
deoxyribonucleotide triphosphate (dNTP) and 9µL RNase free ddH2O.   
Stock 2 consisted of 4µL 5x first-strand buffers, 1µL 0.1M dithiothreitol 
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(DTT), 1µL RNaseOUT recombinant RNase inhibitor (40U/µL) and 1µL 
SuperScript III RT (200U/µL).  Each of these stock solutions was required 
for the reverse transcription of 2µg of RNA and was scaled up accordingly 
for larger sample numbers.  Stock 1, with the addition of 2µL of RNA, was 
denatured at 65°C for 5 minutes, immediately followed by a 1 minute chill 
on ice.  After this, stock 2 was added and heated for 40 minutes at 50°C, 
immediately followed by a further 15 minutes of heating at 70°C to 
terminate the reaction.  The synthesised cDNA was stored at -20°C.   
 
2.12.5 qRT-PCR 
There are several variables that must be considered in order to produce 
accurate, reproducible qRT-PCR data. All reactions were carried out in 
triplicate with the inclusion of a no template control in all reactions, which 
included all reaction components except the cDNA of interest.  This allowed 
the detection of any contaminated reaction components that might have 
reduced the relevance of the data collected.  qRT-PCR offers the advantage 
of detecting inaccurate primer binding, such as the formation of primer 
dimers, through melt curve analysis.  During melt curve analysis the 
temperature of each reaction was increased incrementally providing peak 
fluorescence at a specific temperature. As the temperature increments 
denature the double stranded PCR products the SYBR green dissociates 
with intricate kinetics dependant on the nucleotide sequence, with 
continuous luminescent monitoring.  If target-specific binding has been 
carried out specifically, the dissociation temperature would be the same for 
each reaction due to the sequence homogeneity of the PCR products.  
Therefore as a final verification step melt curve analysis was conducted at 
the end of each amplification, allowing any anomalies to be eliminated 
based upon this analysis. 
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Prior to qRT-PCR the following solutions were prepared:  Primer solutions 
were generated from 10µL sense primer and 10µL antisense primer 
(Invitrogen,UK) diluted in 80µL of Ultra Pure ddH20 (Invitrogen, UK).  A 
PCR reagent stock solution was prepared from 7.5µL SYBR Green single 
tube real time master mix (Bio-Rad, UK), 4.5µL ultraPURE ddH2O and 1µL 
primer solution per reaction. 
Where primers were designed and supplied by Primer Designs Ltd, UK the 
primer mix (Primer Designs Ltd, UK) was reconstituted with 660µL 
ultraPURE ddH2O.  A PCR reagent stock solution was prepared from 10µL 
SYBR Green single tube real time master mix (Bio-Rad, UK), 4µL 
ultraPURE ddH2O and 1µL primer solution per well.    
The cDNA synthesised from the reverse transcription reaction was diluted 
10 fold with ultraPURE DNase, RNase free ddH2O prior to undergoing the 
qRT-PCR reaction.  All PCR reactions were carried out in RNase-free 96 
well plates (Bio-Rad, UK).  In PCR reactions, using in-house designed 
primers, the diluted cDNA was added to each well in triplicates of 2µL then 
13µL of PCR reagent stock solution was added to each well to give a total 
reaction volume of 15µL. In the instance where PCR reactions utilised 
primers provided by Primer Designs, diluted cDNA was added to each well 
in triplicates of 5µL then 15µL of PCR reagent stock solution was added to 
each well to give a total reaction volume of 20µL.  No template controls 
were included in each plate by replacing cDNA with ultraPURE ddH2O to 
identify contaminant DNA in reaction reagents.  At all stages of the 
experimental setup, filtered RNase-free pipette tips were used (Starlab, 
Germany). 
qRT-PCR reactions were carried out using a Bio-Rad i-cycler and the 
standard i-cycler operating platform (Bio-Rad, UK).  qRT-PCR was 
conducted as follows for reactions using primers designed in-house:  Plates 
were denatured for 3 minutes at 95°C, 40 cycles of amplification at 95°C for 
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30 seconds, followed directly by 30 seconds of the optimum annealing 
temperature for the specific primer detailed in table 2.3.  For reactions using 
primers supplied by Primer Designs Ltd, plates were denatured for 10 
minutes at 95°C.  Following this there were 40 cycles of amplification at 
95°C for 15 seconds directly followed by 60 seconds at the annealing 
temperature of 60°C. 
Ct values were calculated when fluorescence from SYBR Green binding to 
double stranded DNA entered its exponential phase during amplification.  
Once amplification had been performed melt curve analysis of the product 
was undertaken where plates were subject to an increase in temperature of 
1°C per second starting at 55°C and terminating at 95°C.  This quantified 
the decrease in fluorescence as the double stranded DNA dissociated.  As 
the melting temperature of double stranded DNA varies depending upon its 
base composition, this analysis indicates the identity of the amplified 
products when compared against the melting temperature of an amplified 
product for a specific primer.  Amplicons were stored at 4°C for further 
analysis using gel electrophoresis. 
 
2.12.6 Agarose Gel Electrophoresis 
qRT-PCR products were subject to electrophoresis using a 1.5% agarose gel 
to confirm the identity of an amplicon  Firstly, a 10% Tris-Borate-EDTA 
(TBE) (Sigma Aldrich, UK) solution was prepared by diluting 100mL TBE 
in 900mL ddH2O (v/v).  Then a 1.5% agarose solution was prepared by 
dissolving 1.5g agarose powder (Sigma Aldrich, UK) in 100mL of 10% 
TBE buffer (w/v) and heated until the agarose had completely dissolved.  
Once the solution had cooled 2µL of ethidium bromide (Merck, Germany) 
was added and the gel was poured into a casting tray including the addition 
of a comb to allow the formation of individual wells.  When the gel had 
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solidified, the comb marking the wells was removed from the gel tray, the 
gel was transferred to the electrophoresis basin and submerged in 1x TBE 
buffer.  5µL of each sample were loaded into each well along with 1µL 6x 
loading buffer (Promega, UK).  One lane was also loaded with 5 µL of a 
100bp DNA ladder (Promega, UK) along with 1µL 6x loading buffer 
(Promega, UK).  An electrical current was then passed through the gel from 
negative to positive at a voltage of 90V for 45 minutes allowing separation 
of different sized DNA fragments.  Once electrophoresis was complete the 
PCR products could be directly visualised, due to the incorporation of 
ethidium bromide into the gel, with UV light illumination using a Multi 
Image light cabinet (GRI LTD, UK).  Images were captured using Alpha 
Imager 2200 software. 
 
2.13 Flow Cytometric Analysis of Nucleofected hEKs 
Quantification of hEKs nucleofected with either GFP-P (Lonza, Germany) 
or miRNA inhibitor (Dharmacon, USA) was performed using flow 
cytometry.  Adherent cells were washed with PBS for 5 minutes at room 
temperature.  This solution was replaced with 10% recombinant 
trypsin/EDTA (Invitrogen,UK) for approximately 5 minutes until 90% of 
cells had become detached, observed by transmitted light microscopy.  The 
cell/trypsin solution was then diluted in an equal volume of defined trypsin 
inhibitor (Invitrogen,UK) to neutralise the reaction and cells collected using 
centrifugation at  2000g for 5 minutes at 4°C.  The cell pellet was 
resuspended in 1mL of sheath fluid (BD-Biosciences, UK) and transferred 
into clean flow cytometry tubes (Elkay, UK) for subsequent analysis using a 
FACsort flow cytometer (BD-Biosciences, UK).  Non-specific fluorescence 
was determined using control samples, which had previously been 
nucleofected in the absence of either GFP-P (Lonza, Germany) or miRNA 
inhibitor (Dharmacon, USA). 
 61 
 
2.14 Differentiation Assay  
Four cell types: miR-145 inhibited hEKs maintained in either hEK or hESC 
media for 5 days prior to directed differentiation, hEKs taken at passage 3 
nucleofected without miR-145 inhibitor and hMSCs taken at passage 4 were 
subject to directed differentiation parameters. 
hEKs were nucleofected as detailed in section 2.2 whilst hMSCs were 
seeded in a monolayer at a density of 5x10
4
 cells/cm
2 
cultured under basal 
conditions for 24 hours before replacing the media with defined 
differentiation media (Table 2.4).  All samples were incubated at 37°C, 5% 
CO2 with media refreshment every 7
th
 day for 28 days.   
 
Osteogenic 
Low Glucose DMEM (1g/L) + 10% FBS 
Chondrogenic 
High Glucose DMEM (4.5g/L) + 1% FBS 
Ascorbate 50µM Pyruvate 1mM 
Dexamethasone 100nm Ascorbate 50µM 
Β-Glycerophosphate 10mM Dexamethasone 100µm 
 TGFβ1 10ng/mL 
Adipogenic 
Low Glucose DMEM (1g/L) + 10% FBS 
Neurogenic 
Low Glucose DMEM (1g/L) + 10% horse serum 
Dexamethasone 1µm All-trans retinoic Acid 300ng/mL 
Hydrocortisone 50µm  
Table 2.4 Soluble factor composition of defined differentiation media 
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2.15 Platelet-Poor Plasma (PPP)-Derived Hydrogel Synthesis 
2.15.1 Blood Plasma Isolation 
20mL of peripheral blood was isolated from consenting healthy humans via 
venipuncture, collected in sterile plastic falcon tubes and anticoagulated 
using 10% 10mM sodium citrate (v/v) (Sigma Aldrich, UK), which inhibits 
clotting through the chelation of Ca
2+
.  Citrated blood samples were allowed 
to remain at room temperature for 2 hours before incubation at 4°C 
overnight.  Blood was centrifuged at 1000g for 10 minutes and the resulting 
supernatant decanted.  This supernatant was then centrifuged once more at 
1000g for 10 minutes to largely remove blood cells.  The citrated, platelet 
poor plasma was then stored at -20°C. 
 
2.15.2 Stable Hydrogel Formation 
A PPP-derived hydrogel was prepared from two distinct components: 
citrated, platelet poor human blood plasma and basal media containing 
calcium.  Components were pre-warmed to 37°C and the blood plasma 
fraction added to the media component at a concentration of 10% (v/v).  The 
combined liquids were incubated for 5 minutes at 37°C resulting in a stable 
hydrogel.  The gellation process occurred as a result of the presence of Ca
2+
 
in the media, which allows blood coagulation to proceed in combination 
with the liquid component of the media, forming a hydrogel. 
   
2.16 Ectopic Bone Formation Model 
All studies adhered to UK home office use of animals in scientific 
procedures guidelines. Subjects (NOD/SCID mice, male, 6 weeks old, 10-
15g) were anaesthetised using a gas and air mix equal ratio of O2/NO 
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supplemented with isofluorane at 2% (v/v). Once the subject was sedate 
(confirmed by the absence of a pedal withdraw reflex), the injection area 
was sterilised using surgical iodine. Buprenorphine (pain relief) and Baytril 
(prophylactic antibiotic) were administered by subcutaneous injection. 
Subjects received four injections, 1 above each each shoulder and each hip.  
4 human cell types were selected for validation: miR-145 inhibited hEKs 
maintained in hEK media, miR-145 inhibited hEKs maintained in hESC 
media, hMSCs maintained in MSCBM and hEKs nucleofected in the 
absence of miR-145 maintained in hEK media.  Each cell type was injected 
both with and without 1% hydroxyapatite beads (w/v) (Biocomposites, 
Keele, UK). 
Each implant site received 5x10
5
 cells, in the case of hEKs passage 2-4 
while all hMSCs were passage 4, in a total injection volume of 300µL.  
Citrated PPP and culture media were pre-warmed then combined at a 
concentration of 10% PPP: media (v/v) immediately prior to implantation 
using a three-way stop cock system (Smiths Medical, UK), shown in Figure 
2.3, before delivery through a 21 gauge needle.  
 
Figure 2.3 Implantation system used for the delivery of cell loaded hydrogel in 
vivo 
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Animals were sacrificed at 4 and 8 weeks post-implantation using 
asphyxiation with CO2 and ectopic tissue explanted for analysis.   
 
2.17 Histological Tissue Processing  
Samples were placed directly into periodate-lysine-paraformaldehyde 
fixative, which was prepared as follows. A 0.2M lysine-HCl solution and a 
0.1M solution of Na2HPO4 were prepared. 60mL of 0.1M Na2HPO4 was 
then added to 300mL of Lysine-HCl to result in a solution with a pH of 7.4. 
Next, a 0.1M NaH2PO4/ Na2HPO4 buffer was prepared. 240mL of this 
phosphate buffer was added to the Lysine-HCl/Na2HPO4 solution resulting 
in a 0.1M concentration of Lysine-HCl.  
Immediately prior to use, 300mL of the phosphate buffered lysine-HCl 
solution was combined with 100mL of 2% (w/v) paraformaldehyde and to 
this was added sodium periodate resulting in a concentration of 0.1M. The 
fixative was then chilled to 4
o
C prior to use. Samples were placed under 
periodate-lysine-paraformaldehyde fixation on a roller for 48hrs at 4
o
C.  
Fixative was aspirated from samples and replaced with a cold washing 
solution, which consisted of the previously described 0.1M phosphate buffer 
modified to contain 7% sucrose and 40mM NH4Cl. Samples were gently 
rolled at 4
o
C for 24 hours. After this time had elapsed, the cold washing 
solution was aspirated and replaced by ice-cold acetone to remove 
phosphate crystals and dehydrate the specimens, for 48 hours at 4
o
C. 
Once samples were suitably dehydrated they were immersed in 100% glycol 
methacrylate (GMA) (TAAB, UK) for 24 hours at 4
o
C, after which, samples 
were moved to ice cold Technovit infiltration solution (TAAB, UK) for a 
further 24 hours at 4
o
C. Specimens were then cast in place in an 
appropriately sized mould, orientated carefully for optimum cutting and 
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submersed in Technovit embedding solution (TAAB, UK). The pre-resin 
surface was covered with mineral oil to prevent oxidation and evaporation, 
sealed with aluminium foil and placed at -55
o
C to infiltrate for 4 days. After 
this time had passed, the incubation temperature was then increased to -
20
o
C for 2 days to facilitate polymerisation of the resin.  
After successful polymerisation followed by subsequent removal from the 
moulds, tissue blocks were sectioned (5μm thick sections) using a polycut 
microtome (Reichert-Jung, USA) and placed onto microscope slides coated 
with 3-aminopropyl triethoxysilane.  
Unless stated otherwise, all reagents were purchased from Sigma Aldrich, 
UK. 
 
2.18 Haematoxylin and Eosin Staining of Resin Embedded Tissue 
Tissue samples were hydrated using ddH2O before being submersed in 
Harris‟s haematoxylin (Sigma Aldrich, UK) for 5 minutes at room 
temperature.  Samples were „blued‟ under running ddH2O for 3 minutes 
before differentiation using ethanol containing 0.01M HCl (v/v) for 10 
seconds.  Samples were washed in ddH2O before being incubated with 1% 
eosin (w/v) (Sigma Aldrich, UK) in ddH2O for 3 minutes at room 
temperature.  Samples were then dehydrated through a gradient of ethanol: 
70%, 90%, 100% (v/v) for 2 minutes each, then cleared using xylene 
(VWR, UK) before finally mounting in DPX mounting medium (VWR, 
UK).  Samples were visualised using transmitted light microscopy where 
tissue structure could be differentiated by varying shades of red/pink whilst 
nuclei appeared blue. 
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2.19 Immunohistochemistry of Resin Embedded Tissue 
Masked epitopes were exposed through digestion of 6µm resin-embedded 
tissue with 0.1% trypsin type III (Sigma Aldrich, UK) in 0.1% calcium 
chloride (CaCl2) (Sigma Aldrich, UK) in ddH2O, pH7.8, for 30 minutes at 
37°C, followed by a 5 minute wash at room temperature using PBS.  Non-
specific binding was then blocked by incubating samples with 1mL horse 
serum (Sigma Aldrich, UK) diluted in 10mL of PBS for 30 minutes at 37°C. 
Primary antibodies were diluted to working concentrations specified in table 
2.1 using 1% BSA (w/v) (Sigma Aldrich, UK) in PBS.  Samples were 
incubated with primary antibodies overnight at 4°C. 
Following incubation with primary antibody, the samples were washed 
using PBS for 5 minutes at room temperature.  Secondary biotin-conjugated 
antibodies (Dakocytomation, Denmark) were diluted to 1:200 using PBS 
and applied to samples for 60 minutes at 37°C. 
Following incubation with secondary antibodies samples were washed in 
PBS for 5 minutes at room temperature before exposure to mouse avidin 
DH and biotinylated alkaline phosphatase H (ABC/AP) tertiary antibody kit 
(Vector Laboratories, UK) for 30 minutes at room temperature.  This was 
immediately followed by a further wash in PBS then incubation with 
alkaline phosphatase substrate solution (Vector Laboratories, UK) diluted in 
0.1M Tris-HCl (Sigma Aldrich, UK) pH8.2 for 20 minutes at room 
temperature.  Finally, samples were washed in PBS then ddH2O respectively 
for 5 minutes each at room temperature before being mounted in aqueous 
mountant (Sigma Aldrich, UK).  Samples were visualised using a 
combination of fluorescent and transmitted light microscopy. 
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2.20 Statistical Analysis 
Statistical analysis was performed using the SPSS statistical
 
package 
(SYSTAT Software Inc.).  Differences between samples were evaluated by 
performing Mann-Whitney U, one-way and two-way ANOVA tests with a 
p-value of
 
<0.05 being considered statistically significant. 
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3.0 Results 
3.1 Characterisation of HESCs 
 
The hESC line (HUES7) was kindly donated by Harvard University and 
maintained without feeder cells in serum-free conditions (section 2.1.2).  A 
number of techniques were used to establish the pluripotency exhibited by 
these cells, providing baseline data to determine the extent of 
reprogramming of hEKs throughout this investigation.  
 
Transmitted light microscopic observations revealed that the hESCs had a 
high nucleus to cytoplasmic ratio with prominent nucleoli and displayed 
compact colony morphology (Figure 3.1) consistent undifferentiated hESC 
phenotype. 
 
 
Figure 3.1 Phase contrast microscopic observation of passage 5 hESCs after 48 
hours in culture, scale bar 100µm  
 
 
An accumulating body of literature highlights key pluripotency regulators, 
identified primarily through studying the synergy between plasticity and 
gene expression.  Oct4, Nanog and Sox2 are now widely regarded as central 
regulators of plasticity and through cooperative interaction, have been 
shown to drive pluripotent-specific expression of a number of genes [164].  
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Initially, immunohistochemical staining of hESCs was performed to confirm 
the expression of these key pluripotency-associated genes.  After 48 hours 
in culture, passage 8 hESCs demonstrated nuclear staining of each of these 
three markers (Figure 3.2).  These proteins were found to be almost 
homogenously expressed, except for a small number of unstained hESCs 
typically found at the periphery of the colonies, suggesting these cells had 
spontaneously differentiated.  
 
 
Figure 3.2 Immunohistochemical characterisation of passage 8 hESCs after 48 
hours of in vitro culture.  Oct4, Nanog, Sox2 and Nuclei, scale bar 50µm  
 
Pluripotent stem cells can also be characterised according to surface 
antigenicity, such as the stage specific embryonic antigens, SSEA3 and 
SSEA4.  These antigens are synthesised during oogenesis and are present on 
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the surface of oocytes, zygotes and early cleavage stage embryos [165].  
Other well established biomarkers of undifferentiated hESCs include the 
keratin sulphate-associated antigens, TRA-1-60 and TRA-1-81, which are 
highly expressed in hESCs and absent in lineage committed stromal cells 
[165].  After 48 hours of culture, hESCs showed strong immunoreactivity 
for SSEA3, SSEA4, TRA-1-60 and TRA-1-81, all of which were localised 
to the cell surface and absent in the nucleus (Figure 3.3). 
 
 
Figure 3.3 Immunohistochemical characterisation of passage 8 hESCs after 48 
hours of in vitro culture. A:  SSEA3, Nuclei.  B:  SSEA4, Nuclei.  C:  TRA-1-60, 
Nuclei.  D:  TRA-1-81, Nuclei, scale bar 50 µm 
 
Another characteristic of pluripotent cells is the expression of alkaline 
phosphatase at high levels, which is known to decrease during 
differentiation [165].  HESCs were maintained under standard culture 
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conditions and stained for alkaline phosphatase after 1, 2, 3 and 5 days.  
Alkaline phosphatase was absent until day 2 and then largely increased after 
3 days, persisting up to 5 days in culture (Figure 3.4). 
 
Figure 3.4 Phase contrast microscopic observation of hESCs stained for alkaline 
phosphatase A: 3 days. B: 5 days in culture.  Scale bar represents A: 200µm. B: 
50µm 
 
To characterise hESCs at a transcriptomal level, qRT-PCR analysis of key 
pluripotency genes was performed.  To meaningfully compare different 
samples, an appropriate reference gene needed to be identified and PCR 
reaction terminated when amplification kinetics of both internal controls and 
genes of interest were proceeding exponentially.  Reference genes are used 
in qRT-PCR to normalise experimental data, such that relative expression 
levels of genes of interest can be quantified against a non-fluctuating 
internal standard.  Therefore it was first necessary to identify an appropriate 
reference gene, which would maintain constitutive expression under the 
parameters of this investigation.  Three of the most commonly used 
reference genes β-actin, Glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) and 18s ribosomal RNAs (rRNAs) were considered as internal 
controls. 
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Primers for these reference genes were designed according to the methods 
detailed in section 2.10.1 and optimised against cDNA isolated from hESCs. 
All primer sets were found to have efficiencies exceeding 98%.  To identify 
which reference gene would be the most appropriate for this investigation 
the experimental conditions hypothesised for the reprogramming of hEKs 
were replicated.  hEKs were subject to nucleofection before quantifying 
each of the internal gene controls and comparing this data with hEKs 
maintained under standard culture conditions.  Each reference gene was 
expressed in all samples, however analysis revealed that β-actin showed the 
least variation post-nucleofection and was therefore selected as the internal 
control for all subsequent gene expression studies. 
 
Once an appropriate reference gene had been established hESCs were 
subject to qRT-PCR to determine expression of pluripotency associated 
genes.   HESCs from passage 7 were cultured for 5 days (section 2.1.2), 
qRT-PCR analysis revealed expression of Oct4, Sox2, Nanog, c-Myc and 
Klf4 all of which are associated with a pluripotent, self-renewing phenotype.   
 
hEKs were also analysed using qRT-PCR to confirm absence of genes 
associated with pluripotency and identify expression of hEK lineage specific 
genes.  hEKs taken from passage 4 were cultured for 5 days (section 2.1.1).  
hEKs did not express Oct4, Sox2 or Nanog and were found to express 
Cytokeratin14, a hEK marker.  Interestingly hEKs were found to express 
Klf4 at comparatively high levels whilst also expressing c-Myc, at reduced 
levels compared with hESCs (Figure 3.5).  It was therefore possible to 
conclude that this panel of primers is capable of distinguishing an 
undifferentiated hESC phenotype from differentiated hEKs. 
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Figure 3.5 Comparison of hESC and hEK gene expression, passage 7 and 4 
respectively, 5 days in vitro culture.  Agarose gel electrophoresis of PCR 
products stained with ethidium bromide and visualised under UV light 
 
 
3.2 Maintenance of hEKs on Human Fibronectin  
 
The extracellular microenvironment provides specific cues to regulate cell 
function in both developing and adult organisms.  It was hypothesised that 
an appropriate, well considered microenvironment may enhance cellular 
reprogramming.  When considering the specifics of extracellular matrices 
(ECM) we find that they contain proteins and tethered soluble factors, 
which promote adhesion, proliferation, migration or differentiation of cells 
via transmembrane receptors, linking the ECM, intracellular cytoskeleton 
and nucleus.  Evidence suggests that these components influence cell 
physiology [166] and suggests that cells in vitro only respond to certain 
signals when cultured in contact with an appropriate microenvironment. 
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hEKs possess extracellular matrix receptors of the integrin family, including 
α5β1, a fibronectin receptor and α2β1, a collagen receptor [167].  When 
considering the epidermis, proliferation is largely restricted to the basal 
layer, as hEKs move through the suprabasal tissues they undergo terminal 
differentiation.  The role of these integrins is to mediate adhesion to the 
basement membrane and regulate the onset of lineage commitment.  Thus it 
was hypothesised that hEK proliferation and differentiation may be affected 
as a direct result of the in vitro ECM microenvironment. 
 
Similarly, hESCs require the support of appropriate substrata to maintain 
pluripotent, self renewing characteristics.  During this investigation, human 
fibronectin (hFN) was used to maintain hESCs in vitro due to the superior 
proliferation and decreased spontaneous differentiation in comparison to 
other available substrates [168].  Therefore it is rational to predict that after 
induction by exogenous soluble stimuli, maintenance on a coating known to 
promote pluripotency may enhance this process.    
 
Routine hEK culture involves seeding cells on tissue culture polystyrene, 
coated with matrix largely composed of recombinant human type-1 collagen 
(hCol I).  To determine whether hFN could be utilised in our strategy for 
reprogramming hEKs, it was necessary to assess whether this protein could 
support hEK proliferation and phenotype.  All concentrations of hFN 
supported varying degrees of hEK attachment, however a coating of 
5µg/cm
2 
was found to
 
provide optimal attachment (Figure 3.6). 
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Figure 3.6 hEK attachment to hFN coated substrate.  Total number of attached 
hEKs was quantified 24 hours post-seeding on a range of hFN concentrations. 
Points represent the mean, error bars represent standard error of the mean, n=3 
 
hEKs attached to hFN coated dishes after 2 hours with the majority 
attaching as single cells (Figure 3.7). 
 
 
Figure 3.7 Phase contrast microscopic observation of hEKs 24 hours post-seeding 
on dishes coated with A:  hFN.  B:  hCol I.  Scale bar represents 200µm  
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Over a period of 7 days hEKs proliferated and exhibited typical hEK 
morphology (Figure 3.8).      
 
 
Figure 3.8 Phase contrast light microscopic observation of hEKs 7 days post-
seeding on dishes coated with A:  hFN.  B:  hCol I 
   
Proliferation of hEKs maintained on either hCol I or hFN at a concentration 
5µg/cm
2 were compared over 96 hours.  hEKs were seeded at a density of 5 
x10
4
 per cm
2 
and maintained using standard culture procedures (section 
2.1.2).  At each time point media was removed and wells washed twice with 
PBS leaving hEKs that had successfully attached.  hEKs were detached and 
enumerated. 
The number of hEKs attached to hFN-coated surfaces was reduced 
compared to hCol I-coated surfaces.  Despite impaired attachment of hEKs 
to hFN, cells which had successfully attached proliferated with a 
comparable profile to those cultured on hCol I (Figure 3.9). 
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Figure 3.9 hEK growth on  hCol I and hFN coated surfaces at 1, 2, 3 and 4 days 
post-seeding.  Points represent the mean, error bars represent standard error of the 
mean, n=3 
 
3.3 Nucleofection  
Another of the major aims of this study was to identify a method of 
delivering factors capable of reprogramming hEKs at a high frequency 
without cytotoxicity.  Although much research has focused on viral systems, 
which have proved an effective method of gene transfer, resultant cells face 
barriers in clinical translation due to complex viral biology associated with 
these vectors [136].  The future of reprogramming therefore lies with non-
viral, non-toxic methods, which efficiently deliver inducing stimuli to 
somatic cells.  At present non-viral methods are substandard demonstrating 
low transfection efficiencies or cytotoxicity [169].  Here we evaluate an 
electroporation technique termed nucleofection, which utilises low voltage 
electroporation in combination with cell-specific reagents to allow direct 
electro-transfer of nucleotides into target cell nuclei whilst maintaining high 
levels of viability, to directly reprogram hEKs [148]. 
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Traditional electroporation methods often reduce viability.  If electrical 
pulses are the incorrect length or intensity, pores caused may fail to close, 
causing loss of mechanical membrane integrity and subsequent apoptosis.  
Therefore it was necessary to establish the level of hEK cell viability post-
nucleofection.  An initial qualitative assessment was achieved by 
performing a live/dead assay 24 hours post-nucleofection.  Observations 
from this assay indicated a high level of viability following nucleofection 
(Figure 3.10). 
 
Figure 3.10 Fluorescent microscopic observation of hEKs 24 hours post 
nucleofection stained using live/dead cytotoxicity kit. A:  Live cells.  B: Dead 
cells.   C:  Nuclei.  Same field of view, scale bars represent 200µm  
 
In order to quantify the overall viability, whole well analysis was 
performed, including both the adherent monolayer and supernatant. Two 
assays were performed to quantify viability 24 hours post-nucleofection: 
trypan-blue dye exclusion (section 2.5) and live/dead staining quantified 
using flow cytometry (section 2.4).  Viability of hEKs subject to a single 
round of nucleofection (section 2.2) and unmodified hEKs subject to 
identical trypsinisation and centrifugation procedures were quantified (Table 
3.1).   
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Table 3.1 Summary of hEK percentage viability 24 hours post-nucleofection 
seeded onto hCol I coated dishes, n=3 
 
To determine the attachment of nucleofected hEKs to either hCol I or hFN-
coated surfaces, adherent cells were harvested 24 hours post-nucleofection, 
trypan-blue dye exclusion assay performed and the percentage viability 
calculated (table 3.2). 
 
Table 3.2 Summary of hEK viability post-nucleofection, n=9 
 
Live/dead assay Trypan-blue exclusion assay 
 Nucleofected Non-
nucleofected 
 Nucleofected Non-
nucleofected 
Mean 
   (%) 
66.2% 
Non-
viability 
12.7% 
Non- 
viability 
Mean 
  (%) 
25.63% 
Viability 
88.38% 
Viability 
SD 3.45 1.3 SD 0.03 2.5 
 hCol I hFN 
 Total no. 
hEKs 
Viability 
 (%) 
Total no.  
hEKs 
Viability  
(%) 
Mean 181,694 25.63 90,370 12.91 
SD 21,032 3.00 19,565 2.79 
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These results confirm that hEKs undergoing nucleofection are subject to 
increased cell death compared to hEKs under identical experimental 
parameters without nucleofection.  When considering hEKs seeded on hCol 
I approximately 25% successfully attached post-nucleofection indicating 
that a number of viable hEKs fail to adhere to the substrate post-
nucleofection.  In addition, an increased number of hEKs failed to adhere to 
hFN coated surfaces, with approximately 12% attachment post-
nucleofection.  Irrespective of coating, hEKs proliferated and exhibit typical 
hEK morphology following nucleofection indicating that the high seeding 
density of 7.0x10
5
 cells per sample (section 2.2)
 
is a crucial factor in 
compensating for the significant number of cells which are non-viable or 
fail to adhere post-nucleofection.  
A number of non-viral transfection techniques are known to differentiate 
hEKs, therefore it was important to assess the effect of nucleofection on 
hEK phenotype before commencing reprogramming.  An established marker 
of hEK terminal differentiation is involucrin, a protein found in 
keratinocytes of the epidermis and other stratified squamous epithelia [170].  
This protein first appears in the cytosol and eventually becomes cross-linked 
to membrane proteins to form an insoluble envelope beneath the plasma 
membrane [170].  Involucrin is synthesised after hEKs have left the basal 
layer and begun to enlarge before the onset of envelope cross-linking, which 
occurs only in the outermost cells. Therefore involucrin is considered to be 
the most reliable marker of the terminal differentiation of hEKs [171]. 
hEKs maintained under adherent culture, suspension culture or subject to 
nucleofection were immunohistochemically stained for cytokeratin14 and 
involucrin.  Positive cytokeratin14 staining was identified in all samples, 
however it was considerably reduced in suspension cultures (Figure 3.11). 
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Figure 3.11 Assessment of hEK phenotype upon different culture conditions.  
Fluorescent microscopic observation of hEKs stained for Cytokeratin14, DAPI.  
(A-B):  adherent culture (C-D):  suspension culture.  (E-F):  24 hours post-
nucleofection, scale bars represent 50µm 
 
Involucrin was absent in hEKs maintained in adherent culture, whilst being 
highly prevalent in hEKs maintained in suspension.  Where samples had 
been nucleofected, only a few cells stained positive for involucrin (Figure 
3.12). 
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Figure 3.12 Assessment of terminal differentiation upon different culture 
conditions. Fluorescent microscopic characterisation of hEKs. Involucrin, DAPI.  
(A-B): adhesion culture.  (C-D):  suspension culture.  (E-F):  24 hours post-
nucleofection, scale bars represent 50µm 
 
 
hEKs nucleofected with GFP-P (section 2.2) were also analysed using qRT-
PCR to assess whether nucleofection had altered the expression of genes 
associated with lineage commitment and differentiation.  Total RNA was 
isolated from hEKs after 1, 3, 5 and 7 days. qRT-PCR analysis revealed that 
expression of Oct4, Sox2, Nanog, c-Myc, Klf4 and cytokeratin-14 remained 
unchanged despite this intervention.  Thus indicating nucleofection alone 
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does not modulate expression of sentinel plasticity associated genes outside 
of primary hEK basal levels. 
 
3.3.1 Nucleofection Plasmid DNA 
To develop a strategy for hEK reprogramming it was necessary to ascertain 
the delivery efficiency of inducing stimuli, such as plasmid DNA, miRNA 
inhibitors or a combination of both.   
hEKs were nucleofected with pmaxGFP control plasmid (GFP-P) (section 
2.2).  Successful delivery was detected as early as 6 hours post-
nucleofection using fluorescent microscopy. After 24 hours successful 
delivery of the plasmid to a large number of hEKs was clearly evident 
(Figure 3.13).  
 
Figure 3.13 hEKs 24 hours post-nucleofection with GFP-P A:  Fluorescent 
observation.  B:  Phase contrast microscopic observation. Same field of view, scale 
bar represents 200µm 
 
To quantify the number of successfully nucleofected hEKs, flow cytometric 
analysis of hEKs nucleofected with GFP-P and seeded onto either hCol I or 
hFN, were performed 24 hours post-nucleofection. The histogram below 
shows flow cytometric data for hEKs nucleofected with GFP-P and seeded 
on hCol I (Figure 3.14).  The marked area to the right of the peak reflects 
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the number of successfully nucleofected hEKs, with GFP fluorescence from 
the plasmid reporter as a smear rather than a defined peak or shoulder.  This 
is a consequence of hEKs receiving differing intercellular concentrations of 
GFP-P thus producing a range of fluorescence intensities.  This was 
confirmed by subtraction of control samples, which underwent the same 
experimental parameters in the absence of GFP-P to offset non-specific 
fluorescence. 
 
Figure 3.14 Histogram illustrating flow cytometric analysis of hEKs subject to 
nucleofection.  Black line represents hEKs nucleofected without GFP-P.  Green 
area represents hEKs nucleofected with GFP-P 24 hours post nucleofection 
 
Post-nucleofection with GFP-P, hEKs were seeded on either hCol I or hFN.  
In order to quantify the transfection efficiency, flow cytometry was 
performed 24 hours post-nucleofection.  Prior to analysis wells were washed 
with PBS in order to remove any non-adherent cells and the remaining 
adherent monolayer analysed (section 2.12). 
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Data indicated that the numbers of GFP
bright
 cells were reduced when seeded 
on hFN (table 3.3). 
 hCol I hFN 
 GFP 
bright
 (%) GFP 
bright
 (%) 
Mean 19.82 8.01 
SD 2.45 2.85 
Table 3.3 Summary of nucleofection efficiency quantified using flow cytometry, 
n=6                                                                                    
Substrate coating is an independent variable and should not directly 
modulate transfection efficiency. However, as hFN is known to influence 
hEK attachment it was hypothesised that the reduced number of GFP
bright
 
cells was due to a number of successfully nucleofected hEKs failing to 
attach.  To confirm this, whole well contents including non-adherent hEKs, 
were analysed.  Flow cytometric analysis of whole well contents revealed 
the mean number of GFP
bright
 cells to be equivalent for hEKs seeded on  
hCol I and hFN with a  mean number of 29.23% ± 3.40%  GFP
bright
 cells for 
both culture variables, n=6 (Figure 3.15). 
 
Figure 3.15 Histogram illustrating flow cytometric whole well analysis of hEKs 
seeded on hFN 24 hours post-nucleofection with GFP-P  
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While this procedure was able to successfully deliver GFP-P to almost 30% 
of hEKs, cells which had not attached to the given substrate after 24 hours 
were considered non-viable and were subsequently removed following 
replacement of media.  Subsequent experiments therefore focused on 
seeding cells initially on hCol I post-nucleofection due to the superior 
attachment of successfully nucleofected hEKs compared to hFN. 
 
To summarise, these results demonstrate that nucleofection is a 
reproducible, non-viral method of delivering plasmid DNA to hEKs.  
Within experimental groups little variation existed with total number of 
GFP
bright
 hEKs ranging between 17.40% and 22.56% ± 2.22 on hCol I and a 
range of 5.46% to 14.56 ± 2.85, n=6 on hFN, demonstrating the 
repeatability of this technique (Figure 3.16). 
 
 
Figure 3.16 Summary of nucleofection efficiency 24 hours post-nucleofection 
quantified by flow cytometry, n=6 and cell viability calculated through trypan-dye 
exclusion assay, n=9  
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3.3.2 Stable or Transient Transfer? 
Transfection is the introduction of foreign DNA into any eukaryotic cell and 
can be stable or transient. In the case of stable transfection foreign DNA is 
permanently integrated into the host genome while transient transfection 
imparts only transient expression of the transfected genetic material, which 
is subsequently diluted then lost through mitosis.  hEKs successfully 
nucleofected with GFP-P were maintained in vitro for 10 days to study 
persistence of GFP-P.   3 days following nucleofection hEKs had 
proliferated and the number of GFP
bright
 cells had increased.  After 5 days 
proliferation continued with hEKs forming a confluent monolayer; however 
GFP expression did not increase further although did persist in a number of 
hEKs. Transmitted light microscopy also showed hEKs maintained typical 
morphology during this period (Figure 3.17).   
 
Figure 3.17 Fluorescent and phase contrast light microscopic observation of hEKs 
nucleofected with GFP-P (A-B) 3 days post-nucleofection, same field of view, 
scale bar represents 200µm.  (C-D) 5 days post-nucleofection, same field of view, 
scale bar represents 100µm 
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hEKs maintained in their original wells up to 10 days post-nucleofection 
demonstrated a notable decrease in the number of GFP
bright
 hEKs.  To 
quantify persistence of GFP-P, hEKs were subject to flow cytometry at 1, 3, 
5, 7 and 10 days post-nucleofection.  In order to enumerate the percentage 
of GFP
bright
 cells, non-GFP-P nucleofected cell fluorescence was subtracted 
from GFP-P nucleofected cell fluorescence.  This revealed that despite a 
peak in the number of GFP bright hEKs, throughout the remainder of the 
experimental time course there was a decrease in fluorescence associated 
with the GFP-P (Figure 3.18). 
 
 
Figure 3.18 Nucleofection efficiency GFP-P.  Points represent percentage of hEKs 
successfully nucleofected with GFP-P quantified using flow cytometry at time 
points post-nucleofection, error bars represent standard error of the mean, n=3 
 
GFP
bright
 populations were passaged 7 days post-nucleofection and 
observed.  GFP was found to be absent in successive populations therefore 
when hEKs were provided with sufficient space to proliferate GFP 
expression was rapidly lost, indicating transient expression persisting 
between 5-7 days.  While stable transfection ensures long-term gene 
expression, transient transfection is attractive in terms of reprogramming 
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therapeutic somatic cells due to non-integration of foreign DNA into the 
nuclear genome leading to eventual clearing through routine mitosis.  This 
data therefore highlights the possibility that multiple repeated transfection of 
hEKs may be required to sustain transgene expression over longer periods 
using the nucleofection technique. 
 
3.3.3 Nucleofection MiRNA Inhibitors 
It was hypothesised that a combination of plasmid DNA and miRNA 
inhibitors may provide a potent mixture for hEK reprogramming. One 
specific miRNA, miR-145, was highlighted during this investigation due to 
its association with major pluripotency regulators: Oct4, Sox2 and Klf4 
[119], all of which feature in Yamanaka‟s classic combination of 
reprogramming factors.  It was proposed that an inhibitor of miR-145 could 
provide a means of elevating expression of these pluripotency genes, 
facilitating hEK reprogramming. 
Prior to delivering the miRNA inhibitor of interest a control miRNA 
inhibitor containing a fluorescent reporter, supplied by Dharmacon, was 
used to optimise delivery (section 2.2).  All experimental conditions 
remained the same as for nucleofection of plasmid DNA, however a range 
of miRNA inhibitor control concentrations was evaluated, ranging between 
10pM and 100nM.  Fluorescent microscopy revealed a large number of 
hEKs successfully nucleofected with 100nM control miRNA inhibitor.  
Lower concentrations of 10nM also demonstrated high occurrence of 
nucleofection however the number of hEKs incorporating the miRNA 
inhibitor appeared reduced and the inhibitor was found to be distributed 
throughout the cell rather than the clear nuclear localisation observed in the 
case of 100nM.  Lower concentrations of 100pM and 10pM were 
unsuccessfully delivered (Figure 3.19). 
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Figure 3.19 Fluorescent and phase contrast microscopic observations of hEKs 24 
hours post-nucleofection with (A-B) 100nM; (C-D) 10nM; (E-F) 100pM; (G-H) 
10pM miRNA inhibitor control, same field of view for each concentration assayed, 
scale bar represents 50µm 
 91 
 
To optimise an appropriate concentration for delivery of miRNA inhibitors, 
varying miRNA inhibitor control concentrations were evaluated in terms of 
their effect on viability and delivery efficiency.  Flow cytometry of hEKs 
nucleofected with different concentrations of miRNA inhibitor control were 
performed to quantify efficiency of delivery in conjunction with a trypan-
blue exclusion assay to determine viability 24 hours post-nucleofection.  
Control samples consisted of hEKs nucleofected without miRNA inhibitor 
control. This revealed that altering the concentration of miRNA inhibitor 
control did not notably alter viability while delivery efficiency increased as 
a function of increasing the concentration of miRNA inhibitor control 
(Figure 3.20). 
 
 
Figure 3.20 Effect of miRNA inhibitor control concentration on cell viability and 
nucleofection efficiency.  Viability was quantified using trypan-blue exclusion 
assay and efficiency quantified using flow cytometry 24 hours post-nucleofection, 
n=3 
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The flow cytometric data obtained for hEKs, which had been nucleofected 
with 100nM of miRNA inhibitor control showed a distinct peak compared 
to the broader range of fluorescence observed for samples nucleofected with 
GFP-P (Figure 3.21).  In addition, a significantly higher number of hEKs 
were nucleofected with miRNA inhibitor control than GFP-P, with a mean 
nucleofection efficiency of 88.58% ± 1.87, n=6 observed 24 hours post-
nucleofection.  
 
 
Figure 3.21 Flow cytometric analysis of hEKs nucleofected with miRNA inhibitor 
control 24 hours post-nucleofection 
 
Therefore concurrent with initial visualisation, a concentration of 100nM 
miRNA inhibitor control demonstrated the highest level of nucleofection 
efficiency with no significant difference in viability compared to other 
concentrations investigated (Figure 3.20). This concentration was therefore 
selected for successive miRNA inhibitor functional investigations. 
To assess the longevity of miRNA inhibitors over time, samples were 
nucleofected with 100nM miRNA inhibitor control, maintained under 
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standard culture conditions (section 2.2) and observed after 1, 3 and 5 days 
using fluorescent microscopy.  hEKs had proliferated following 
nucleofection and the miRNA inhibitor control was observed throughout 
this culture period (Figure 3.22). 
 
Figure 3.22 Fluorescent and phase contrast microscopic observation of hEKs (A-
B) 1 day (C-D) 3 days (E-F) 5 days post-nucleofection with miRNA inhibitor 
control, same field of view for each given time point, scale bar represents 50µm 
A 
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hEKs were maintained for 10 days post-nucleofection with a gradual 
decrease in the number of miRNA inhibitor control positive cells.  To 
quantify persistence of the miRNA inhibitor control during this period, 
hEKs were subject to flow cytometry at 1, 3, 5, 7 and 10 days post-
nucleofection.  This confirmed that miRNA inhibitor delivery is 
considerably more efficient than plasmid DNA delivery.  While miRNA 
inhibitor expression is also transient in nature and is found to gradually 
decrease over time it does however persist at much higher levels than GFP-
P over the same time period (Figure 3.23). 
  
 
Figure 3.23 Comparison of GFP-P and miRNA inhibitor control nucleofection 
efficiency.  Points plotted represent the mean number of hEKs successfully 
nucleofected with either miRNA inhibitor control  (red) or GFP-P (black) 
quantified using flow cytometry at specific time points post-nucleofection, error 
bars represent standard error of the mean, n=3  
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3.3.4 Repeated Rounds of Nucleofection  
Due to the transient nature of this technique it was hypothesised that, to 
sustain an appropriate level of stimulation to induce reprogramming, 
additional rounds of nucleofection may be required. To assess the feasibility 
of repeated rounds of nucleofection, hEKs were nucleofected with GFP-P or 
miRNA inhibitor control and maintained for 5 days.  Each well then 
typically contained 3x10
4
 cells per cm
2
, therefore the contents of three wells 
were harvested to yield the required number of hEKs for each additional 
round of nucleofection.  After the second round of nucleofection, delivery of 
GFP-P or miRNA inhibitor control was observed.  A comparison was made 
with samples nucleofected without inclusion of GFP-P or miRNA inhibitor 
control during the second round of nucleofection.   
Samples subject to a second round of nucleofection with GFP-P resulted in 
a number of successfully nucleofected hEKs compared those without GFP-
P, which failed to express GFP (Figure 3.24). 
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Figure 3.24 Fluorescent and phase contrast microscopic observations of hEKs 
subject to a second round of nucleofection (A–B) with GFP-P; (C-D) without GFP-
P after 48 hours, same field of view, scale bar represents 100µm   
 
hEKs subject to a second round of nucleofection with of GFP-P were 
maintained for a further 9 days, a total of 14 days since the initial round of 
nucleofection and observed using  fluorescent and transmitted light 
microscopy after 5, 7 and 9 days.  The GFP-P was observed in a number of 
hEKs during this culture period (Figure 3.25), thus highlighting the ability 
to sustain plasmid DNA expression through successive rounds of 
nucleofection. 
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Figure 3.25 Fluorescent and phase contrast microscopic observations of hEKs 
subjected to a second round of nucleofection with GFP-P (A-B) 5 days; (C-D) 7 
days; (E-F) 9 days post-nucleofection, same field of view for each given time 
point,  scale bar represents 100µm 
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Flow cytometry of hEKs undergoing a second round of nucleofection with 
GFP-P was performed to quantify successfully nucleofected hEKs.  This 
revealed an increase in the number of hEKs incorporating GFP-P and 
mirrored previous results with a decrease over time and persistence at high 
levels between 5-7 days post-nucleofection (Figure 2.26). 
 
 
Figure 3.26 Nucleofection efficiency second round of nucleofection GFP-P.  
Points plotted represent the mean number of hEKs successfully nucleofected with 
GFP-P quantified using flow cytometry at specific time points post-nucleofection, 
error bars represent standard error of the mean, n=3 
 
hEKs nucleofected with miRNA inhibitor control were also harvested after 
5 days and subjected to further rounds of nucleofection. This revealed a 
number of successfully nucleofected hEKs compared to nucleofected in the 
absence of miRNA inhibitor control, which failed to maintain miRNA 
inhibitor expression (Figure 3.27). 
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Figure 3.27 Fluorescent and phase contrast microscopic observations of hEKs 
subjected to second round of nucleofection after 48 hours (A–B) with miRNA 
inhibitor control; (C-D) without of miRNA inhibitor control, same field of view for 
each sample, scale bar represents 100µm  
 
hEKs which had undergone a second round of nucleofection in the presence 
of miRNA inhibitor control were maintained for a further 9 days, a total of 
14 days since the initial round of nucleofection and observed using  
fluorescent and transmitted light microscopy after 5, 7 and 9 days.  This 
revealed the persistence of miRNA inhibitor control in a number of hEKs 
during this culture period (Figure 3.28).  
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Figure 3.28 Fluorescent and phase contrast microscopic observations of hEKs 
subjected to a second round of nucleofection with miRNA inhibitor control (A-B) 5 
days; (C-D) 7 days; (E-F) 9 days post-nucleofection, same field of view for each 
given time point, scale bar represents 100µm 
 
Flow cytometry demonstrated that a second round of nucleofection resulted 
in an increase in hEKs successfully incorporating the miRNA inhibitor 
control and mirrored previous results with a gradual decrease in miRNA 
inhibitor control over time (Figure 3.29).  However, despite a decrease, 
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transcription of miRNA inhibitor control remained high throughout the 
culture period. 
 
 
Figure 3.29 Nucleofection efficiency second round of nucleofection miRNA 
inhibitor control.  Points plotted represent mean number of hEKs successfully 
nucleofected with miRNA inhibitor control quantified using flow cytometry at 
specific time points post-nucleofection, error bars represent standard error of the 
mean, n=3 
 
This data showed increased fluorescence intensity when hEKs had 
undergone a further round of nucleofection (Figure 3.30).  The red area 
represents hEKs after a second round of nucleofection with miRNA 
inhibitor control while the blue line indicates hEKs after an initial round of 
nucleofection with miRNA inhibitor control.  The shift in fluorescence 
suggests increased miRNA inhibitor present in these cells. 
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Figure 3.30 Representative histogram  of hEKs nucleofected with miRNA 
inhibitor control.  Blue line represents initial round of nucleofection.  Red area 
represents second round of nucleofection 24 hours post-nucleofection 
 
3.3.5 Co-Nucleofection  
Nucleofection is a flexible non-viral method of delivering both plasmid 
DNA and miRNA inhibitors to primary cells.  In order to develop an 
effective reprogramming strategy it was necessary to establish whether 
plasmid DNA and miRNA inhibitors could be delivered in combination.  
hEKs were subject to nucleofection with GFP-P and microRNA inhibitor 
control at previously optimised concentrations (section 3.3.3) and 
characterised.  Nuclear transfer of both substrates was visible after 24 hours 
using fluorescent microscopy.  As expected, the majority of cells had 
incorporated miRNA inhibitor control compared to a much smaller number 
incorporating GFP-P (Figure 3.31).  It was also evident that that a number of 
hEKs had been successfully nucleofected with both GFP-P  and miRNA 
inhibitor control.   
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Figure 3.31 Co-nucleofection of hEKs A:  miRNA inhibitor control fluorescent 
microscopic observation 24 hours post nucleofection.  B:  GFP-P fluorescent 
microscopic observation.  C:  Light microscopic observation.  Arrow indicates cell 
that has received both substrates, same field of view 
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Flow cytometry of co-nucleofected hEKs after 24 hours revealed the vast 
majority had incorporated miRNA inhibitor control, 59.68% ± 3.03, n=3, 
whilst  11% ± 1.69, n=3  received GFP-P.  It could also be deduced that 
7.64% ± 0.76, n=3 of hEKs had successfully incorporated both miRNA 
inhibitor control and GFP-P (Figure 3.32).  
 
Figure 3.32 Representative dot plot of hEKs 24 hours post-co-nucleofection. Red: 
miRNA inhibitor control, Green:  GFP-P, Blue: miRNA inhibitor control and 
GFP-P  
 
3.4 Nucleofection of miR-145 Inhibitor 
As detailed previously, miR-145, has been highlighted due to its 
relationship with major pluripotency genes.  To conclude effects of this 
specific miRNA on the major regulators of a pluripotent phenotype, we 
established a knock-out study whereby the function of this miRNA could be 
deduced by studying the effects of its inhibition on cell phenotype.   
To assess the effect of miR-145 inhibition, hEKs were nucleofected with an 
miR-145 antisense inhibitor and the genomic effects of forced inhibition 
evaluated by quantifying expression of an array of genes known to influence 
somatic cell reprogramming.  So that an accurate analysis of miR-145 
inhibited hEKs could be achieved, a number of controls were included.  A 
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negative control was established whereby the miR-145 inhibitor was 
replaced with a scrambled miRNA inhibitor, which does not compliment 
any native miRNA or mRNA sequence in mouse, rat or human and is 
therefore non-effective in influencing gene pathways.  A mock-treated 
control sample was included whereby cells were subjected to all of the 
experimental conditions in the absence of a miRNA inhibitor such that non-
specific effects conferred solely as a consequence of transfection 
biochemistry could be monitored.  In conjunction, untreated controls were 
included which comprised of cells which had not undergone nucleofection 
to give a baseline of cellular activity.  Total RNA was subsequently isolated 
from hEKs at 1, 3, 5, 7 and 9 days post-nucleofection.     
qRT-PCR analysis revealed that inhibition of miR-145, resulted in 
significant changes in expression of key pluripotency-associated genes 
(section 2.10.5).  Figure 3.33 illustrates RT–PCR analysis of the 
pluripotency marker, Oct4, following miR-145 inhibition relative to hEKs 
nucleofected in the absence of miR-145, showing significant upregulation 3 
days post-nucleofection.  Most significant was the increase in Oct4 
expression, in excess of 10 fold, detected 5 days post-nucleofection with 
miR-145 inhibitor.  Expression of Oct4 subsequently decreased however 9 
days post-nucleofection Oct4 expression remained significantly elevated 
compared to hEKs nucleofected in the absence of miR-145 inhibitor. 
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Figure 3.33 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent mean fold change of Oct4 expression relative to hEKs 
nucleofected in the absence of miR-145 inhibitor.  Error bars represent the standard 
error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
 
Another key mediator of a pluripotency is Sox2, which is closely associated 
with neural development and differentiation.  It was possible to observe an 
increase in the expression of Sox2 following nucleofection with miR-145 
inhibitor.  A significant increase in Sox2 expression was detected as early as 
1 day post-nucleofection and increased in excess of 30 fold 9 days post-
miR-145 inhibition (Figure 3.34).  A similar pattern of expression was also 
noted for Klf4 with a significant increase exceeding 25 fold 9 days post-
miR-145 inhibition (Figure 3.35) relative to hEKs nucleofected in the 
absence of miR-145. 
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Figure 3.34 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent the mean fold change of Sox2 expression relative to hEKs 
nucleofected in the absence of miR-145 inhibitor. Error bars represent the standard 
error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
 
 
Figure 3.35 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent the mean fold change of Klf4 expression relative to hEKs 
nucleofected in the absence of miR-145 inhibitor.  Error bars represent the standard 
error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
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Inhibition of miR-145 also corresponded to an increase in c-Myc expression 
with more than 10 fold upregulation detected 5 days post-nucleofection with 
miR-145 inhibitor (Figure 3.36). 
 
 
Figure 3.36 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent the mean fold change of c-Myc expression relative to hEKs 
nucleofected in the absence of miR-145 inhibitor.  Error bars represent the standard 
error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
  
Although Nanog expression was also altered following miR-145 inhibition, 
effects were more difficult to interpret.  Initially following nucleofection 
Nanog expression was significantly upregulated however this was followed 
by a significant decrease in expression.  Between days 3 and 5 post-
nucleofection Nanog expression increased again but was not found to be 
statistically significant.  The most significant increase in Nanog expression 
was 7 days post-nucleofection with more than a 5 fold increase however 
once again Nanog expression decreased after this point (Figure 3.37). 
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Figure 3.37 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent the mean fold change of Nanog expression relative to hEKs 
nucleofected in the absence of miR-145 inhibitor.  Error bars represent the standard 
error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
 
To detect whether activation of pluripotency associated genes affected 
expression of hEK specific genes, qRT-PCR analysis of cytokeratin14 
expression was performed.   A significant decrease in cytokeratin14 
expression was detected 1 day following nucleofection with miR-145 
inhibitor however over the period of culture cytokeratin14 expression 
returned to basal levels (Figure 3.38). 
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Figure 3.38 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor over 
time.  Bars represent the mean fold change of cytokeratin14 expression relative to 
hEKs nucleofected in the absence of miR-145 inhibitor.  Error bars represent the 
standard error of the mean, n=3.  Mann Whitney U statistical test *p-value = 0.05 
 
3.5 hESC Media to Promote Pluripotency  
Considering miR-145 inhibition is capable of activating expression of 
normally silenced pluripotency genes in hEKs it was hypothesised that a 
reprogramming strategy could be developed based upon miR-145 inhibition.  
To provide hEKs with an environment to promote expression of 
pluripotency genes it was hypothesised that serum-free media, typically 
used for the routine culture of hESCs without feeder cells, may provide 
stimulatory growth factors to promote a more plastic genotype,  facilitating 
reprogramming.  hEKs were taken from passage 2-5, nucleofected with 
miR-145 inhibitor and 24 hours post-nucleofection hEK media was replaced 
with hESC media.   
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This resulted in a rapid morphological change with miR-145 inhibited hEKs 
maintained under hESC culture conditions forming distinct colonies, a 
characteristic of hESCs. hEKs which had also received the miR-145 
inhibitor and were subsequently maintained in hEK media remained as a 
monolayer (Figure 3.39). 
 
 
Figure 3.39 Morphology of miR-145 inhibited hEKs maintained either in hESC 
media (top) or hEK media (bottom).  Phase contrast microscopic observation A-C: 
1 day post-nucleofection.  B-D:  5 days post-nucleofection 
 
To investigate effects of hESC media at a genomic level qRT-PCR analysis 
was performed on hEKs nucleofected with miR-145 inhibitor and 
subsequently maintained in either hESC or hEK media post-nucleofection.  
Concordant with previous results 5 days was selected as a significant time 
point with Oct4 expression found to peak at this time following miR-145 
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inhibition.  Gene expression was analysed after hEKs received the miR-145 
inhibitor and were cultured in hESC or hEK media for 5 days.  The data 
presented here represent the fold change in gene expression relative to hEKs 
which had undergone nucleofection in the absence of the miR-145 inhibitor.  
It was possible to detect a significant increase in Oct4 expression when 
miR-145 inhibited hEKs were maintained in either hESC or hEK media 
compared to hEKs nucleofected in the absence of miR-145 inhibitor. 
 
 
Figure 3.40 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue) or hEK (red) media.  Bars represent the 
mean fold change of Oct4 expression relative to hEKs nucleofected in the absence 
of miR-145 inhibitor.  Error bars represent the standard error of the mean, n=3. 
Mann Whitney U statistical test *p-value = 0.05 
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To observe Oct4 at the proteomic level both hEKs, nucleofected with miR-
145 inhibitor and subsequently cultured in either hESC or hEK media were 
subject to immunohistochemistry (Section 2.3).  In both cases re-expression 
of this pluripotency master regulator led to successful translation of the Oct4 
protein (Figure 3.41). 
 
Figure 3.41 Oct4 protein expression 5 days post-nucleofection with miR-145 
inhibitor.  Fluorescent microscopic observation of Oct4, DAPI miR-145 inhibited 
hEKs maintained in (A-C): hESC media.  (D-F): hEK media.  
 
qRT-PCR analysis showed that in the case of miR-145 inhibited hEKs 
cultured in hESC media, Sox2 expression had risen more than 70 fold 
compared to the 10 fold increase detected when maintained in hEK media 
(Figure 3.42).  Furthermore qRT-PCR revealed that Nanog expression had 
also risen significantly when miR-145 inhibited hEKs were maintained 
under hESC conditions with more than a 7 fold expression increase 
compared to approximately 1 fold in the case of miR-145 inhibited hEKs 
maintained in hEK media (Figure 3.43), again representing a significant 
difference in pluripotency gene expression between the two culture systems. 
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Figure 3.42 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue) or hEK (red) media.  Bars represent the 
mean fold change of Sox2 expression relative to hEKs nucleofected in the absence 
of miR-145 inhibitor.  Error bars represent the standard error of the mean, n=3. 
Mann Whitney U statistical test *p-value = 0.05 
 
Figure 3.43 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue)or hEK (red) media.  Bars represent the 
mean fold change of Nanog expression, error bars represent the standard error of 
the mean, n=3. Mann Whitney U statistical test *p-value = 0.05 
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Immunohistochemistry was performed to observe how altered gene 
expression affects synthesis of both Sox2 and Nanog proteins confirming  
translation of Sox2 (Figure 3.44) and Nanog (Figure 3.45) in miR-145 
inhibited hEKs maintained in both hEK and hESC media.  
Figure 3.44 Sox2 protein expression 5 days post-nucleofection with miR-145 
inhibitor.  Fluorescent microscopic observation of Sox2, DAPI miR-145 inhibited 
hEKs maintained in (A-C): hESC media. (D-F): hEK media.  
 
Figure 3.45 Nanog protein expression 5 days post-nucleofection with miR-145 
inhibitor.  Fluorescent microscopic observation of Nanog, DAPI miR-145 
inhibited hEKs maintained in (A-C): hESC media. (D-F): hEK media. 
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Expression of Klf4 and c-Myc were also increased significantly when hEKs 
were maintained under hESC culture conditions.  Figure 3.46 demonstrates 
that under hESC culture conditions Klf4 expression increased more than 7 
fold compared to less than 4 fold when maintained in hEK media post-
nucleofection.  Furthermore, Figure 3.47 illustrates a significant increase in 
c-Myc expression following maintenance of miR-145 inhibited hEKs in 
hESC media almost doubling the fold change compared to those maintained 
in hEK media for 5 days. 
 
 
Figure 3.46 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue) or hEK (red) media.  Bars represent the 
mean fold change of Klf4 expression relative to hEKs nucleofected in the absence 
of miR-145 inhibitor.  Error bars represent the standard error of the mean, n=3. 
Mann Whitney U statistical test *p-value = 0.05 
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Figure 3.47 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue) or hEK (red) media.  Bars represent the 
mean fold change of c-Myc expression relative to hEKs nucleofected in the absence 
of miR-145 inhibitor.  Error bars represent the standard error of the mean, n=3. 
Mann Whitney U statistical test *p-value = 0.05 
 
The expression of cytokeratin14 was also investigated to identify an altered 
genotype following miR-145 inhibition and culture in hESC media.  We had 
previously identified that cytokeratin14 expression decreased upon 
inhibition of miR-145 followed by maintenance in hEK media (Figure 
3.35). Substituting hEK media with hESC media provided more profound 
effects on cytokeratin14 expression, with a mean fold change of -8 x10
3
 
(Figure 3.48) strongly suggesting an altered phenotype, which may have 
lead to the distinct change in cell morphology. 
 118 
 
 
Figure 3.48 qRT-PCR analysis of hEKs 5 days post-nucleofection with miR-145 
inhibitor maintained in either hESC (blue) or hEK (red) media.  Bars represent the 
mean fold change of cytokeratin-14 expression relative to hEKs nucleofected in the 
absence of miR-145 inhibitor.  Error bars represent the standard error of the mean, 
n=3. Mann Whitney U statistical test *p-value = 0.05 
 
 3.6 Direct Reprogramming of miR-145 Inhibited hEKs 
To establish whether miR-145 inhibited hEKs remained lineage committed, 
they were subject to defined differentiation parameters to orchestrate 
phenotype changes toward functional lineages.  In vitro differentiation of 
adult stem cells into osteoblasts, chondrocytes and adipocytes is a gold 
standard experiment for concluding cell plasticity [172].  Therefore we 
subjected cells to established tri-lineage differentiation criteria to 
demonstrate acquired plasticity of miR-145 inhibited hEKs. 
hEKs were nucleofected with miR-145 inhibitor and subsequently cultured 
in either hEK or hESC media for 5 days before being subject to tri-lineage 
differentiation using defined osteogenic, chondrogenic and adipogenic 
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media formulations (section 2.13).  hEKs nucleofected in the absence of 
miR-145 inhibitor were also subject to the same differentiation parameters 
as a negative control while tri-lineage differentiation of hMSCs was 
conducted using the same media formulations as a positive control.   
 
3.6.1 Osteogenic Differentiation  
One of the earliest indicators of osteogenesis is the osteogenic master gene; 
core binding factor α1 (CBFA1/RUNX2).  All samples, except for hEKs 
nucleofected without miR-145 inhibitor, were found to express CBFA1 
when observed immunohistochemically 5 days post-directed differentiation 
(Figure 3.49).  The induction of osteogenic phenotype was further 
confirmed by observation of osteocalcin 21 days post-induction (Figure 
3.50). 
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Figure 3.49 Fluorescent microscopic observation of hEKs stained for  CBFA1, DAPI, F-Actin  after 5 days directed osteogenic 
differentiation (A-C): miR-145 inhibited hEKs maintained in hESC media prior to osteogenic differentiation.  (D-F):   miR-145 inhibited 
hEKs maintained in hEK media prior to osteogenic differentiation.  (G-I):  hMSCs  
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Figure 3.50 Fluorescent microscopic observation of hEKs stained for  Osteocalcin, DAPI, F-Actin after 21 days directed osteogenic 
differentiation (A-C): miR-145 inhibited hEKs maintained in hESC media prior to osteogenic differentiation.  (D-F):   miR-145 inhibited 
hEKs maintained in hEK media prior to osteogenic differentiation.  (G-I):  hMSCs  
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Von Kossa and Alizarin Red S staining were also performed and provided 
further confirmation of terminal functional osteogenesis (Figures 3.51- 3.52) 
 
Figure 3.51 Histological observation of Von Kossa staining in situ after 21 days 
directed osteogenic differentiation (A): miR-145 inhibited hEKs maintained in 
hESC media prior to osteogenic differentiation.  (B):   miR-145 inhibited hEKs 
maintained in hEK media prior to osteogenic differentiation.  (C):  hMSCs, arrows 
indicate mineralisation, scale bar represents 100µm 
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Figure 3.52 Histological observation of Alizarin Red S staining in situ after 21 
days directed osteogenic differentiation (A): miR-145 inhibited hEKs maintained 
in hESC media prior to osteogenic differentiation.  (B):   miR-145 inhibited hEKs 
maintained in hEK media prior to osteogenic differentiation.  (C):  hMSCs, scale 
bar represents 50µm  
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qRT-PCR analysis provided further insight into genomic changes occurring 
during osteogenesis.  CBFA1 expression increased significantly between 1 
and 3 days, in the case of hMSCs and miR-145 inhibited hEKs pre-
incubated in hESC media following osteogenic induction.    In both cases 
CBFA1 expression peaked after 5 days with more than a 200 fold increase 
detected when miR-145 inhibited hEKs had been pre-incubated in hESC 
media compared to hEKs nucleofected without miR-145 prior to osteogenic 
differentiation.  This was followed by a progressive decrease in CBFA1 
expression for both hMSCs and miR-145 inhibited hEKs pre-incubated in 
hESC media. In the case of miR-145 inhibited hEKs pre-incubated in hEK 
media, CBFA1 expression was also found to significantly increase, reaching 
a maximum at the later time point of 7 days.  This increase in CBFA1 
expression was the lowest of the three groups investigated, nevertheless a 
significant change exceeding 100 fold was detected after 7 days of directed 
osteogenic differentiation compared to hEKs nucleofected in the absence of 
miR-145 inhibitor subjected to the same osteo-induction parameters (Figure 
3.53).   
An increase in osteonectin expression was detected between 14 and 21 days 
for both miR-145 inhibited hEKs and hMSCs (Figure 3.54).  This indicated 
a shift in expression of early osteogenic transcription factors, such as 
CBFA1, to genes responsible for the induction of terminal functional 
osteogenesis.  This was further emphasised by an increase in osteocalcin 
expression, which is also involved in calcium ion binding and subsequent 
ossification and matrix mineralisation, detected after 21 days of defined 
osteogenic differentiation (Figure 3.55). 
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Figure 3.53 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined osteogenic differentiation.  Bars represent the mean fold change of CBFA1 expression relative to hEKs subjected to the 
same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3.  Two-way ANOVA 
statistical test *p<0.05, **p<0.01 
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Figure 3.54 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined osteogenic differentiation.  Bars represent the mean fold change of Osteonectin expression relative to hEKs subjected to 
the same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3. Two-way ANOVA 
statistical test *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.55 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined osteogenic differentiation.  Bars represent the mean fold change of Osteocalcin expression relative to hEKs subjected to 
the same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3. Two-way ANOVA 
statistical test *p<0.05, **p<0.01, ***p<0.001
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Following qRT-PCR, amplicons were subject to gel electrophoresis to 
confirm their identity.  All amplicons were represented by a single band 
ranging between 100-200 bp (Figure 3.56).  
 
Figure 3.56 Osteogenic PCR product validation.  Agarose gel electrophoresis of 
osteogenic PCR products was performed stained with ethidium bromide and 
visualised under UV light  
 
3.6.2 Chondrogenic Differentiation  
The same transfection variables were introduced to defined chondrogenic 
differentiation stimuli (Table 2.3).  Aggrecan is an early marker of 
chondrogenic differentiation; 7 days post-chondrogenic induction, aggrecan 
was clearly observed in most samples with the exception being hEKs that 
had not received the miR-145 inhibitor prior to chondrogenic differentiation 
(Figure 3.57). 
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Figure 3.57 Fluorescent microscopic observation of (A-C): miR-145 inhibited hEKs pre-incubated in hESC media.  (D-F):   miR-145 
inhibited hEKs pre-incubated in hEK media (G-I):  hMSCs stained for Aggrecan, DAPI, F-Actin after 7 days directed chondrogenic 
differentiation, scale bar represents 50µm 
 130 
 
After 21 days of defined chondrogenic culture immunohistochemical 
analysis of type II collagen (Col II) was performed.  Col II is highly 
prevalent in chondrocyte ECM occupying 50%  total matrix protein and 70-
80% total collagen [173].  Immunohistochemistry revealed an abundance of 
Col II (Figure 3.58). 
 
Figure 3.58 Fluorescent microscopic observation of (A-C): miR-145 inhibited 
hEKs pre-incubated in hESC media.  (D-F):   miR-145 inhibited hEKs pre-
incubated in hEK media.  (G-I):  hMSCs stained for Col II, DAPI, F-Actin after 
21 days of defined chondrogenic stimulation, scale bar represents 100µm (A-C) 
50µm (D-H) 
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Van Gieson staining was performed in order to confirm chondrogenic 
differentiation histologically (Section 2.8).  This protocol stains collagen 
indicated as pink/red staining shown in Figure 3.59. 
 
Figure 3.59 Histological observation of Van Gieson staining in situ indicating an 
abundance of collagen after 21 days directed chondrogenic differentiation (A): 
miR-145 inhibited hEKs maintained in hESC media prior to chondrogenic 
differentiation.  (B):   miR-145 inhibited hEKs maintained in hEK media prior to 
chondrogenic differentiation.  (C):  hMSCs, scale bar represents 50µm 
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To gain insight into genomic changes occurring during chondrogenesis, 
qRT-PCR was performed to investigate Col II gene expression.  A 
significant increase in Col II was detected in hMSCs subject to defined 
chondrogenic culture with expression reaching a maximum after 21 days 
(Figure 3.60).  Col II expression was also found at high levels where miR-
145 inhibited hEKs had been subject to defined chondrogenic 
differentiation.  A significant increase in Col II expression was detected at 
all time points except for 7 days where miR-145 inhibited hEKs had been 
pre-incubated in hESC media. Col II expression also significantly increased 
where miR-145 inhibited hEKs had been pre-incubated in hEK media at 
days 1 and 14 (Figure 3.61).   
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Figure 3.60 qRT-PCR analysis of hMSCs subjected to defined chondrogenic differentiation.  Bars represent the mean fold change of hCol II 
expression relative to hEKs subjected to the same experimental parameters except for miR-145 inhibition, error bars represent the standard 
error of the mean, n=3.  Two-way ANOVA statistical test *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.61 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media then subjected to 
defined chondrogenic differentiation.  Bars represent the mean fold change of hCol II expression relative to hEKs subjected to the same 
experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3.  Two-way ANOVA 
statistical test *p<0.05, **p<0.01, ***p<0.001
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Following qRT-PCR, amplicons were subject to gel electrophoresis to 
confirm their identity.  Together this data provides confirmation of the 
directed reprogramming of miR-145 inhibited hEKs towards a chondrogenic 
phenotype (Figure 3.62).  
 
Figure 3.62 Chondrogenic PCR product validation.  Agarose gel electrophoresis 
of chondrogenic PCR products was performed stained with ethidium bromide and 
visualised under UV light  
 
3.6.3 Adipogenic Differentiation  
To complete demonstration that miR-145 inhibited hEKs can be directed 
through tri-lineage commitment, adipogenic differentiation was conducted 
by replacing either hEK or hESC media with the adipogenic media (table 
2.4), 5 days post-nucleofection with miR-145 inhibitor.  In addition to miR-
145 inhibited hEKs, hMSCs were also subject to adipogenic differentiation 
as a positive control.  Furthermore hEKs nucleofected in the absence of 
miR-145 inhibitor prior to adipogenic culture allowed us to establish 
baseline data. 
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The gold standard for identifying adipocytes is histological staining with Oil 
Red O (Section 2.9).  Cells were subject to Oil Red O staining throughout 
the culture period and lipid encapsulation was visualised as early as 3 days 
post-induction.  By day 14 lipid droplets were clearly visible in a large 
number of cells (Figure 3.63). 
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Figure 3.63 Histological observation of Oil Red O staining in situ after 14 days 
directed adipogenic differentiation (A): miR-145 inhibited hEKs maintained in 
hESC media prior to adipogenic differentiation.  (B):   miR-145 inhibited hEKs 
maintained in hEK media prior to adipogenic differentiation.  (C):  hMSCs, arrows 
indicate lipid filled vacuoles, scale bar represents 50µm 
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To identify expression of key adipogenic associated genes, qRT-PCR 
analysis was also performed.  The expression of periosome proliferator-
activated receptor γ (PPARγ) was investigated due to the role of this 
receptor complex in adipogenesis.  Activation of PPARγ results in 
homodimerisation with the retinoid X receptor (RXR) to form a 
transcription factor complex, which promotes transcription of genes 
responsible for adipogenic development [174].  Initiation of adipogenesis 
was therefore characterised by an increase in PPARγ observed after 1 day of 
adipogenic culture (Figure 3.64).  PPARγ was significantly upregulated in 
the majority of samples with the exception of hEKs nucleofected in the 
absence of miR-145 inhibitor prior to adipogenic differentiation.  PPARγ 
expression decreased after 1 day in all samples consistent with its role in 
early adipogenesis. 
Adiponectin is abundant in terminal adipose tissue and has a functional role 
in glucose and lipid metabolism.  A significant increase in adiponectin was 
detected at 1, 5, 7 and 14 days post-adipogenic differentiation, in the case of 
hMSCs, exceeding 100 fold after 1 day.  miR-145 inhibited hEKs pre-
incubated in hESC media prior to defined differentiation significantly 
increased adiponectin expression after 1, 3 and 21 days to a reduced extent 
with maximum expression at 35 fold after 1 day.    Where miR-145 
inhibited hEKs had been pre-incubated in hEK media prior to adipogenic 
differentiation, considerably lower levels of adiponectin were observed 
peaking after 21 days (Figure 3.65).  The levels observed indicated no 
statistically significant upregulation in adiponectin expression in the case of 
miR-145 inhibited hEKs pre-incubated in hEK media. 
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Figure 3.64 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined adipogenic differentiation.  Bars represent the mean fold change of PPARγ expression relative to hEKs subjected to the 
same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3. Two-way ANOVA 
statistical test *p<0.05, **p<0.01, ***p<0.001
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Figure 3.65 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined adipogenic differentiation.  Bars represent the mean fold change of Adiponectin expression relative to hEKs subjected to 
the same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3.  Two-way 
ANOVA statistical test *p<0.05, **p<0.01, ***p<0.001
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A selection of the amplicons produced from qRT-PCR experiments were 
subject to gel electrophoresis.  Together this data suggests the direct 
reprogramming of miR-145 inhibited hEKs towards an adipogenic 
phenotype, with miR-145 inhibited hEKs pre-incubated in hESC media 
having an increased efficacy compared to miR-145 inhibited hEKs pre-
incubated in hEK media (Figure 3.66). 
 
Figure 3.66 Adipogenic PCR product validation.  Agarose gel electrophoresis of 
adipogenic PCR products was performed, stained with ethidium bromide and 
visualised under UV light  
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3.6.4 Neurogenic Differentiation  
To assess the differentiation potential of miR-145 inhibited hEKs, neural 
differentiation was selected.  Neurogenic differentiation was chosen given 
the high levels of Sox2 expressed by miR-145 inhibited hEKs, a master 
regulator of neural stem cells.  In line with previous experiments hEKs were 
subject to nucleofection with miR-145 inhibitor and cultured in either hEK 
or hESC media.   Basal media was replaced after 5 days with neural 
differentiation media supplemented with 300ng/mL all-trans retinoic acid to 
induce neurogenesis. 
Nestin was selected as an early marker of neurogenesis, as it is widely 
regarded as being ubiquitously expressed in neural precursor cells [175].  
Nestin expression is notoriously transient and due to the rapid switching and 
termination of translation can often be difficult to detect.  Nevertheless 
Nestin was successfully observed in the majority of samples (Figure 3.67), 
with expression maxima after 3 days for hMSCs and miR-145 inhibited 
hEKs pre-incubated in hESC media while miR-145 inhibited hEKs pre-
incubated in hEK media demonstrated delayed expression after 5 days.  The 
most significant increase in Nestin expression was noted for miR-145 
inhibited hEKs pre-incubated in hESC media, demonstrating more than 30 
fold increase in expression after 3 days neural induction, perhaps not 
surprising given the increased expression of Sox2 observed prior to 
neurogenic induction. 
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Figure 3.67 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined neurogenic differentiation.  Bars represent the mean fold change of Nestin expression relative to hEKs subjected to the 
same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3.  Two-way ANOVA 
statistical test *p<0.05, **p<0.01, ***p<0.001
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During neurogenesis Nestin is replaced with tissue-specific intermediate 
filament proteins, such as neurofilament and βIII-tubulin.  
Immunohistochemistry provided evidence of neurogenesis through 
detection of neurofilament (Figure 3.68) and βIII-tubulin (Figure 3.69) after 
21 days of defined neural differentiation.  The expression of neurofilament 
was confirmed using qRT-PCR, which showed significant elevation of this 
gene between 14 and 21 days post-neurogenic differentiation in all cases 
(Figure 3.70). 
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Figure 3.68 Fluorescent microscopic observation of hEKs after 21 days of defined neurogenic stimulation. (A-C): miR-145 inhibited 
hEKs pre-incubated in hESC media.  (D-F):   miR-145 inhibited hEKs pre-incubated in hEK media.  (G-I):  hMSCs Neurofilament, DAPI, 
F-Actin, scale bar represents 50µm 
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Figure 3.69 Fluorescent microscopic observation  of hEKs after 21 days of defined neurogenic stimulation. (A-C): miR-145 inhibited 
hEKs pre-incubated in hESC media.  (D-F):   miR-145 inhibited hEKs pre-incubated in hEK media.  (G-I):  hMSCs βIII tubulin, DAPI, F-
Actin, scale bar represents 50µm
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Figure 3.70 qRT-PCR analysis of hEKs nucleofected with miR-145 inhibitor pre-incubated in either hESC or hEK media and hMSCs 
subjected to defined neurogenic differentiation.  Bars represent the mean fold change of Neurofilament expression relative to hEKs subjected 
to the same experimental parameters except for miR-145 inhibition, error bars represent the standard error of the mean, n=3.  Two-way 
ANOVA statistical test *p<0.05, **p<0.01, ***p<0.001
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Appropriate wells were selected following qRT-PCR and amplified 
products subjected to gel electrophoresis to confirm their identity.  Together 
this data provides confirmation of the directed reprogramming of miR-145 
inhibited hEKs towards a neurogenic phenotype (Figure 3.71). 
 
Figure 3.71 Neurogenic PCR product validation.  Agarose gel electrophoresis of 
neurogenic PCR products, stained with ethidium bromide and visualised under UV 
light  
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3.7 Ectopic Bone Formation Model 
We hypothesised that miR-145 inhibited hEKs, which demonstrated 
osteogenic differentiation in vitro, could differentiate to a functional 
osteoblast lineage in vivo and when delivered with an appropriate scaffold 
give rise to ectopic mineralised tissue.   
One group of polymeric materials, which has shown excellent promise in 
the field of biomaterials and regenerative medicine, are hydrogels.  
Hydrogels are a class of hydrophilic cross-linked polymers, produced from 
either organic or inorganic components.  Foremost, this class of materials is 
renowned for their cellular compliance, in the case of proteinaceous 
hydrogels, providing a matrix mimetic substrate on which primary cells can 
adhere and proliferate [176].  Additionally, hydrogels can be delivered via 
minimally invasive procedures in a liquid phase, often engineered to use a 
patient‟s autologous physiology to facilitate gellation, allowing scaffold 
assembly in situ [177].   
 
Therefore for the purpose of this investigation we adopted a host-derived 
blood plasma approach to generate a completely autologous matrix for cell 
delivery and expansion, which is able to overcome the post-surgical 
complications associated with a lack of scaffold histocompatibility [178].   
The exogenous array of growth factors, cytokines and other regulatory 
peptides found within plasma removes the dependency on xenogenic animal 
serum from the cell culture matrix.   
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3.7.1 Validation of PPP-Hydrogel for Maintenance of Pluripotency 
HESCs were chosen as a candidate for the validation of a PPP-derived 
hydrogel as a supportive matrix for the maintenance of a pluripotent, self-
renewing phenotype.  Expansion and phenotype of hESCs has 
conventionally been maintained though co-culture with feeder cells, 
typically MEFs [179].  While MEFs provide contact signalling and secreted 
solutes, which hESCs require to expand and self renew, this method is a 
double edged sword exposing hESCs to potential xeno-contaminants. 
Ideally pharmacopeia-grade hESCs should be maintained in xeno-free 
culture using materials of human or completely synthetic origin in order to 
increase their clinical potential.  Therefore this PPP-derived hydrogel 
derived in conjunction with chemically defined medium, would be 
particularly attractive to cell based therapies.  To validate whether a PPP 
hydrogel was able to maintain a pluripotent self-renewing phenotype, 
hESCs were taken from passage 8 and embedded within a 4mm hydrogel 
layer at a density of 5.0x10
3
cells/cm
2
.  HESCs were also maintained on TCP 
coated with 5µg/mL of hFN and maintained using the same media 
formulation detailed in section 2.1.2 as a positive control.    
A fundamental feature of any culture system is its cytocompatibility, 
therefore to validate whether the hydrogel was able to provide an 
environment capable of maintaining cell viability a live/dead assay was 
performed. To confirm whether components of this assay were first able to 
diffuse throughout the hydrogel to successfully interact with the cells 
encapsulated within, a control was established whereby hESCs embedded 
within the hydrogel were subject to 70% ethanol for 10 minutes, at room 
temperature, inducing cell death.  Upon staining, hESCs were found to 
exclusively fluoresce red (Ex510, Em595) indicating that the hydrogel 
permits diffusion of assay reagents.  Viability tests confirmed that hESCs 
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cultured within PPP-derived hydrogel remained viable after 72 hours in 
culture (Figure 3.72).   
 
Figure 3.72 Cytotoxicity of PPP-derived hydrogel.  Live/dead staining of hESCs 
embedded within PPP-derived hydrogel after 72 hours in culture A: Live cells.  B: 
Dead cells. C: Nuclei, same field of view.  Scale bar represents 50µm 
 
Undifferentiated hESCs typically exhibit a high nucleus to cytoplasm ratio 
and form tightly packed colonies.  hESCs embedded within the hydrogel 
were observed to proliferate and successfully formed colonies displaying 
typical hESC morphology.  Expansion of hESC populations continued until 
reaching confluency after 72 hours (Figure 3.73). 
 
Figure 3.73 Cell morphology of hESCs maintained under PPP-hydrogel 
conditions.  Phase contrast  light microscopic observation of hESCs after 72 hours 
of culture A: hFN.  B:  PPP-derived hydrogel.  Scale bars represent 200µm 
 
 152 
 
This confirmed that PPP hydrogel was capable of maintaining hESC 
expansion.  While morphological analysis of hESCs embedded within the 
hydrogel suggested hESCs remained undifferentiated, to confirm this 
observation immunohistochemistry was performed.  Transcription factors 
Oct4, Nanog and Sox2, all of which are typically expressed by hESCs in 
standard culture [58, 180, 181] were selected as indicators of pluripotency.  
After 72 hours in culture, all nuclear transcription factors were clearly 
identified in all experimental samples after 10 passages (Figure 3.74).   
 
Figure 3.74 Fluorescent microscopic observation of hESCs stained within PPP 
hydrogel after 10 passages. A-B Oct4, DAPI.  C-D Nanog, DAPI.  E-F Sox2, 
DAPI Scale bars represent 50µm 
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Expression of pluripotency markers Oct4, Nanog and Sox2, were also 
analysed up to 10 passages using qRT-PCR.  Significant levels of each of 
these markers were identified for hESCs maintained on hFN or embedded 
within PPP-derived hydrogels.  The expression of Oct4, Nanog and Sox2 
was comparable over a number of passages with no significant difference in 
expression (Figures 3.75 - 3.77). 
 
Figure 3.75 qRT-PCR analysis of hESC maintained under PPP-derived hydrogel 
conditions. Bars represent the mean fold change of Oct4 expression relative to 
hESCs maintained on hFN, error bars represent the standard error of the mean, n=3 
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Figure 3.76 qRT-PCR analysis of hESC maintained under PPP-derived hydrogel 
conditions. Bars represent the mean fold change of Nanog expression relative to 
hESCs maintained on hFN, error bars represent the standard error of the mean, n=3 
 
Figure 3.77 qRT-PCR analysis of hESC maintained under PPP-derived hydrogel 
conditions. Bars represent the mean fold change of Sox2 expression relative to 
hESCs maintained on hFN, error bars represent the standard error of the mean, n=3 
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To establish whether this matrix was capable of maintaining hESC 
phenotype over an extended period of culture, hESCs embedded within the 
PPP hydrogel construct were cultured through 25 passages (section 2.1.2).  
No changes in morphology, viability or phenotype were observed over the 
extended culture period thus the ability of the PPP-hydrogel to maintain 
undifferentiated expansion of hESCs in vitro was confirmed (Figure 3.78). 
 
Figure 3.78 Long-term maintenance of hESCs using PPP-derived hydrogel system.  
Phase contrast microscopic observation of hESCs after 10 passages cultured within 
the PPP-derived hydrogel  
 
Teratomas were induced 6 weeks post-injection and observed both 
macroscopically and microscopically following H&E staining of explanted 
tissue.  Structures derived from all three germ layers of the developing 
organism were identified, confirming that the hESCs maintain their 
differentiation potential when maintained within this PPP-derived hydrogel 
(Figure 3.79). 
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Figure 3.79 Teratoma formation indicates differentiation into derivatives of the 
three germ layers. A:  Macroscopic observation of teratoma formation.  B: 
Endoderm (arrow indicates glandular structure) C:  Mesoderm and ectoderm (black 
arrow indicates myofibres and white arrow hair follicle) .  D:  Mesoderm (arrow 
indicates blood vessel. 
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3.6.2 Validation of Hydroxyapatite Hydrogel 
To investigate whether reprogrammed hEKs were capable of differentiating 
towards osteogenic lineages in vivo an ectopic bone formation model was 
designed to include the incorporation of hydroxyapatite (HA) in order to 
promote osteogenesis.  To determine an appropriate concentration HA to 
incorporate into PPP hydrogels, concentrations ranging from 0.5% to 10% 
(w/v) were prepared and gellation time monitored.   Stable hydrogel 
formation was concluded when the polymeric solution no longer flowed 
when inverted. 
Hydrogels infused with 0.5% to 1% HA formed stable hydrogels when 
incubated at 37°C after 5 minutes while an increased concentration of 3% 
HA resulted in an increased gellation time of 10 minutes.  Higher HA 
concentrations of 5% and 10% took significantly longer to gellate with 
hydrogel formation occurring after 20 and 30 minutes respectively.  The 
increase in gellation time correlated with an increase in HA concentration, 
which is unusual as it was hypothesised that the abundance of calcium in 
HA would decrease gellation time however this may be ascribed to HA 
intervening in the crosslinking process thus weakening this process.  As 
gellation should occur at a sufficiently rapid rate for clinical use 
concentrations ranging from 3% to 10% were eliminated.  
Prior to delivery hydrogels infused with 0.5% to 1% HA were compared by 
performing an in vitro cytocompatibility test.  hMSCs were embedded 
within the HA-hydrogels at a density of 1x10
4
 cells per mL of HA-hydrogel 
suspension and incubated at 37°C, 5% CO2.  Viability was evaluated using a 
live/dead cytotoxicity assay at 1, 3 and 5 days.   
Viability after 1 day embedded within the hydrogel appeared to favour a HA 
concentration of 0.5% over 1% HA and HA-free hydrogels (Figure 3.80).    
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Figure 3.80 Fluorescent microscopic observation of live, dead, nuclei hMSCs 
after 24 hours of culture, embedded in PPP-derived hydrogel (A-C) HA-free.  (D-
F):  0.5% HA.  (G-I):  1% HA  
 
Upon maintaining hMSCs for a further 2 days it was possible to observe an 
increase in viable cells within all hydrogel constructs.  In terms of the 
number of dead cells the 0.5% hydrogel appeared superior with a noticeable 
reduction in the number of dead cells compared to 1% and HA-free 
hydrogels (Figure 3.81).  
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Figure 3.81 Fluorescent microscopic observation of live/ dead, nuclei hMSCs 
after 72 hours of culture, embedded in PPP-derived hydrogel (A-C) HA-free.  (D-
F):  0.5% HA.  (G-I):  1% HA  
 
After 5 days embedded within the hydrogel constructs hMSCs proliferated 
and maintained high viability (Figure 3.82). 
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Figure 3.82 Fluorescent microscopic observation of live/ dead, nuclei hMSCs 
after 5 days of culture, embedded in PPP-derived hydrogel A-C) HA-free.  (D-F):  
0.5% HA.  (G-I):  1% HA  
 
The PPP hydrogel was therefore validated as an appropriate scaffold capable 
of maintaining hMSCs in vitro.  When considering the incorporation of HA 
within the hydrogel a concentration of 0.5% was selected for subsequent 
investigations as it demonstrated superiority in promoting hMSC viability.  
 
 
 
 
 161 
 
3.7.3 Ectopic Tissue Formation Model 
Four cell types of interest: miR-145 inhibited hEKs maintained in either 
hEK or hESC media for 5 days prior to implant, hEKs taken at passage 3 
that had been nucleofected without miR-145 inhibitor and hMSCs taken at 
passage 4 were delivered in PPP-derived hydrogel with and without HA into 
6 week old SCID mice.  Animals were sacrificed four weeks post-
implantation and tissue formation was initially observed macroscopically.  
At each of the sites receiving either miR-145 inhibited hEKs or hMSCs with 
and without HA soft white tissue was identified (Figure 3.83).  No 
macroscopic tissue formation was observed at sites receiving hEKs 
nucleofected without miR-145 implanted with or without HA. 
 
Figure 3.83 Macroscopic observation of tissue formation at site receiving miR-145 
inhibited hEKs pre-incubated in hESC media implanted without HA.  Arrow 
indicates de novo ectopic tissue 
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Tissue was dissected from each of the implanted sites, which were then 
prepared as detailed in section 2.14).  Samples were subject to tinctural 
histopathology using H&E (section 2.16).  Atypical glandular-like structures 
were identified in a number of samples, which received hMSCs or miR-145 
inhibited hEKs implanted with and without HA.   
In an attempt to characterise de novo tissue, samples were subjected to 
CBFA1 and osteocalcin immunohistochemical staining, however staining 
for both was negative so proved inconclusive that implanted cells had 
undergone osteogenesis as hypothesised.  As such, further characterisation 
will need to be conducted in order to identify the de novo tissue formed 
upon implantation in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 163 
 
4.0 Discussion 
Somatic cell reprogramming has developed rapidly over the past decade 
with research focusing on establishing safer, more efficient methods.  The 
main objective of this study was to establish a successful, non-viral method 
of delivering reprogramming stimuli to replace oncogenic transcription 
factors.  To avoid unpredictable exogenous reprogramming factor 
reactivation, a transient strategy was sought and ultimately direct 
reprogramming was pursued to yield functional cells. 
 
4.1 Basal characterisation of hESCs 
To establish baseline data, pluripotent stem cells were maintained and 
characterised.  The hESC line, HUES7, was selected as it has been 
extensively characterised [182-184].  Throughout extended culture, hESCs 
demonstrated prominent nucleoli, high ratio of nucleus to cytoplasm and 
displayed compact colony morphology.  In addition, hESCs were positive 
for molecular markers of an undifferentiated pluripotent phenotype; 
including Oct4, Nanog, Sox2, SSEA3, SSEA4, TRA-1-60, TRA-1-81 and 
alkaline phosphatase (Figures 3.2-3.4).  This is consistent with the literature, 
which details these markers as a prerequisite of pluripotency [185].  In order 
to compare hEK and hESC genotypes, qRT-PCR of total cDNA was 
performed.    Interestingly, this revealed that while hEKs did not express 
Oct4, Nanog or Sox2, they did express moderate levels of Klf4 and to a 
much lesser extent c-Myc, which is in agreement with published data 
reporting that keratinocytes express higher levels of Klf4 and c-Myc 
compared to other somatic cells, such as fibroblasts [128].  As expected, 
hEKs expressed high levels of Cytokeratin-14 therefore a panel of markers 
was established to distinguish pluripotent hESC from differentiated hEK 
phenotypes (Figure 3.5). 
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4.2 Deriving a mimetic pluripotent stem cell microenvironment 
It is well documented that the cellular microenvironment greatly influences 
lineage specification and cell behavior [186, 187].  If we consider the 
embryonic microenvironment we deduce that the ECM is an important 
source of regulatory signals that influence pluripotent cells to adopt specific 
fates.  Research has elucidated many cell-cell and cell-matrix interactions 
occurring between embryonic stem cells and their microenvironment, 
however mimicking this complexity in vitro has yet to be achieved.   
Nevertheless, exciting studies have shown that signals derived from the 
microenvironment influence fate of both ESCs and adult progenitor cells 
[168, 188].  Considering the powerful role that the microenvironment plays 
in influencing plasticity and lineage determination, it was proposed that 
providing hEKs with an ECM homologue known to support a pluripotent, 
self-renewing phenotype may promote hyperplasia.   
The feeder-free system used in this study for maintenance of hESCs is 
composed of two distinct components, a hFN substrate and serum-free 
media, containing growth factors previously validated for maintenance of 
hESC phenotype [168].  Initially hFN was considered for the maintenance 
of hEKs to provide an environment known to promote repogramming.  It 
was rational that hEKs would adhere to hFN as they possess α5β1 integrins, 
which mediate attachment to fibronectin [167, 189].  As predicted, hEKs 
adhered to a range of hFN concentrations and cell counts revealed that hEKs 
preferentially adhered to a concentration of 5µg/mL (Figure 3.6), which is 
routinely used for the feeder-free maintenance of hESCs [168].  Whilst a 
large proportion of hEKs successfully adhered to hFN, initial attachment 
was impaired compared to hCol I (Figure 3.9), which is commonly used for 
the culture of hEKs in vitro, facilitating attachment via α2β1 integrins [167, 
190].  It is recognised that cell attachment occurs through interactions 
between integrins, cell adhesion receptors and extracellular proteins 
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therefore a number of factors could affect the attachment of hEKs to hFN.  
One suggestion is that hEKs possess an increased number of integrins, such 
as α2β1 thus increasing attachment to hCol I.  Despite an initial reduction in 
attachment, hEKs seeded on hFN proliferated at a similar rate to hCol I, 
demonstrating that hFN is capable of sustaining hEKs over an extended 
culture period, validating the possibility of incorporating this substrate in 
hEK reprogramming. 
 
4.3 Identification and validation of a non-viral method of delivering 
inducing stimuli 
Due to the risk of insertional mutagenesis, non-viral methods for somatic 
cell reprogramming are increasingly sought.  When developing this novel 
strategy for directly reprogramming hEKs, one of the main priorities was to 
establish a non-viral method of delivering inducing stimuli.  Previous non-
viral and non-integrating methods have included adenoviruses [136], 
plasmids [191], excision of reprogramming factors using Cre-loxP [139] or 
piggyBac transposition [84].  However, as detailed in chapter 1 these 
techniques often suffer from low efficiencies therefore an alternative 
solution was sought. 
A number of alternative non-viral transfection methods were considered 
including electroporation and liposomal delivery.  These approaches are 
limited by low efficiency, high cytotoxicity and inability to deliver nucleic 
acids past the nuclear envelope.  Nucleofection however was identified as a 
promising method of intracellular molecular delivery.  Nucleofection is 
based on electroporation whereby application of voltage temporarily 
compromises the integrity of the plasma membrane allowing extracellular 
molecules to enter.  Unlike traditional electroporation, nucleofection is 
based on cell–type specific, high voltage pulses created by a nucleofector 
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device.  This facilitates transitory creation of small pores in the nuclear 
envelope.  In combination with cell-type specific reagents this allows 
efficient transfer of nucleic acids directly into the nuclei with minimal 
cytotoxicity [148, 192].  Proprietary reagents consist of modular protein 
complexes that combine with charged particles, such as nucleic acids, to 
form a nucleoprotein complex.  Different protein, complexes facilitate 
separate functions, such as cell membrane association, endosomal release 
and nuclear transport [193].  
Two prominent studies which have also successfully utilised nucleofection 
for delivery of their reprogramming stimuli include reprogramming of 
human adipose stem cells using a minicircle vector [144] and 
reprogramming of human embryonic fibroblasts using a piggyBac 
transposon system [84].  The first study utilised minicircle vectors 
consisting of supercoiled DNA molecules containing Oct4, Sox2, Lin28 and 
Nanog while the piggyBac transposon system makes use of a single vector 
containing OKSM.  In both cases each of the reprogramming factors were 
separated by the self-cleaving peptide 2A, which allowed subsequent 
excision of exogenous genes following reprogramming.  Whilst both studies 
demonstrate significant advances in reprogramming facilitated by 
nucleofection both rely heavily on large amounts of foreign DNA including 
the known oncogenes, c-Myc and Klf4 while the novel strategy detailed 
herein addresses these issues through a miRNA approach. 
Prior to delivery of inducing factors it was necessary to optimise a number 
of outcomes, such as viability, efficiency and persistence of inducing 
stimuli.   
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4.3.1 Viability post-nucleofection 
Quantification of hEK viability post-nucleofection was performed using a 
combination of live/dead staining and trypan-blue dye exclusion.  Whole 
well analysis assessed cells residing both in the adherent monolayer and 
supernatant compared to hEKs which had undergone identical trypsinisation 
and centrifugation procedures to ascertain viability as a direct result of 
nucleofection.  Both assays confirmed increased apoptosis compared to non-
nucleofected controls with approximately 25% remaining viable post-
nucleofection (table 3.2).  This level of viability is relatively low, levels as 
high as 40-60% have been previously reported [194].  However the viability 
reported here is not unusual with other studies reporting hEK viability of 
23% post-nucleofection [195] and in one case 14% [196].   
One variable known to considerably affect viability is media composition.  
The media formulation, KGM-Gold (Lonza, UK), is suggested for optimal 
viability post-nucleofection [194], however this media was not adopted in 
this strategy.  Deviation from the suggested media may have led to a 
decrease in the overall cell viability, however despite increased cell death 
hEKs proliferated and demonstrated typical morphology following 
nucleofection (Figure 3.8).  This is likely to be a result of the high number 
of cells used in each nucleofection, which meant the significant cell death 
incurred did not detrimentally affect subsequent culture of hEKs.  
Nucleofection was subsequently performed many times throughout this 
investigation and the level of viability remained constant, successfully 
demonstrating the repeatability of this technique. 
 
4.3.2 Optimising reprogramming microenvironment 
As identified previously hFN was considered as a substrate to promote the 
reprogramming of hEKs.  As such, hFN was investigated post-nucleofection 
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to establish the feasibility of utilising this substrate in this reprogramming 
strategy.  Consistent with earlier experiments a decreased number of hEKs 
attached to hFN compared to hCol I following nucleofection (table 3.2).  In 
addition, when evaluating adherent hEKs following GFP-P nucleofection, 
hFN significantly reduced the percentage of GFP
bright 
cells from 
approximately 20% to 8%, suggesting that a number of nucleofected hEKs 
failed to attach to the substrate and remained in the supernatant.  This was 
confirmed by whole well analysis, which revealed that the total number of 
GFP
bright
 cells was comparable between the two systems (Figure 3.15).  
Onset of terminal differentiation is known to result in decreased fibronectin 
binding due to loss of α5β1 integrin from the cell surface [197].  Reduced 
attachment post-nucleofection may therefore have been exacerbated due to 
the induction of terminal differentiation.  It was concluded from this series 
of experiments that hColI was the optimal substrate post-nucleofection for 
increasing efficiency of the reprogramming strategy. 
 
4.3.3 Phenotype post-nucleofection 
Commonly used transfection methods, such as liposome-mediated DNA 
transfer can induce the terminal differentiation of somatic cells [198] and 
these alterations in differentiation state may affect the response of 
transfected hEKS to the investigated gene product.  Therefore prior to 
delivery of inducing stimuli phenotypic analysis of hEKs post-nucleofection 
was undertaken.  Cytokeratin-14 and involucrin were highlighted as markers 
of hEK lineage commitment [171, 197, 198].  To establish a positive 
control, hEKs were subject to suspension culture.  This model increases 
expression of involucrin and subsequently induces terminal differentiation 
[197, 199].  Cytokeratin-14 was found to be abundant in hEKs maintained 
under adherent culture and also following nucleofection whilst hEKs 
maintained in suspension demonstrated considerably reduced expression of 
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this protein.  In addition, a number of hEKs maintained in suspension 
became hypertrophic and demonstrated positive staining for involucrin, 
confirming that this culture system had resulted in terminal differentiation 
of the majority of hEKs, consistent with previous literature [200].  hEKs 
subject to nucleofection displayed only a few involucrin positive cells 
suggesting this procedure had not considerably altered their phenotype.  
This was further confirmed through qRT-PCR, which revealed that 
nucleofection alone did not alter hEK genotype with both hEK specific 
genes, such as cytokeratin-14 and pluripotency genes, such as Oct4, Sox2 
and Nanog remaining unaltered.     
 
4.3.4 Nucleofection efficiency 
Upon establishing the viability and phenotype of hEKs post-nucleofection, 
it was crucial that the feasibility of delivering inducing stimuli was 
investigated.  It was hypothesised that combinations of plasmid DNA and 
miRNA may provide a compelling approach for reprogramming hEKs 
therefore delivery of both substrates needed to be evaluated.  A range of 
appropriate parameters were available for the nucleofection of plasmid 
DNA [194], however delivery of miRNA required further optimisation, 
which ultimately identified a favourable concentration of 100nM (Figure 
3.20).  In both cases the same electrical pulse parameters were used in order 
to maintain consistency between samples. 
Remarkable differences were noted in terms of both DNA and miRNA 
delivery.  Both were rapidly incorporated into the nuclei of hEKs however 
distinct differences were noted in copy number/cell and delivery efficiency.  
In the case of GFP-P, a range of cellular fluorescence intensities were 
detected (Figure 3.14).  Reference to previous literature confirmed that this 
was not an unusual phenomenon with one publication reporting an average 
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of 1000 plasmid copies per cell following nucleofection, however the 
standard deviations of these measurements were large suggesting that there 
can be huge variation in copy number/cell [201].  The efficiency of GFP-P 
delivery was reproducible with 19.82% ± 2.45, n=6 hEKs successfully 
nucleofected after 24 hours.  The literature indicates that transfection 
efficiency of hEKs varies considerably with some studies reporting similarly 
low efficiencies between 5-20% [195, 202] however several studies report 
much higher efficiencies between 50-60% [202].  If we compare the 
efficiency of nucleofection reported herein to other non-viral transfection 
methods, the efficiency of plasmid nucleofection is relatively high with 
reported efficiencies of 0.1 - 11% using liposomal based transfection 
reagents [202, 203] 
Delivery of miRNA inhibitors provided somewhat different results.  Flow 
cytometric data showed a distinct peak and decrease in fluorescence 
intensity compared to GFP-P nucleofection (Figure 3.21).  In addition, the 
number of hEKs successfully incorporating the miRNA inhibitor was 
significantly increased, with a mean efficiency of 88.58% compared to 
19.82% detected 24 hours post-nucleofection. The number of studies 
describing nucleofection of miRNA is limited, however existing reports 
detail similar efficiencies of 90% [204].  The increased efficiency of 
miRNA inhibitor delivery suggests uptake is more consistent in terms of the 
quantity however the difference in fluorescent intensity could be attributed 
to the difference in fluorochrome labelling each substrate,   
 
4.3.5 Stable or transient transfer? 
To investigate longevity of both substrates and ascertain whether transfer is 
stable or transient, hEKs were maintained in their original wells for 10 days 
following nucleofection.  A similar pattern emerged between the two 
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substrates with expression peaking for both constructs after 3 days and 
decreasing over time.  When hEKs received miRNA inhibitor, this molecule 
remained in approximately 80% hEKs after 10 days, while GFP-P had 
largely been cleared by this point.  This may be due to the initially increased 
cytoplasmic concentration of miRNA inhibitor retaining detectable intensity 
after several round of mitosis.    
To confirm transfer was transient and also assess the feasibility of 
successive rounds of nucleofection, hEKs were subject to a further round of 
nucleofection.  hEKs that received either GFP-P or miRNA inhibitor 
demonstrated an increased number of successfully nucleofected cells and in 
the case of miRNA inhibitor, an increase in fluorescence was also observed.  
This suggests an increase in substrate transferred to each cell and that hEKs 
nucleofected during initial nucleofection were more amenable to receiving 
substrates during serial nucleofections.  In addition, hEKs nucleofected in 
the absence of either GFP-P or miRNA inhibitor during the second round 
demonstrated an absence of either substrate, providing confirmation that 
transfer is transient and substrates are eventually cleared through mitosis if 
not repeatedly transfected [205]. 
Co-nucleofection has been adopted by many groups as an effective way of 
delivering a number of substrates [206-208] and it was hypothesised that to 
develop an effective reprogramming strategy it may be necessary to deliver 
a number of inducing stimuli.  During this investigation it was possible to 
demonstrate successful delivery of both GFP-P and miRNA inhibitor to 
hEKs.  Flow cytometry revealed that 7.64% of adherent hEKs received both 
constructs.  Considering the low levels of nucleofection reported in other 
strategies, with only 10.8% of hASCs receiving the minicircle vector before 
undergoing reprogramming [144] it is not unreasonable to consider co-
nucleofection of plasmid DNA and miRNA inhibitors as a practicable 
strategy for reprogramming hEKs.  
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4.4 Inhibition of miR-145 
miR-145 was highlighted early in this study as a potential mediator of 
pluripotency [119].  It was hypothesised that modulating its expression may 
alter the expression of key pluripotency regulators.  This investigation 
successfully demonstrated that inhibition of miR-145 activated pluripotency 
genes in hEKs that are normally silenced.  In the case of Oct4, expression 
was significantly upregulated following miR-145 inhibition, with an 
expression peak after 5 days.  Previous studies have focused on initiating 
reprogramming through introduction of a number of genes with the vast 
majority including Oct4 [45, 144].  Another study, which mirrors the level 
of transcriptional regulation described herein, utilised small interfering RNA 
(siRNA) to mediate expression of scaffold attachment factor A (SAF-A) 
[209].   This study demonstrates that decreasing SAF-A mRNA through 
siRNA transfection subsequently decreased Oct4 expression and vice versa  
This supports the findings presented in this thesis, which suggest that 
indirect activation of Oct4 expression can replace exogenous Oct4.   The 
majority of reprogramming strategies involve the induction of Oct4, 
consistent with its role as a mediator of a pluripotent state suggesting that 
Oct4 is involved in transcriptional activation of itself or as a heterodimer 
with Sox2.   
Literature has shown that miR-145 is associated with both Oct4 and Sox2 
[119] therefore discovery that miR-145 is capable of activating Oct4 
expression in hEKs suggested that miR-145 may mediate expression of 
other pluripotency associated genes.  As hypothesised, expression of Sox2 
was found to have significantly increased upon miR-145 inhibition.  The 
pattern of expression was different to that observed for Oct4 with a 
progressive increase peaking at 9 days, with more than a 25 fold increase 
detected compared to hEKs nucleofected in the absence of miR-145 
inhibitor.  If we consider another direct target of miR-145, Klf4, we 
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observed a similar pattern of re-expression to that of Sox2.  Expression 
gradually increased over time and peaked at more than 25 fold after 9 days, 
which is distinctly similar to Sox2 re-expression.  With previous studies 
highlighting miR-145 as directly targeting Oct4, Sox2 and Klf4 3‟ UTRs 
[119] it is not surprising that miR-145 inhibition produced this biologically 
significant effect.  Whilst miR-145 directly targets all three genes, the fact 
that Oct4 does not follow the same pattern of re-expression nor reaches the 
same level is not surprising given the tight multifactorial regulation that this 
gene demonstrated in previous studies [62, 210]. 
The interaction between miR-145 and c-Myc has not received as much 
attention as its effect on Oct4, Sox2 and Klf4.  However, miR-145 has been 
shown to directly silence c-Myc, an oncogenic phosphoprotein, which plays 
a key role in regulating cell cycle progression, apoptosis and transformation 
[211].  Inhibition of miR-145 resulted in a significant increase in c-Myc 
expression, which peaked after 5 days and exceeded more than 10 fold 
upregulation.  This echoes another study whereby miR-145 inhibition 
enhanced c-Myc expression.  This study demonstrated the link between p53 
and c-Myc by identifying that p53 transcriptionally induces expression of 
miR-145 through interaction with a p53 response element in the miR-145 
promoter.  miR-145 then proceeds to silence c-Myc, however this process is 
reversible demonstrated by miR-145 inhibition upregulating c-Myc 
expression via p53 [212].  
There have been no reports of miR-145 directly targeting Nanog, however it 
was hypothesised that Nanog expression may be significantly altered as a 
result of increased levels of Oct4 and Sox2 given the intrinsic, cooperative 
regulation of these master regulators [181].  Gene expression data did not 
conclusively indicate Nanog re-expression, despite a statistically significant 
upregulation in Nanog expression detected after 1 and 7 days.  This suggests 
that miR-145 inhibition alone is not sufficient to induce pluripotency.     
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To ascertain whether miR-145 inhibition had altered the genotype of hEKs, 
the expression of the ubiquitously expressed cytokeratin-14, was 
investigated.  qRT-PCR analysis revealed an initial decrease in expression, 
which increased over time resuming to basal levels after 9 days.  This 
reflects the transient nature of miRNA inhibition and provides further 
evidence that miR-145 inhibition is insufficient to induce a pluripotent state. 
 
4.5 hESC media formulation promotes pluripotency gene expression 
To promote increased expression of pluripotency associated genes it was 
hypothesised that the reprogramming microenvironment should mimic that 
of the embryo as far as possible.  miR-145 inhibited hEKs were provided 
with media (section 2.1.2), routinely used for culture of hESCs, providing 
growth factors known to promote pluripotency.   
One growth factor of particular relevance is FGF2, which is thought to 
maintain the pluripotency transcription program via activation of the MAPK 
pathway [213].  Also incorporated in this media is Activin A, a key 
regulator in the maintenance of stemness in hESCs, known to induce 
expression of Oct4 and Nanog, promote Wnt3 and suppress BMP signals 
[214].  This media formulation has previously been validated for use in the 
absence of feeder cells in combination with hFN substrates [168].   
Upon providing miR-145 inhibited hEKs with growth factor supplemented 
hESC media, a rapid morphological change occurred.   Cells maintained in 
hESC media clustered together to form distinct colonies whilst those 
maintained in hEK media remained as a monolayer (Figure 3.39).  This 
distinctive morphological change suggested that miR-145 inhibited hEKs 
maintained in hESC media had undergone noteworthy biological changes. 
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In order to investigate these changes at the genomic level, qRT-PCR 
analysis was performed to compare the two culture systems. In terms of 
Oct4 there was little change in expression between the two systems and 
proteomic analysis demonstrated successful translation of Oct4 in both cases 
(Figure 3.41). 
There were however differences in Sox2 expression between the two 
systems.  miR-145-inhibited hEKs maintained in hESC media post-
nucleofection displayed increased Sox2 expression, of 70 fold relative to 
hEKs nucleofected in the absence of miR-145 inhibitor (Figure 3.42).  This 
profound increase in expression may be attributed to the neural supplements 
included in this hESC media formulation, N2 and B27.  These are known to 
promote a neural precursor phenotype, however they are also often 
employed for the maintenance of undifferentiated hESCs [168, 215].  In 
both cases Sox2 expression was successfully translated as validated using 
immunohistochemistry (Figure 3.43). 
As discussed earlier, Nanog expression failed to reach the same levels as the 
other pluripotency associated genes.  Upon providing miR-145 inhibited 
hEKs with hESC media Nanog expression was upregulated.  Despite this 
statistically significant upregulation, Nanog expression remained lower than 
other pluripotency-associated genes however successful translation was 
identified by immunohistochemistry (Figure 3.45). 
Both c-Myc and Klf4 underwent further upregulation in the presence of 
hESC media confirming the original hypothesis that providing miR-145 
inhibited hEKs with growth factors found in the embryonic 
microenvironment would increase expression of pluripotency-associated 
genes. 
In order to assess whether genomic changes were extended to hEK-specific 
genes, cytokeratin14 expression was evaluated under hESC conditions.  
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This revealed a prominent decrease in cytokeratin14 expression of 8x10
3
 
fold, strongly suggesting a transformed phenotype.  Therefore it was 
concluded that inhibition of miR-145 combined with growth factor 
stimulation was capable of activating normally silenced pluripotency genes, 
promoting acquisition of a stem cell-like phenotype.   
The benefits of gaining a fully reprogrammed state were at this point re-
evaluated.  Whilst pluripotent stem cells are unsurpassed in their 
differentiation capabilities, they come with their own set of limitations as 
the extensive differentiation capabilities demonstrated in vitro translates to 
undesirable tumorigenesis in vivo.  While iPSCs provide an opportunity to 
derive patient-specific stem cells for use in cell replacement therapies and 
generate new models for human disease this requires establishment of 
defined differentiation strategies.  Despite substantial progress during the 
previous decade to optimise generation of functionally competent cells from 
a variety of pluripotent sources, it remains technically difficult to obtain a 
homogenous population of lineage-specific cells from a pluripotent stem 
cell.  It was proposed that devising a strategy to direct hEK fate into 
desirable, functional cell lineages rather than completely reversing their 
phenotype through a pluripotent intermediate would be more advantageous 
in many respects. 
 
4.6 Direct reprogramming of miR-145 inhibited hEKs 
To direct reprogramming, a series of differentiation media formulations 
were established (table 2.4).  These media formulations have previously 
been validated for directed differentiation of hMSCs [216-219], which 
display a number of stemness properties exhibited by miR-145 inhibited 
hEKs, such as Oct4 expression [220].  Therefore it was proposed that these 
formulations may stimulate differentiation of hEKs into desirable lineages. 
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This novel direct reprogramming approach demonstrated that miR-145 
inhibited hEKs underwent functional osteogenic differentiation.  This was 
initially demonstrated through identification of the earliest and most specific 
marker of osteoblast differentiation, Cbfa1, after 5 days of differentiation 
culture (Figure 3.49).  Forced expression of Cbfa1 in hMSCs leads to 
osteoblastic differentiation highlighting the influential role of this master 
regulator in orchestrating osteogenesis [221].  qRT-PCR analysis, indicated 
an increase in Cbfa1 expression after 3 days directed osteogenic 
differentiation in hMSCs and miR-145 inhibited hEKs pre-incubated in 
hESC media and at the later time point of 7 days for miR-145 inhibited 
hEKs pre-incubated in hEK media (Figure 3.53).  This is similar to data 
obtained in a previous study, which reports detection of Cbfa1 after 2 days 
where hMSCs are subject to identical osteogenic differentiation parameters 
[216].  Other studies report maximal upregulation of Cbfa1 after 7 days of 
directed differentiation confirming that early upregulation of this osteogenic 
master gene is typical [222].  Similarities in Cbfa1 expression profiles 
suggest miR-145 inhibited hEKs cultured in hESC media share a phenotype 
more akin to hMSCs than miR-145 inhibited hEKs maintained in hEK 
media.   
CBFA1 acts upstream of osteocalcin and  osteonectin [223] therefore it was 
hypothesised that upregulation of CBFA1 would induce these genes.  Gene 
expression data revealed an upregulation of both osteonectin and 
osteocalcin after 14 and 21 days respectively (Figures 3.54-3.55).  This is 
consistent with previous studies reporting osteonectin expression maxima 
after 14 days [224, 225].  Osteocalcin expression also increases in a time-
dependent manner and is often only upregulated after 21 days of osteogenic 
differentiation [222] confirming the development of an osteoblastic 
phenotype [225].  Changes reported herein for all osteogenic genes were  
relatively high, often exceeding 100 fold at the maxima, compared to other 
studies, typically between 10-50 fold [226].  This can be attributed to the 
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genomic data described herein being presented relative to lineage committed 
hEKs nucleofected in the absence of miR-145 inhibitor rather than 
multipotent hMSCs.  There are no previous reports of osteogenic, 
chondrogenic, adipogenic or neurogenic differentiation of miR-145 
inhibited cells therefore it is impossible to draw any direct comparison.  
However this data provides an indication of the genomic changes occurring 
compared to hMSCs and along with immunohistochemical and histological 
staining provides confirmation of directed differentiation into multiple 
lineages.  To conclude osteoblast functionality, histological staining was 
performed.  A combination of Von Kossa and Alizarin Red S staining were 
able to provide confirmation of extracellular mineralisation after 21 days 
(Figures 3.51-3.52).   
Application of defined chondrogenic differentiation media was also able to 
direct the differentiation of miR-145-inhibited hEKs identified by a number 
of chondrocyte-specific markers.  Initially this was demonstrated through 
the identification of aggrecan, an early marker of chondrogenesis, after 7 
days directed differentiation (Figure 3.57).  This is consistent with previous 
literature, which details a time dependent accumulation of aggrecan between 
6-12 days [227].  In addition, this direct reprogramming strategy was able to 
induce markers associated with terminal chondrogenesis, such as Col II.  
hMSCs demonstrated typical Col II expression profile with a gradual 
increase in expression, peaking after 21 days, except for an increase after 1 
day (Figure 3.60).  miR-145 inhibited hEKs demonstrated reduced 
expression of this marker compared to hMSCs however the expression 
profile did follow the same pattern with a peak in expression after 1 day 
followed by a general increase in Col II expression over time (Figure 3.1).  
This observation does not exactly replicate that found in the literature with 
chondrogenic differentiation typically characterised by detection between 7-
14 days followed by a peak in expression after 21 days [228].  However 
different media formulations can provide distinctly different chondrogenic 
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potential, which may alter the pattern of expression.  What this clearly 
demonstrates is the acquisition of a chondrogenic phenotype with 
consistency between hMSCs and miR-145 inhibited hEKs.  Van Gieson 
staining also identified the abundance of collagen present in both miR-145 
inhibited hEKs and hMSCs providing further evidence for the acquisition of 
a chondrogenic phenotype (Figure 3.59). 
To further probe the stem cell-like phenotype of miR-145 inhibited hEKs 
adipogenic differentiation media was applied.  PPARγ, an early initiator of 
adipogenesis [174, 229],  was detected after 1 day in hMSCs and miR-145 
inhibited hEKs.  PPARγ expression decreased after this point, however it 
remained significantly upregulated until day 14 in the case of hMSCs and 
miR-145 inhibited hEKs pre-incubated in hESC media (Figure 3.64), which 
correlates with previous reports, which also indicate early initiation of this 
gene [230, 231].  Adiponectin is also heavily implicated in adipogenesis and 
is often associated with later stages of differentiation [232]. Gene expression 
data revealed an increase in adiponectin after 1 day, which subsequently 
decreased but remained significantly upregulated at 14 days in the case of 
hMSCs and 21 days in miR-145 inhibited hEKs pre-incubated in hESC 
media (Figure 3.65).  qRT-PCR analysis therefore revealed an increased 
affinity of these two groups to undergo adipogenesis compared to miR-145 
inhibited hEKs pre-incubated in hEK media, perhaps due to the increased 
expression of pluripotency associated genes in the first instance.  To 
confirm adipocyte functionality, Oil Red O staining was performed, which 
clearly identified lipid droplets after 3 days in both hMSCs and miR-145 
inhibited hEKs subject to adipogenic differentiation.  The abundance of 
lipid droplets increased up to 14 days (Figure 3.63), consistent with previous 
studies, which detail time dependent accumulation of lipid filled vacuoles 
[233].   
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Finally, to demonstrate the differentiation potential of miR-145 inhibited 
hEKs, a neurogenic differentiation strategy was selected.  The high levels of 
the neural precursor gene, Sox2, demonstrated by miR-145 inhibited hEKs 
in hESC media led to the hypothesis that these cells may be directed 
towards a neural phenotype.  Expression of the early neural marker nestin 
provided evidence of the neurogenic differentiation of miR-145 inhibited 
hEKs pre-incubated in hESC media [175].  Nestin expression was found to 
be significantly elevated throughout the culture period decreasing in a time 
dependent manner, which is consistent with other reports of neurogenesis 
[234]. 
hMSCs also demonstrated significant expression of this early marker after 3 
days, however at reduced levels compared to miR-145 inhibited hEKs pre-
incubated in hESC media.  This is consistent with previous literature, which 
widely characterises hMSCs according to their „tri-lineage‟ potential.  
However reports of neural differentiation are far less common suggesting 
increased restrictions in achieving neural transdifferentiation.  If we 
consider the expression of nestin in miR-145 inhibited hEKs pre-incubated 
in hEK media, a similar increase was observed after 5 days as detected for 
hMSCs after 3 days.  The delayed expression of lineage specific genes for 
miR-145 inhibited hEKs pre-incubated in hEK media is a consistent theme 
throughout this investigation suggesting the initial decreased expression of 
pluripotency associated genes may have imparted restrictions on subsequent 
differentiation. 
Terminal markers of neurogenesis, neurofilament and βIII-tubulin, were 
detected at the later time points of 14 to 21 days.  Gene expression data 
indicated significant upregulation of neurofilament in miR-145 inhibited 
hEKs pre-incubated in hESC and hEK media after 14 and 21 days 
respectively (Figure 3.70).  Although hMSCs demonstrated significant 
upregulation of neurofilament after 21 days, the level of expression was 
 181 
 
reduced compared to miR-145 inhibited hEKs supporting an increased 
ability of reprogrammed cells to undergo neurogenesis.  Despite varying 
levels of neural-specific genes all three cell types were βIII-tubulin positive 
confirming successful acquisition of a neuronal phenotype after 21 days 
directed neurogenic culture (Figure 3.69) consistent with other reports, 
which verify a neuronal phenotype based on the identification of βIII-
tubulin [235]. 
 
4.7 Maintenance of a hESC phenotype using PPP-derived hydrogel 
To evaluate the effect of an in vivo environment on stem cell phenotypes an 
appropriate implantation model was formulated, incorporating a PPP-
derived hydrogel, which had previously been validated in terms of its ability 
to maintain human MSCs, dermal fibroblasts, articular chondrocytes and 
osteoblasts [178].   
Considering the native 3D microenvironment of hESCs it was hypothesised 
that they required a structural framework and morphogenic cues to mediate 
cell fate and function.  The PPP-derived hydrogel possesses many ideal 
characteristics with its 3D composition, mechanical integrity and excellent 
mass transport properties contributing to its cytocompatibility.  Prior to 
implantation, the ability of this PPP-derived hydrogel to maintain a self-
renewing, undifferentiated hESC phenotype was evaluated.  Both cell 
viability and morphological analysis suggested that this matrix was capable 
of supporting a hESC phenotype in vitro (3.72-3.73).  hESCs primarily 
express integrins recognising the RGD peptide sequence present in most 
ECM proteins.  It is likely that fibronectin within the PPP-derived hydrogel 
played an important role in promoting maintenance of hESCs through 
facilitating attachment via integrin binding to RGD sequences [236, 237].  
The main component of the matrix is fibrin, which also has multiple 
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interacting sites that serve as adhesion motifs, including binding sites for 
α5β1 integrins [237], it is therefore possible that the abundance of fibrin 
within the hydrogel may also have served to mediate attachment and 
proliferation of hESCs.  In addition, the conversion of the soluble protein 
fibrinogen to the insoluble protein fibrin during gellation, generates a 
network of fibres comparable to that found within natural ECM.  In 
combination with soluble growth factors supplied in the culture media this 
system provides a microenvironment, which promotes a self-renewing, 
undifferentiated phenotype . 
This novel, feeder-free, PPP-derived hydrogel system was used to culture 
hESCs up to 25 passages demonstrating the ability of this system to support 
the long-term maintenance of an undifferentiated phenotype.  Throughout 
the culture period their pluripotent phenotype was validated through a 
combination of qRT-PCR and immunohistochemical staining of the 
pluripotency markers Oct4, Sox2 and Nanog consistent with validation of 
other feeder-free culture systems [238, 239].  This was directly compared to 
the previously reported fibronectin, feeder-free system [168] with no 
significant differences in pluripotency gene expression noted between both 
systems.  In addition, hESCs implanted within PPP-derived hydrogels in 
vivo demonstrated successful teratoma formation, the gold standard for 
confirming a pluripotent phenotype [240].  Together these data demonstrate 
a new platform for studying pluripotent stem cell biology both in vitro and 
in vivo.  
 
4.8 Ectopic Tissue Formation Model 
To provide miR-145 inhibited hEKs with stimulation to direct their 
differentiation in vivo, an ectopic bone formation model was formulated to 
incorporate HA within cell-loaded hydrogels.  This is consistent with other 
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ectopic bone formation strategies, which make use of the osteoinductive 
properties of HA to promote osteogenesis [241].  To determine an optimal 
concentration of HA, an in vitro viability assay was performed, which 
revealed that a concentration of 0.5% HA promoted hMSC growth.  This is 
comparable to a previous study which demonstrated a high level of hMSC 
cytocompatibility using 1% HA poly(ethylene glycol) dimethacrylate 
(PEGDMA) hydrogels [242]. 
Previous studies describing hydrogel-derived bone tissue typically use stem 
cells, such as hMSCs directed into critically sized bone defects rather than 
generating bone ectopically.  One such example used a hyaluronic acid 
polymer in conjunction with BMP-2 and hMSCs implanted into a rat 
calvarial defect of critical size.  This demonstrated complete healing of the 
defect after 4 weeks, the neo-bone being difficult to discern from the host 
tissue [243].  An ectopic bone formation strategy was adopted in this 
investigation to aid clear indication of donor-derived tissue formation. 
Implantation into NOD/SCID mice provided evidence that both hMSCs and 
miR-145 inhibited hEKs contributed to de novo tissue formation in vivo, 
identified macroscopically as white tissue masses in both HA and HA-free 
implanted groups (Figure 3.83).  Histological staining identified atypical 
glandular structures in a number of samples, which received either hMSCs 
or miR-145 inhibited hEKs, while these structures were absent at sites that 
had received untreated hEKs (Figure 3.84) providing further evidence that 
the stem cell characteristics of miR-145 inhibited hEKs and hMSCs had 
resulted in de novo tissue formation in vivo. 
To characterise this tissue a number of markers associated with an 
osteogenic phenotype were selected with previous studies reporting 
identification of both CBFA1 and Osteocalcin after 4 weeks confirming 
ectopic bone formation [244].  Negative detection of these markers 
suggested that these cells had not undergone osteogenesis as hypothesised.  
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Considering the stem cell-like phenotype of miR-145 inhibited hEKs it is 
possible that the in vivo microenvironment may have stimulated these cells 
into a number of possible lineages therefore further characterisation of the 
tissue will be required to elucidate their in vivo differentiation capabilities. 
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5.0 Conclusions 
 
This investigation successfully validated nucleofection as an effective 
method of introducing both plasmid DNA and miRNA inhibitors to hEKs; 
avoiding many of the complications associated with viral-mediated 
transfection.  This non-viral technique has previously been reported for the 
reprogramming of human progenitor cells, however in both cases plasmid 
DNA was utilised.  This is the first report of nucleofection-mediated, 
miRNA inhibitor delivery facilitating the reprogramming of human lineage 
committed cells. 
Inhibition of miR-145 successfully activated silenced pluripotency genes in 
hEKs.  The activation of Oct4 is of considerable significance as this 
transcription factor is considered to be a proxy for stemness and a 
prerequisite for pluripotency.  The results detailed herein demonstrated that 
inhibition of miR-145 indirectly activated expression of endogenous Oct4 
while also significantly upregulating Sox2, Klf4 and c-Myc expression. 
Growth factor supplemented media routinely used for the maintenance of 
hESCs was found to further stimulate expression of pluripotency associated 
genes Sox2, Nanog, Klf4 and c-Myc however did not alter the expression of 
Oct4.  In addition the hEK marker, cytokeratin14 was found to have notably 
decreased under these culture conditions.  This altered genotype was 
reflected in a rapid morphological change with cells clustering together to 
form colonies strongly suggestive of a distinct phenotypic change. 
Direct reprogramming of miR-145 inhibited hEKs towards tri-lineage and 
transgermal fates was successfully achieved using defined differentiation 
media formulations previously validated for the directed differentiation of 
hMSCs.  Osteogenic, chondrogenic, adipogenic and neurogenic lineages 
were confirmed using an array of proteomic and genomic markers.  This 
 186 
 
novel, non-viral, miRNA approach for the direct reprogramming of somatic 
cells yielded transdifferentiated functional cells offering significant 
advances for clinical translation. 
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